H. Lundbeck A/S et al v. Lupin Limited, et al
| Takeda Pharmaceuticals International AG, H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceuticals America, Inc. |
| Apotex Inc., Apotex Research Private Limited, Apotex Corp., Lek Pharmaceuticals d.d., Alembic Global Holding S/A, Macleods Pharma USA, Inc., Cipla Limited, Cipla USA Inc., Zydus Pharmaceuticals (USA) Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Amneal Pharmaceuticals of New York LLC, Macleods Pharmaceuticals Ltd., MSN Pharmachem Private Limited, MSN Laboratories Private Limited, Hetero USA Inc., Hetero Labs Limited, Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc., Alkem Laboratories Ltd., MSN Pharmaceuticals Inc., Cadila Healthcare Ltd., Amneal Pharmaceuticals Pvt. Ltd., Prinston Pharmaceutical Inc., Amneal Pharmaceuticals Company GmbH, Sigmapharm Laboratories LLC, Apicore US LLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd, Lupin Pharmaceuticals Inc., Hetero Labs Limited Unit-V, Sandoz AG, Sandoz Inc. and Lupin Limited |
| Takeda Pharmaceutical Company Ltd. |
| Unichem Laboratories, Limited |
| 1:2018cv00088 |
| January 12, 2018 |
| US District Court for the District of Delaware |
| Wilmington Office |
| New Castle |
| Leonard P Stark |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. § 271 Patent Infringement |
| Defendant |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 16, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 1102
TRANSCRIPT REQUEST -- Transcript Purchase Order -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. before Judge The Honorable Leonard P. Stark. (Dellinger, Megan)
|
|
Filing 1101
NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1098 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc. USCA Case Number 2022-1246. (ntl)
|
|
Filing 1100
TRANSCRIPT REQUEST by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Filing 1099
TRANSCRIPT REQUEST by Lek Pharmaceuticals D.D., Sandoz Inc. before Judge Leonard P. Stark, (Gattuso, Dominick)
|
|
Filing 1098
NOTICE OF CROSS APPEAL to the Federal Circuit of #1090 Judgment . Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick)
|
|
Notification regarding #1098 Notice of Cross Appeal sent to Reporter Gaffigan (myr)
|
|
APPEAL - Credit Card Payment of $505.00 received re #1098 Notice of Cross Appeal filed by Lek Pharmaceuticals D.D., Sandoz Inc.. ( Filing fee $505, receipt number ADEDC-3758535.) (Gattuso, Dominick)
|
|
Notification regarding #1098 Notice of Cross Appeal sent to Reporter Gunning (myr)
|
|
Notice of Cross Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1098 Notice of Cross Appeal. (myr)
|
|
Filing 1097
CORRECTED CONSENT JUDGMENT regarding Torrent Pharmaceuticals Limited and Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 12/2/21. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00149-LPS, 1:18-cv-00672-LPS (ntl)
|
|
Filing 1096
NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1093 Notice of Appeal (Federal Circuit) filed by Lupin Pharmaceuticals Inc., Lupin Limited. USCA Case Number 2022-1208. (ntl)
|
|
Filing 1095
PROPOSED CONSENT JUDGMENT (Corrected) by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Connolly, Arthur)
|
|
Filing 1094
NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re #1092 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. USCA Case Number 2022-1194. (ntl)
|
|
Filing 1093
NOTICE OF APPEAL to the Federal Circuit of #1090 Judgment, #1076 Order, #1075 Opinion . Appeal filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Notification regarding #1093 Notice of Appeal (Federal Circuit) sent to Reporter Gaffigan. (nmg)
|
|
APPEAL - Credit Card Payment of $505.00 received re #1093 Notice of Appeal (Federal Circuit) filed by Lupin Pharmaceuticals Inc., Lupin Limited. ( Filing fee $505, receipt number ADEDC-3751130.) (Lennon, James)
|
|
Notification regarding #1093 Notice of Appeal (Federal Circuit) sent to Reporter Gunning. (nmg)
|
|
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1093 Notice of Appeal (Federal Circuit). (nmg)
|
|
Filing 1092
NOTICE OF APPEAL to the Federal Circuit of #912 Order, 801 Oral Order,,,,,,,,,,,,,, #357 Memorandum Opinion, #358 Order, #1090 Judgment, #682 Memorandum Opinion, #683 Order . Appeal filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
APPEAL - Credit Card Payment of $505.00 received re #1092 Notice of Appeal (Federal Circuit), filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc.. ( Filing fee $505, receipt number ADEDC-3750309.) (Dellinger, Megan)
|
|
Notification regarding #1092 Notice of Appeal (Federal Circuit), sent to Reporter Gaffigan (mal)
|
|
Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re #1092 Notice of Appeal (Federal Circuit),. (mal)
|
|
Notification regarding #1092 Notice of Appeal (Federal Circuit), sent to Reporter Gunning (mal)
|
|
Filing 1091
Report to the Commissioner of Patents and Trademarks. (ntl)
|
|
Filing 1090
FINAL JUDGMENT (See document for further details) (CASE CLOSED). Signed by Judge Leonard P. Stark on 10/28/21. (ntl)
|
|
Filing 1089
ORAL ORDER: Having reviewed the parties' Proposed Final Judgment (D.I. 1085), as well as Plaintiffs' and Lupin's letters relating to a dispute in connection with that proposal (see D.I. 1083, 1084, 1086, 1087), IT IS HEREBY ORDERED that Plaintiffs' request that Lupin be enjoined from launching its products until after the expiration of the '626 Patent is DENIED WITHOUT PREJUDICE to renew after the completion of any appellate process. On the record as it presently exists, the Court agrees with Lupin that Plaintiffs have failed to show they will be irreparably injured by any action Lupin may take (with respect to its proposed drug product) between now and the expiration of the '626 Patent in 2027. As Lupin acknowledges, "If the status quo is maintained on any appeal, because of the compound patents, Plaintiffs will enjoy continued market exclusivity until June 17, 2026." (D.I. 1083 at 2) Plaintiffs' request to submit additional evidence and briefing in support of its requested injunction, at this time, is also DENIED. It would not be a wise use of judicial resources to take more evidence and review more briefing to decide an issue that cannot become ripe for at least several years, particularly when one or more parties (including Plaintiffs and Lupin) may be prepared to pursue their appellate options. ORDERED by Judge Leonard P. Stark on 10/28/21. (ntl)
|
|
Filing 1088
REDACTED VERSION of #1084 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc.. (Dellinger, Megan)
|
|
Filing 1087
Letter to The Honorable Leonard P. Stark from James M. Lennon regarding response re: injunctive relief - re 1082 Order,,,, #1084 Letter. (Lennon, James)
|
|
Filing 1086
Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Lupin dispute - re 1082 Order,,,, #1083 Letter. (Blumenfeld, Jack)
|
|
Filing 1085
PROPOSED ORDER -- Final Judgment -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1084
[SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Lupin dispute - re 1082 Order,,,,. (Blumenfeld, Jack)
|
|
Filing 1083
Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Injunctive Relief - re 1082 Order,,,,. (Lennon, James)
|
|
Filing 1082
CORRECTED ORAL ORDER (Replacing D.I. 1081): Having reviewed the parties' joint letter of October 7 (D.I. 1080), IT IS HEREBY ORDERED that: (i) no later than Tuesday, October 19, the parties shall submit a proposed final judgment consistent with the Court's September 30 opinion, clearly marked to show any points of disagreement; (ii) also no later than October 19, any party may submit a letter, not to exceed three pages, addressing any points of disagreement in the proposed final judgment; and (iii) any party may, no later than October 20, file a responsive letter, not to exceed two pages, further addressing the points of disagreement in the proposed final judgment. IT IS FURTHER ORDERED that, on the same schedule and in letters (separate from the letters noted above) of the same maximum lengths as ordered above (i.e., 3 pages per side on October 19 and 2 pages per side on October 20), both Plaintiffs and Lupin shall file letters addressing their dispute identified in paragraph 2 of the October 7 letter. ORDERED by Judge Leonard P. Stark on 10/14/21. (ntl)
|
|
Filing 1081
ORAL ORDER: Having reviewed the parties' joint letter of October 7 (D.I. 1080), IT IS HEREBY ORDERED that: (i) no later than Tuesday, October 20, the parties shall submit a proposed final judgment consistent with the Court's September 30 opinion, clearly marked to show any points of disagreement; (ii) also no later than October 20, any party may submit a letter, not to exceed three pages, addressing any points of disagreement in the proposed final judgment; and (iii) any party may, no later than October 21, file a responsive letter, not to exceed two pages, further addressing the points of disagreement in the proposed final judgment. IT IS FURTHER ORDERED that, on the same schedule and in letters (separate from the letters noted above) of the same maximum lengths as ordered above (i.e., 3 pages per side on October 20 and 2 pages per side on October 21), both Plaintiffs and Lupin shall file letters addressing their dispute identified in paragraph 2 of the October 7 letter. ORDERED by Judge Leonard P. Stark on 10/14/21. (ntl)
|
|
Filing 1080
Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding status report - re #1076 Order. (Blumenfeld, Jack)
|
|
Filing 1079
NOTICE of Withdrawal of Evan T. Sumner as Counel by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited (Pedi, Nicole)
|
|
Filing 1078
REDACTED PUBLIC VERSION of #1075 Opinion. (ntl)
|
|
Filing 1077
[SEALED] RESPONSE to Order re #1076 Order, #1075 Opinion Defendant Lupin's Unopposed Memorandum in Support of Redaction to Portions of the Court's September 30, 2021 Opinion filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B)(Lennon, James)
|
|
Filing 1076
ORDER re #1075 Opinion regarding bench trial decision. Signed by Judge Leonard P. Stark on 9/30/21. (ntl)
|
|
Filing 1075
[SEALED] OPINION re bench trial decision. Signed by Judge Leonard P. Stark on 9/30/21. This Opinion has been emailed to local counsel. (ntl)
|
|
Filing 1074
NOTICE requesting Clerk to remove Alaina Whitt as co-counsel. Reason for request: No longer with firm. (Dellinger, Megan)
|
|
Filing 1073
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' August 12, 2021 Letter. (Dellinger, Megan)
|
|
Filing 1072
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding August 5, 2021 decision. (Gattuso, Dominick)
|
|
Filing 1071
NOTICE of Change of Firm Affiliation by Lek Pharmaceuticals D.D., Sandoz Inc. Laura A. Lydigsen, Mark H. Remus, Jason W. Schigelone and Jieun Lee should be served at CROWELL & MORING (Gattuso, Dominick)
|
|
Filing 1070
Exhibit List -- Parties' Joint List of the Admitted Exhibits -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1069
NOTICE of Lodging of Defendants Demonstrative Exhibits used at the bench trial by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick)
|
|
Filing 1068
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' April 21, 2021 Letter. (Attachments: #1 Exhibit A-B)(Dellinger, Megan)
|
|
Filing 1067
REDACTED VERSION of #1057 POST Trial Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1066
REDACTED VERSION of #1056 Statement, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1065
Letter to Chief Judge Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Opposing Plaintiffs' Request to Strike DTX 1138 as Set Forth in Plaintiffs' Post-Trial Reply Brief - re #1054 POST Trial Brief,. (Gattuso, Dominick)
|
|
Filing 1064
REDACTED VERSION of #1053 Amended Document by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1063
REDACTED VERSION of #1052 POST Trial Brief, by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1062
REDACTED VERSION of #1054 POST Trial Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1061
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Hyperlinked Post-Trial Briefs. (Phillips, John)
|
|
Filing 1060
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Hyperlinked Post Trial Briefs. (Dellinger, Megan)
|
|
Filing 1059
POST TRIAL BRIEF -- (Corrected) Plaintiffs' Post Trial Brief on Validity (D.I. 1045) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1058
STATEMENT re #1044 Proposed Findings of Fact (Corrected) Findings of Fact on Validity by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1057
[SEALED] POST TRIAL BRIEF -- (Corrected) Plaintiffs' Opening Post Trial Brief on Infringement (D.I. 1013) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1056
[SEALED] STATEMENT re #1012 Proposed Findings of Fact (Corrected) Findings of Fact on Infringement by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1055
NOTICE requesting Clerk to remove Stephen F. Raiola as co-counsel.. (Dellinger, Megan)
|
|
Filing 1054
[SEALED] POST TRIAL BRIEF [Plaintiffs' Reply Post Trial Brief on Infringement] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1053
[SEALED] AMENDED DOCUMENT by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. Amendment to #1046 Proposed Findings of Fact (Corrected). (Haney, Megan)
|
|
Filing 1052
[SEALED] POST TRIAL BRIEF Defendants' Reply Post-Trial Brief on the Invalidity of the Asserted Claims of U.S. Patent Nos. 7,144,884, 8,476,279, 9,090,575, 9,125,910 and 9,278,096 by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
SO ORDERED, re #1049 STIPULATION TO EXTEND TIME Deadline for defendants to file redacted versions of Defendants' Post Trial Proposed Findings of Fact on Non-Infringement and Defendants' Post-Trial Brief on Non-Infringement to April 6, 2021 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/6/21. (ntl)
|
|
Filing 1051
REDACTED VERSION of #1046 Proposed Findings of Fact by Sigmapharm Laboratories LLC. (Haney, Megan)
|
|
Filing 1050
REDACTED VERSION of #1047 POST Trial Brief by Sigmapharm Laboratories LLC. (Haney, Megan)
|
|
Filing 1049
STIPULATION TO EXTEND TIME Deadline for defendants to file redacted versions of Defendants' Post Trial Proposed Findings of Fact on Non-Infringement and Defendants' Post-Trial Brief on Non-Infringement to April 6, 2021 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1048
STATEMENT -- Parties' Joint Errata Sheets for Trial Transcripts January 15-January 28, 2021 -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1047
[SEALED] POST TRIAL BRIEF Defendants' Post-Trial Brief on Non-Infringement by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1046
[SEALED] Proposed Findings of Fact by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1045
POST TRIAL BRIEF [Plaintiffs' Post Trial Brief on Validity] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1044
Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1043
Official Transcript of Case Management Conference held on June 19, 2018 before Chief Judge Leonard P. Stark. Court Reporter/Transcriber Stacy Ingram of Hawkins Reporting, phone (302) 658-6697. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/16/2021. Redacted Transcript Deadline set for 4/26/2021. Release of Transcript Restriction set for 6/24/2021. (bpg)
|
|
Filing 1042
REDACTED VERSION of #1012 Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1041
REDACTED VERSION of #1013 POST Trial Brief by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
SO ORDERED, re #1040 STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of Plaintiffs' Proposed Findings of Fact and Opening Post-Trial Brief to March 15, 2021 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 3/15/21. (ntl)
|
|
Filing 1040
STIPULATION TO EXTEND TIME for Plaintiffs to file redacted versions of Plaintiffs' Proposed Findings of Fact and Opening Post-Trial Brief to March 15, 2021 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1039
Official Transcript of Bench Trial - Volume I held on January 28, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1038
[SEALED] Transcript of Bench Trial - Volume H held on January 27, 2021 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 1037
Official Transcript of Bench Trial - Volume H held on January 27, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1036
[SEALED] Transcript of Bench Trial - Volume G held on January 26, 2021 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 1035
Official Transcript of Bench Trial - Volume G held on January 26, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1034
[SEALED] Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 1033
[SEALED] Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg)
|
|
Filing 1032
Official Transcript of Bench Trial - Volume F held on January 25, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1031
Official Transcript of Bench Trial - Volume E held on January 22, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1030
[SEALED] Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 1029
[SEALED] Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg)
|
|
Filing 1028
Official Transcript of Bench Trial - Volume D held on January 21, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg)
|
|
Filing 1027
[SEALED] Transcript of Bench Trial - Volume C held on January 20, 2021 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 1026
[SEALED] Transcript of Bench Trial - Volume C held on January 20, 2021 before Judge Chief Judge Leonard P. Stark. Lundbeck and Sigmapharm sealed transcript. (bpg)
|
|
Filing 1025
Official Transcript of Bench Trial - Volume C held on January 20, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg)
|
|
Filing 1024
[SEALED] Transcript of Bench Trial - Volume B held on January 19, 2021 before Chief Judge Leonard P. Stark.(bpg)
|
|
Filing 1023
Official Transcript of Bench Trial - Volume B held on January 19, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1022
[SEALED] Transcript of Bench Trial - Volume A held on January 15, 2021 before Judge Chief Leonard P. Stark. (bpg)
|
|
Filing 1021
Official Transcript of Bench Trial - Volume A held on January 15, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021.(bpg)
|
|
Filing 1020
Official Transcript of Pretrial Conference held on January 8, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/5/2021. Redacted Transcript Deadline set for 4/12/2021. Release of Transcript Restriction set for 6/10/2021. (bpg)
|
|
Filing 1019
Redaction of #1004 Transcript. Telephone Conference held on February 10, 2021.(bpg)
|
|
Filing 1018
REDACTED VERSION of #1010 Proposed Findings of Fact by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1017
REDACTED VERSION of #1011 POST Trial Brief by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1016
REDACTED VERSION of #1009 MOTION to Redact #1004 Transcript,, (Unopposed) by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Proposed Order)(Haney, Megan)
|
|
Filing 1015
ORDER re #1009 MOTION to Redact #1004 Transcript (Unopposed) filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 3/9/21. (ntl)
|
|
Filing 1014
NOTICE of Lodging of demonstrative exhibits used at bench trial by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (Dellinger, Megan)
|
|
Filing 1013
[SEALED] POST TRIAL BRIEF by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1012
[SEALED] Proposed Findings of Fact by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1011
[SEALED] POST TRIAL BRIEF Defendants' Opening Post-Trial Brief on Invalidity by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1010
[SEALED] Proposed Findings of Fact by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 1009
[SEALED] MOTION to Redact #1004 Transcript,, (Unopposed) - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Proposed Order)(Haney, Megan)
|
|
Filing 1008
REDACTED VERSION of #1005 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1)(Dellinger, Megan)
|
|
Filing 1007
REDACTED VERSION of #1001 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 1006
ORAL ORDER: Having reviewed the parties' February 12 letter (D.I. 1005), IT IS HEREBY ORDERED that Plaintiffs' proposal for post-trial submissions as set out in that letter (id. at 2) is ADOPTED. IT IS FURTHER ORDERED that no later than April 16 the parties shall submit electronic versions of all briefs with hyperlinks to all exhibits. ORDERED by Judge Leonard P. Stark on 2/15/21. (ntl)
|
|
Filing 1005
[SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Post-Trial Briefing. (Attachments: #1 Exhibit 1)(Blumenfeld, Jack)
|
|
Filing 1004
[SEALED] Official Transcript of Telephone Conference held on February 10, 2021 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. (bpg) Modified on 3/9/2021 (ntl).
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 2/10/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 1003
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Post-Trial Briefing - re #1001 Letter, 1000 Order,,,,,,,. (Attachments: #1 Exhibit 1)(Phillips, John)
|
|
Filing 1002
ORAL ORDER: Having reviewed today's letter from Plaintiffs (D.I. 1001), and understanding that Defendants evidently do not oppose the briefing schedule and page limits ordered yesterday by the Court (D.I. 1000), IT IS HEREBY ORDERED that the Court will hold a status teleconference tomorrow, February 10, at 3pm to discuss with the parties whether the Court should modify the schedule and page limits it has set out and to address how and when issues relating to invalidity will be briefed. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 2/9/21. (ntl)
|
|
Filing 1001
[SEALED] Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding post-trial briefing - re 1000 Order,,,,,,,. (Attachments: #1 Exhibits 1-2)(Blumenfeld, Jack)
|
|
Filing 1000
ORAL ORDER: Having reviewed the parties' letter regarding the post-trial briefing schedule (D.I. 999), which appears to contemplate in excess of 500 pages of briefing and an additional almost 500 pages of proposed findings of fact, having further considered that the parties propose to take three months to complete briefing and have made no proposal (to date) "regarding potential launches discussed at the conclusion of the trial" (id. at 2), and considering the Court's schedule and other commitments as well as its detailed familiarity with the extensive record created at the recent trial, IT IS HEREBY ORDERED that the parties' proposal is REJECTED. Instead, IT IS FURTHER ORDERED that the following page limits and schedule shall apply: (i) on infringement, Plaintiffs' opening briefing of no more than 100 pages and findings of fact of no more than 100 pages are due on February 23; (ii) on infringement, answering briefing of no more than 100 pages (in total, adding up all Defendants' briefs) and findings of fact of no more than 100 pages (in total, adding up all Defendants' proposals) are due on March 16, 2021; and (iii) on infringement, Plaintiffs' reply briefing of no more than 50 pages is due on March 26. Briefing on invalidity will proceed according to a separate schedule with separate page limits after the Court receives further input from the parties. Any party that strenuously objects to this Order shall, no later than 12:00 p.m. tomorrow, February 9, submit a short letter brief requesting reconsideration and including a proposal more reasonable than the one the Court has today rejected. In the absence of any such request, the Court will adhere to this Order and, in that instance, the parties are further directed to submit (by no later than February 10) a revised proposal(s) for briefing the invalidity issues. ORDERED by Judge Leonard P. Stark on 2/8/21. (ntl)
|
|
Filing 999
Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding post-trial briefing schedule. (Blumenfeld, Jack)
|
|
Filing 998
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding status report. (Phillips, John)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial completed on 1/28/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/27/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/26/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/25/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
SO ORDERED, re #996 MOTION for Pro Hac Vice Appearance of Attorney Stephen F. Raiola filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/25/21. (ntl)
|
|
Filing 997
Redaction of #959 Transcript. Transcript of discovery dispute held on September 25, 2020 before Judge Hall. (bpg)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/22/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 996
MOTION for Pro Hac Vice Appearance of Attorney Stephen F. Raiola - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/21/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/20/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/19/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
SO ORDERED, re #995 Consent Judgment -- Party MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. terminated. Attorney Matthew L. Fedowitz and Geoffrey Graham Grivner terminated. Signed by Judge Leonard P. Stark on 1/19/21. (ntl)
|
|
Filing 995
PROPOSED CONSENT JUDGMENT by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Bench Trial held on 1/15/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
CORRECTING ENTRY: Corrected Exhibit 12 added to D.I. 988 per request of counsel. (ntl)
|
|
Filing 994
ORAL ORDER: The Bench Trial is available to the public using the following dial-in for audio access: 703-552-8058 and the conference code is 646321. Audio reproduction of the proceeding is strictly prohibited. ORDERED by Judge Leonard P. Stark on 1/13/21. (ntl)
|
|
Filing 993
ORAL ORDER: IT IS HEREBY ORDERED that D.I. 794 (a motion to dismiss by former defendants) is DENIED AS MOOT. (See D.I. 946). ORDERED by Judge Leonard P. Stark on 1/8/21. (ntl)
|
|
Filing 992
ORDER re #963 MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/8/21. (ntl)
|
|
Filing 991
MEMORANDUM ORDER re #908 Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 1/8/21. (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Pretrial Conference held on 1/8/2021. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 990
MEMORANDUM ORDER regarding the Court's decisions on motions in limine, pretrial order issues, and other trial related matters. Signed by Judge Leonard P. Stark on 1/7/21. (ntl)
|
|
CORRECTING ENTRY: Attachment 1 of DI 988 replaced with corrected version at the request of counsel. (etg)
|
|
Filing 989
Letter of Request to the Ministry of Justice, Paris, France. Signed by Judge Leonard P. Stark on 12/31/20. (ntl)
|
|
SO ORDERED, re #980 MOTION for Pro Hac Vice Appearance of Attorney Brian Sodikoff filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Leonard P. Stark on 1/5/21. (ntl)
|
|
SO ORDERED, re #983 PROPOSED CONSENT JUDGMENT as to Alkem Laboratories Ltd. Party Alkem Laboratories Ltd. terminated. Attorney Kendall K. Gurule; Pilar Gabrielle Kraman; Adam Wyatt Poff; Tedd W. Van Buskirk; Aaron S. Eckenthal and Russell W. Faegenburg terminated. Signed by Judge Leonard P. Stark on 1/4/21. (ntl)
|
|
Filing 988
[SEALED] Proposed Pretrial Order (Volume 4 of 4 -- Exhibits 12-14) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 12-14)(Dellinger, Megan) (Attachment 1 replaced on 1/7/2021) (etg). (Attachment 1 replaced on 1/15/2021) (ntl).
|
|
Filing 987
[SEALED] Proposed Pretrial Order (Volume 3 of 4 -- Exhibits 3-11) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 3-11)(Dellinger, Megan)
|
|
Filing 986
[SEALED] Proposed Pretrial Order (Volume 2 of 4 -- Exhibits 2-2J) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 2-2J)(Dellinger, Megan)
|
|
Filing 985
[SEALED] Proposed Pretrial Order (Volume 1 of 4 -- Exhibits 1-1J) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-1J)(Dellinger, Megan)
|
|
Filing 984
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Supplemental Objections and Responses to Plaintiffs' Requests for Admissions Nos. 12-16 and Nos. 27-28 [HIGHLY CONFIDENTIAL-SUBJECT TO PROTECTIVE ORDER] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 983
PROPOSED CONSENT JUDGMENT as to Alkem Laboratories Ltd. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 982
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Response to Oral Order - re 979 Order. (Phillips, John)
|
|
Filing 981
Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Court's Oral Order dated December 29, 2020 [D.I. 979] - re 979 Order. (Delcollo, Renee)
|
|
Filing 980
MOTION for Pro Hac Vice Appearance of Attorney Brian Sodikoff - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Pro Hac Vice Attorney Matthew M. Kamps for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 979
ORAL ORDER: IT IS HEREBY ORDERED that Defendants shall file a letter response indicating their position on the Plaintiffs' #978 letter of request by no later than 4:00 pm tomorrow. ORDERED by Judge Leonard P. Stark on 12/29/20. (ntl)
|
|
Filing 978
Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding expert testimony. (Attachments: #1 proposed Letter of Request)(Blumenfeld, Jack)
|
|
Filing 977
ORAL ORDER: IT IS HEREBY ORDERED that, for reasons discussed during the December 9, 2020 teleconference, and having reviewed the parties' joint status report (D.I. 975), the bench trial in this matter is RESCHEDULED and will be held on some or all of the following dates, subject to the parties' time limits: January 15-29, 2021. The pretrial conference will be held on January 8, 2021 at 2:30 p.m. and the proposed pretrial order is due on January 4, 2021. ORDERED by Judge Leonard P. Stark on 12/14/20. (ntl)
|
|
Filing 976
Official Transcript of Telephone Conference held on December 9, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/4/2021. Redacted Transcript Deadline set for 1/11/2021. Release of Transcript Restriction set for 3/11/2021.(bpg)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 12/9/2020. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 975
Joint STATUS REPORT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 974
ORAL ORDER: IT IS HEREBY ORDERED that a status teleconference is scheduled for December 9, 2020 at 4:30 p.m. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that the parties shall submit a joint status report on December 8, 2020. ORDERED by Judge Leonard P. Stark on 12/7/2020. (ntl)
|
|
Filing 973
NOTICE OF SERVICE of Defendants' Notice of Prior Art Under 35 U.S.C. 282 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Pro Hac Vice Attorney Kendall K. Gurule for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
Filing 972
MOTION for Pro Hac Vice Appearance of Attorney Kendall K. Gurule - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Pro Hac Vice Attorney Jonathan B. Turpin for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
SO ORDERED, re #972 MOTION for Pro Hac Vice Appearance of Attorney Kendall K. Gurule filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 12/1/20. (ntl)
|
|
Pro Hac Vice Attorney Stephen R. Howe for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Pro Hac Vice Attorney August Melcher for Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 971
MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Howe and Matthew M. Kamps - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Certification of Stephen R. Howe, #2 Certification of Matthew M. Kamps)(Haney, Megan)
|
|
SO ORDERED, re #969 Consent Judgment -- Party Torrent Pharma Inc., Torrent Pharmaceuticals Limited terminated. Attorney Alton L. Hare, III; Brandon Ryan Harper; Stephanie S. Riley; Hemant Keeto Sabharwal; Cedric C. Y. Tan; Yun Wei; Ahmed Abdel-Rahman and Arthur G. Connolly, III terminated. Signed by Judge Leonard P. Stark on 11/23/20. (ntl)
|
|
SO ORDERED, re #971 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Howe and Matthew M. Kamps filed by Sigmapharm Laboratories LLC, #970 MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin and August Melcher filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 11/23/20. (ntl)
|
|
Filing 970
MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin and August Melcher - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Turpin Pro Hac Certification, #2 Melcher Pro Hac Certification)(Haney, Megan)
|
|
Filing 969
PROPOSED CONSENT JUDGMENT between Lundbeck and Takeda and Torrent by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon)
|
|
Filing 968
NOTICE to Take Deposition of Allan S. Myerson, Ph.D. on November 13, 2020 filed by Sigmapharm Laboratories LLC.(Phillips, John)
|
|
Filing 967
NOTICE to Take Deposition of Dr. Allan S. Myerson on November 16, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 966
NOTICE to Take Deposition of Dr. Allan S. Myerson on November 13, 2020 beginning at 12:00 p.m. filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 965
NOTICE to Take Deposition of Allan S. Myerson on November 12, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 964
REDACTED VERSION of #963 MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-B)(Dellinger, Megan)
|
|
Filing 963
[SEALED] MOTION to Redact #959 Transcript Portions of the September 25, 2020 Discovery Dispute Teleconference Transcript (Unopposed) - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Text of Proposed Order)(Dellinger, Megan)
|
|
Filing 962
REDACTED VERSION of #961 Stipulation and Proposed Order Regarding Evidentiary Treatment by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon)
|
|
SO ORDERED, re #961 STIPULATION and Order Regarding Evidentiary Treatment filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc.. Signed by Judge Leonard P. Stark on 10/23/20. (ntl)
|
|
Filing 961
[SEALED] STIPULATION Regarding Evidentiary Treatment by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Harper, Brandon)
|
|
Filing 960
NOTICE of Intent to Request Redaction by Megan Elizabeth Dellinger re #959 Transcript. (Dellinger, Megan)
|
|
SO ORDERED, re #958 STIPULATION of Dismissal (Partially) Dismissing without Prejudice Counts VII and VIII of Plaintiffs' Third Amended Complaint and Defendant Sandoz Inc.'s Eleventh and Twelfth Counterclaims. Signed by Judge Leonard P. Stark on 10/5/20. (ntl)
|
|
Filing 959
[SEALED] Transcript of discovery dispute held on September 25, 2020 before Judge Hall.. (vjg)
|
|
SO ORDERED, re #955 STIPULATION and [Proposed] Order Permitting Expert Depositions Outside of Discovery Period. Signed by Judge Leonard P. Stark on 10/5/20. (ntl)
|
|
Filing 958
STIPULATION of Dismissal (Partially) Dismissing without Prejudice Counts VII and VIII of Plaintiffs' Third Amended Complaint and Defendant Sandoz Inc.'s Eleventh and Twelfth Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 957
REDACTED VERSION of #952 Letter,, regarding response to Plaintiff discovery dispute letter by Sandoz Inc.. (Attachments: #1 Exhibit 1-4, #2 Exhibit 5, #3 Exhibit 6)(Gattuso, Dominick)
|
|
Filing 956
ORAL ORDER: IT IS HEREBY ORDERED that the transcript of the September 25, 2020 discovery dispute teleconference shall serve as the Order of the Court. ORDERED by Judge Jennifer L. Hall on 9/25/2020. (ceg)
|
|
Filing 955
STIPULATION and [Proposed] Order Permitting Expert Depositions Outside of Discovery Period by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute Teleconference held on 9/25/2020. (*Court Reporter Valerie Gunning.) (ceg)
|
|
SO ORDERED, re #946 Consent Judgment -- Party Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. terminated. Attorney Steven J. Fineman; Yixin H. Tang; Shashank D. Upadhye; Brent A. Batzer and Tyler E. Cragg terminated. Signed by Judge Leonard P. Stark on 9/18/20. (ntl)
|
|
Filing 954
NOTICE of Withdrawal of Certain Pro Hac Counsel by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited (Grivner, Geoffrey)
|
|
Filing 953
REDACTED VERSION of #947 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 952
[SEALED] Letter to The Honorable Jennifer L. Hall from Dominick T. Gattuso, Esq. regarding Response to Plaintiffs Discovery Dispute Letter - re 941 Order Setting Teleconference,,,, #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d.. (Attachments: #1 Exhibit (CONFIDENTIAL) EX 1 to Letter, #2 Exhibit (CONFIDENTIAL EX 2 to Letter, #3 Exhibit (CONFIDENTIAL) EX 3 to Letter, #4 Exhibit (CONFIDENTIAL) EX 4 to Letter, #5 Exhibit (CONFIDENTIAL) EX 5 to Letter, #6 Exhibit (CONFIDENTIAL) EX 6 to Letter, #7 Certificate of Service to Letter)(Gattuso, Dominick)
|
|
Filing 951
NOTICE to Take Deposition of Mendy M. Gould on September 25, 2020, beginning at 9:00 a.m. filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 950
NOTICE to Take Deposition of Mendy M. Gould on September 25, 2020 filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 949
NOTICE to Take Deposition of Roger S. McIntyre, M.D. on September 19, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 948
REDACTED VERSION of #944 Reply to Response to Motion, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 947
[SEALED] Letter to The Honorable Jennifer L. Hall from Jack B. Blumenfeld regarding discovery dispute with Sandoz - re 941 Order Setting Teleconference,,,, #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d.. (Attachments: #1 Exhibits A-H)(Blumenfeld, Jack)
|
|
Filing 946
PROPOSED CONSENT JUDGMENT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 945
NOTICE to Take Deposition of Mickael Morin, Ph.D. on September 16, 2020 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 944
[SEALED] REPLY to Response to Motion re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 943
REDACTED VERSION of #938 Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 942
REDACTED VERSION of #937 Response to Motion,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 941
ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #938 ). A discovery dispute teleconference is scheduled for September 25, 2020 at 2:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than September 15, 2020 the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than September 22, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Counsel shall send dial-in information directly to the Court, no later than 24 hours prior to the hearing, using the following e-mail address: Cailah_Garfinkel@ded.uscourts.gov. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 9/8/2020. (ceg)
|
|
Filing 940
REDACTED VERSION of #934 Stipulation, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Letter to the Court)(Delcollo, Renee)
|
|
Filing 939
NOTICE of Defendants' Notice of Deposition of Dr. Carl C. Peck, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick)
|
|
Filing 938
[SEALED] Joint MOTION for Teleconference to Resolve Discovery Disputes between Plaintiffs and Sandoz Inc. & Lek Pharmaceuticals d.d. - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 937
[SEALED] RESPONSE to Motion re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 936
NOTICE to Take Deposition of Fabia Gozzo on September 3, 2020 filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Harper, Brandon)
|
|
Filing 935
NOTICE to Take Deposition of Fabia Gozzo on September 3, 2020 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
SO ORDERED, re #934 [SEALED] STIPULATION and [Proposed] Order filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 9/1/20. (ntl)
|
|
Filing 934
[SEALED] STIPULATION and [Proposed] Order by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding enclosed Stipulation and Proposed Order)(Delcollo, Renee)
|
|
Filing 933
NOTICE OF SERVICE of Expert Report of Dr. Carl C. Peck, M.D. in Reply to the Rebuttal Expert Report of Dr. Peter Rheinstein filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 932
NOTICE to Take Deposition of Grace Kim on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 931
NOTICE to Take Deposition of Dr. Jacques Ledru on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 930
NOTICE to Take Deposition of Brianne Bharkhda on September 11, 2020 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 929
NOTICE to Take Deposition of Dr. Paul Reider on August 31, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 928
REDACTED VERSION of #910 Declaration,, #911 Declaration, Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-I, #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 927
REDACTED VERSION of #909 Opening Brief in Support,, Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 926
REDACTED VERSION of #904 Letter,, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Exhibit A-D)(Delcollo, Renee)
|
|
Filing 925
REDACTED VERSION of #903 SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely I by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order Proposed Order)(Delcollo, Renee)
|
|
Filing 924
REDACTED VERSION of #906 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Filing 923
REDACTED VERSION of #900 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit 1-2)(Lennon, James)
|
|
Filing 922
REDACTED VERSION of #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit D-E)(Lennon, James)
|
|
Filing 921
REDACTED VERSION of #905 Letter,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 920
NOTICE to Take Deposition of Dr. Gregory M. Mattingly on August 26, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 919
NOTICE of change of State of Incorporation by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick)
|
|
Filing 918
NOTICE to Take Deposition of Grace Kim on September 3, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John)
|
|
Filing 917
NOTICE to Take Deposition of Jacques Ledru on September 2, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John)
|
|
Filing 916
NOTICE to Take Deposition of Brianne Bharkhda on September 1, 2020 filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Phillips, John)
|
|
Filing 915
REDACTED PUBLIC VERSION of #912 [SEALED] ORDER re 899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) filed by Lupin Pharmaceuticals Inc., Lupin Limited is GRANTED. Signed by Judge Leonard P. Stark on 8/20/20. (etg)
|
|
Filing 914
NOTICE of Appearance by Brandon Ryan Harper on behalf of Torrent Pharma Inc., Torrent Pharmaceuticals Limited (Harper, Brandon)
|
|
Filing 913
NOTICE to Take Deposition of Christopher A. Vellturo on August 25, 2020 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 912
[SEALED] ORDER re #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747)filed by Lupin Pharmaceuticals Inc., Lupin Limited is GRANTED. Signed by Judge Leonard P. Stark on 8/20/20. This order has been emailed to local counsel. (ntl)
|
|
CORRECTING ENTRY: Corrected document added to D.I. 907 per request of counsel. (ntl)
|
|
CORRECTING ENTRY: Text from DI #908 Modified per Counsels Request. (apk)
|
|
Filing 911
[SEALED] DECLARATION re #910 Declaration,, Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit I, #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 910
[SEALED] DECLARATION re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings Declaration of Jieun Lee In Support of Defendants Lek Pharmaceuticals d.d. and Sandoz Inc.'s Motion to Dismiss by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit A-H, #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 909
[SEALED] OPENING BRIEF in Support re #908 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Opening Brief in Support of Their Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Com MOTION for Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc..Answering Brief/Response due date per Local Rules is 9/2/2020. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 908
MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter Defendants Sandoz Inc. And Lek Pharmaceuticals D.D.S Motion for Partial Judgment On The Pleadings As To Counts V-VI of Plaintiffs Third Amended Complaint and To Dismiss For Lack Of Subject Matter Jurisdiction [With Proposed Order], MOTION for Judgment on the Pleadings - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick) Modified on 8/20/2020 (apk).
|
|
Filing 907
NOTICE to Take Deposition of Dr. David MacMillan on August 21, 2020 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) (Main Document 907 replaced on 8/20/2020) (ntl).
|
|
Filing 906
[SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Support of Expedited Motion to Enforce Prior Order and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports - re #900 Letter, #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747), #748 Letter, #764 Letter,. (Lennon, James)
|
|
Filing 905
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s Motion to Expedite to Enforce this Court's Prior Order and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports - re #900 Letter, #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747). (Attachments: #1 Exhibits 1-3)(Dellinger, Megan)
|
|
Filing 904
[SEALED] SEALED Letter to The Honorable Chief Judge Leonard P. Stark from Rene Mosley Delcollo regarding re: Motion to Enforce This Court's Prior Order and Renewed Motion to Strike - re #903 SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely I. (Attachments: #1 Exhibit A-D)(Delcollo, Renee)
|
|
Filing 903
[SEALED] SEALED MOTION to Enforce This Court's Prior Order (D.I. 801) and Renewed Motion to Strike Plaintiffs' Untimely Infringement Contentions (D.I. 749) re 801 Oral Order,,,,,,,,,,,,,, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee)
|
|
Filing 902
NOTICE of Defendants' Notice of Deposition of Dr. Anita Clayton, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick) (Main Document 902 replaced on 8/17/2020) (ntl).
|
|
Filing 901
ORAL ORDER: IT IS HEREBY ORDERED that Lupin's request to expedite consideration of its renewed motion to strike is GRANTED. The Court agrees that this dispute should be resolved in advance of the forthcoming deposition. Accordingly, IT IS FURTHER ORDERED that any party opposing the relief requested by Lupin file a letter brief, not to exceed five pages, no later than tomorrow, August 18; and Lupin may file a reply letter brief, not to exceed two pages, no later than Wednesday, August 19. ORDERED by Judge Leonard P. Stark on 8/17/20. (ntl)
|
|
CORRECTING ENTRY: Corrected document added to D.I. 902 per request of counsel. (ntl)
|
|
CORRECTING ENTRY: Correct exhibits added to D.I. 899-900 per request of counsel. (ntl)
|
|
Filing 900
[SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Support of Expedited Motion to Enforce and Renewed Motion to Strike - re #899 MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747). (Lennon, James) (Additional attachment(s) added on 8/14/2020: #1 Exhibit 1, #2 Exhibit 2) (ntl). Modified on 8/14/2020 (ntl).
|
|
Filing 899
[SEALED] MOTION to Expedite to Enforce this Court's Prior Order (DI 801) and Renewed Motion to Strike Portions of Plaintiffs' Expert Reports (DI 747) - filed by Lupin Limited, Lupin Pharmaceuticals Inc. (Attachments: #1 Exhibit D, #2 Exhibit E)(Lennon, James) (Attachment 1 replaced on 8/14/2020) (ntl). (Attachment 2 replaced on 8/14/2020) (ntl). Modified on 8/14/2020 (ntl).
|
|
Filing 898
NOTICE OF SERVICE of Expert Report of Dr. Carl C. Peck, M.D. in Reply to the Responsive Expert Report of Anthony J. Rothschild, M.D. and the Rebuttal Expert Report of Victor I. Reus, M.D. filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 897
NOTICE of Deposition of Brianne Bharkhda by Lek Pharmaceuticals D.D., Sandoz Inc. (Gattuso, Dominick)
|
|
Filing 896
REDACTED VERSION of #884 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 895
REDACTED VERSION of #883 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 894
REDACTED VERSION of #885 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 893
NOTICE OF SERVICE of Reply Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 892
NOTICE OF SERVICE of Reply Expert Report of Gregory Stephenson, Ph.D. Regarding Invalidity of the Polymorph Patents filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 891
NOTICE OF SERVICE of Reply Expert Report of Dr. Salvatore Lepore filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 890
NOTICE OF SERVICE of Reply Expert Report of Victor L. Reus, M.D. filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 889
NOTICE OF SERVICE of Expert Report of Jonathan W. Steed, Ph.D. in Rebuttal to the Opening Expert Report of Myerson [HIGHLY CONFIDENTIAL] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 888
NOTICE OF SERVICE of Expert Report of Dr. Peter Rheinstein in Rebuttal to the Opening Expert Report of Carl C. Peck, M.D. [HIGHLY CONFIDENTIAL] filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 887
NOTICE OF SERVICE of Defendants' Reply Expert Report of Anthony J. Rothschild, M.D. filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 886
ANSWER to #856 Answer to Amended Complaint, Counterclaim -- Answer to Torrent's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 885
[SEALED] ANSWER to #854 Answer to Amended Complaint, Counterclaim -- Answer to MSN's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 884
[SEALED] ANSWER to #850 Answer to Amended Complaint, Counterclaim -- Answer to Alkem's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 883
[SEALED] ANSWER to #845 Answer to Amended Complaint,, Counterclaim, -- Answer to Sandoz Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 882
REDACTED VERSION of #867 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 881
REDACTED VERSION of #869 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 880
REDACTED VERSION of #868 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 879
[SEALED] SO ORDERED, re #860 PROPOSED CONSENT JUDGMENT between Plaintiffs and Apotex Inc., Apotex Corp., and Apotex Research Private Limited. Signed by Judge Leonard P. Stark on 7/28/20. (ntl)
|
|
Filing 878
NOTICE of Withdrawal of Counsel by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (Dellinger, Megan)
|
|
SO ORDERED, re #861 STIPULATION TO EXTEND TIME for the parties to serve their reply expert reports to dates as outlined in stipulation filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #873 STIPULATION TO EXTEND TIME to file Redacted Version of Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Answer, Defenses, and Counterclaims to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 856) to July 27, 2020 filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 7/28/20. (ntl)
|
|
Filing 877
REDACTED VERSION of #860 Proposed Consent Judgment, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 876
ORAL ORDER: Having reviewed the parties' recent letters relating to expert discovery (D.I. 858, 859, 862, 863, 864), IT IS HEREBY ORDERED that Defendants' request that the Court reconsider its July 6 Order (D.I. 829) is GRANTED to the limited extent that each defendant contesting infringement shall have a maximum of 7 additional hours (not the previously-ordered 4 additional hours) to depose Dr. Myerson and either Dr. Morin or Dr. Gozzo), as applicable, on infringement issues specific and unique to that defendant, provided that each such defendant shall notify Plaintiffs in advance of the beginning of expert depositions how many hours each defendant seeks to use with which of Drs. Myerson, Morin, and Gozzo. Reconsideration is warranted because 7 additional hours is the amount of time Plaintiffs had proposed and the Court does not intend to provide Defendants fewer hours than even Plaintiffs proposed. ORDERED by Judge Leonard P. Stark on 7/28/20. (ntl) Modified on 7/28/2020 (ntl).
|
|
Filing 875
ORAL ORDER: Having reviewed the joint status report (D.I. 839), as well as subsequent letters of July 22 and 23, IT IS HEREBY ORDERED that Plaintiffs and/or the Sandoz Defendants may file a motion to dismiss any claims or counterclaims relating to the '910 and/or '096 patents, but the Court is not granting any relief at this time based on the status report and any limited argument that has been provided to date. ORDERED by Judge Leonard P. Stark on 7/28/20. (ntl)
|
|
Filing 874
REDACTED VERSION of #856 Answer to Amended Complaint, Counterclaim by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie)
|
|
SO ORDERED, re #871 STIPULATION TO EXTEND TIME to Respond to Sandoz's Counterclaims to July 31, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/27/20. (ntl)
|
|
Filing 873
STIPULATION TO EXTEND TIME to file Redacted Version of Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Answer, Defenses, and Counterclaims to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 856) to July 27, 2020 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie)
|
|
Filing 872
REDACTED VERSION of #854 Answer to Amended Complaint, Counterclaim by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey)
|
|
Filing 871
STIPULATION TO EXTEND TIME to Respond to Sandoz's Counterclaims to July 31, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 870
ANSWER to #844 Answer to Amended Complaint, Counterclaim -- Answer to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 869
[SEALED] ANSWER to #846 Answer to Amended Complaint, Counterclaim -- Answer to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 868
[SEALED] ANSWER to #843 Answer to Amended Complaint, Counterclaim -- Answer to Prinston Pharmaceutical Inc.'s Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 867
[SEALED] ANSWER to #841 Answer to Amended Complaint, Counterclaim -- Answer to Lupin Limited's Counterclaims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 866
REDACTED VERSION of #850 Answer to Amended Complaint, Counterclaim by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 865
REDACTED VERSION of #855 Answer to Amended Complaint by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Filing 864
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Plaintiffs letter filed July 22, 2020 - re #863 Letter. (Gattuso, Dominick)
|
|
Filing 863
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding depositions - re #862 Letter. (Dellinger, Megan)
|
|
Filing 862
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esq. regarding Plaintiffs' July 20, 2020 letter - re #859 Letter. (Gattuso, Dominick)
|
|
Filing 861
STIPULATION TO EXTEND TIME for the parties to serve their reply expert reports to dates as outlined in stipulation - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 860
[SEALED] PROPOSED CONSENT JUDGMENT between Plaintiffs and Apotex Inc., Apotex Corp., and Apotex Research Private Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 859
Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding defendants' request for more deposition hours - re #858 Letter. (Blumenfeld, Jack)
|
|
Filing 858
Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Clarification of July 6, 2020 Oral Order - re 829 Order,,,,,,,,,,,, Set Deadlines/Hearings,,,,,,,,,,,. (Phillips, John)
|
|
Filing 857
REDACTED VERSION of #846 Answer to Amended Complaint, Counterclaim to Third Amended Complaint by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly)
|
|
Filing 856
[SEALED] ANSWER to Amended Complaint, re: #811 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Attachments: #1 Certificate of Service)(Riley, Stephanie)
|
|
Filing 855
[SEALED] ANSWER to Amended Complaint, re: #812 Amended Complaint, Affirmative Defenses by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Phillips, John)
|
|
Filing 854
[SEALED] ANSWER to Amended Complaint, re: #807 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 853
REDACTED VERSION of #841 Answer to Amended Complaint, Counterclaim by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Filing 852
REDACTED VERSION of #843 Answer to Amended Complaint, Counterclaim by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Cragg, Tyler)
|
|
Filing 851
REDACTED VERSION of #842 Answer to Amended Complaint, Counterclaim by Apotex Corp., Apotex Inc.. (Dorsney, Kenneth)
|
|
Filing 850
[SEALED] ANSWER to Amended Complaint, re: #803 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 849
REDACTED VERSION of #845 Answer to Amended Complaint,, Counterclaim, Defendants Answer and Affirmative Defenses and Sandoz's Counterclaims to the Third Amended Complaint for Patent Infringement, by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 848
ANSWER to #831 Answer to Amended Complaint, Counterclaim -- Answer to Sigmapharm Laboratories, LLC's Counterclaims to Second Amended Complaint -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 847
REDACTED VERSION of #839 Status Report, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 846
[SEALED] ANSWER to Amended Complaint, re: #806 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 845
[SEALED] ANSWER to Amended Complaint, re: #809 Amended Complaint, with Jury Demand Defendants Answer and Affirmative Defenses and Sandozs Counterclaims to the Third Amended Complaint for Patent Infringement, COUNTERCLAIM against All Plaintiffs by Sandoz Inc., Lek Pharmaceuticals D.D.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 844
ANSWER to Amended Complaint, re: #802 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc..(Farnan, Kelly)
|
|
Filing 843
[SEALED] ANSWER to Amended Complaint, re: #808 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc..(Fineman, Steven)
|
|
Filing 842
[SEALED] ANSWER to Amended Complaint, re: #804 Amended Complaint, the third amended complaint, COUNTERCLAIM against All Plaintiffs by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Filing 841
[SEALED] ANSWER to Amended Complaint, re: #805 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
SO ORDERED, re #819 Stipulation, filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #818 STIPULATION TO EXTEND TIME for Plaintiffs and Defendants Sandoz Inc. and Lek Pharmaceuticals d.d. to Submit Their Joint Status Report to July 8, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #840 STIPULATION TO EXTEND TIME for Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. to answer, move or otherwise respond to Plaintiffs' Third Amended Complaint for Patent Infringement against Zydus Pharmaceuticals (USA) Inc. and filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd., #817 STIPULATION TO EXTEND TIME for the parties to submit their joint letter regarding expert discovery to July 1, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #821 STIPULATION TO EXTEND TIME by which Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. shall respond to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 811) to July 17, 2020 filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc. Signed by Judge Leonard P. Stark on 7/10/20. (ntl)
|
|
Filing 840
STIPULATION TO EXTEND TIME for Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. to answer, move or otherwise respond to Plaintiffs' Third Amended Complaint for Patent Infringement against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (D.I. 812) to July 17, 2020 - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
SO ORDERED, re #838 STIPULATION TO EXTEND TIME for Alkem to Respond to 3rd Amended Complaint to July 17, 2020 filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 7/9/20. (ntl)
|
|
Filing 839
[SEALED] Joint STATUS REPORT (Plaintiffs' and Sandoz Defendants') by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 838
STIPULATION TO EXTEND TIME for Alkem to Respond to 3rd Amended Complaint to July 17, 2020 - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 837
REDACTED VERSION of #804 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-F)(Dellinger, Megan)
|
|
Filing 836
REDACTED VERSION of #819 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 835
REDACTED VERSION of #831 Answer to Amended Complaint, Counterclaim by Sigmapharm Laboratories LLC. (Phillips, John)
|
|
Filing 834
STIPULATION TO EXTEND TIME For MSN Defendants to Answer Second Amended Complaint to July 17, 2020 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey)
|
|
SO ORDERED, re #834 STIPULATION TO EXTEND TIME For MSN Defendants to Answer Second Amended Complaint to July 17, 2020 filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 7/7/20. (ntl)
|
|
Filing 833
REDACTED VERSION of #811 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 832
REDACTED VERSION of #812 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan)
|
|
Filing 831
[SEALED] ANSWER to Amended Complaint, re: #810 Amended Complaint, Affirmative Defenses, and, COUNTERCLAIM against All Plaintiffs by Sigmapharm Laboratories LLC.(Phillips, John)
|
|
Filing 830
REDACTED VERSION of #806 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 829
ORAL ORDER: IT IS HEREBY ORDERED that, for reasons discussed during the recent teleconference (see D.I. 815), and having reviewed the parties' joint letter (D.I. 820), the bench trial in this matter is RESCHEDULED and will be held on some or all of the following dates, subject to the parties' time limits: January 4-8 and January 26-29, 2021. The pretrial conference will be held on December 22, 2020 at 4:00 p.m. and the proposed pretrial order is due on December 15. As the parties have agreed, the expert discovery deadline is now September 25, 2020. IT IS FURTHER ORDERED that: (i) Dr. Myerson's deposition on common issues of infringement and invalidity will not last more than 7 hours; (ii) each defendant contesting infringement (nine defendants) shall have a maximum of 4 additional hours to depose Dr. Myerson and either Dr. Morin (five defendants) or Dr. Gozzo (three defendants), as applicable, on infringement issues specific and unique to that defendant, provided that each such defendant shall notify Plaintiffs in advance of the beginning of expert depositions how many hours each defendant seeks to use with which of Drs. Myerson, Morin, and Gozzo; (iii) Dr. MacMillan's deposition will be limited to 9 hours; (iv) Dr. Lepore's deposition will be limited to 9 hours; (v) Dr. Rothschild's deposition will be limited to 14 hours; and (vi) all other depositions will be limited to 7 hours. The Court believes these limits reflect a reasonable and appropriate exercise of the Court's discretion, considering all circumstances, including the fact that this consolidated case is, in reality, multiple cases, and that each defendant asserting non-infringement must be given a full and fair opportunity to conduct expert discovery in preparation for trial. Plaintiffs' complaint that the aspects of Defendants' proposal the Court has adopted "would allow Defendants much more time with Plaintiffs' experts" is unpersuasive under the circumstances. Finally, IT IS ALSO ORDERED that: (i) Defendants' request for leave to serve a responsive expert report to Dr. Peck is GRANTED; (ii) Defendants shall file their responsive expert report two weeks from the date Plaintiffs approve their expert; and (iii) Plaintiffs may file a reply report no later than two weeks before Dr. Peck's deposition. Allowing Defendants to file a responsive report is justified and harmless because the Court only recently denied Defendants' motion to strike Dr. Peck's report, there is sufficient time in the schedule to allow all parties to take reasonable and necessary discovery on the issues addressed by Dr. Peck (and there is good cause for the further scheduling order modification requested by Defendants), and the Court will find having a full record on these issues useful to it as factfinder. ORDERED by Judge Leonard P. Stark on 7/6/20. (ntl)
|
|
Filing 828
REDACTED VERSION of #810 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 827
REDACTED VERSION of #809 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 826
REDACTED VERSION of #808 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 825
REDACTED VERSION of #807 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 824
REDACTED VERSION of #805 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan)
|
|
Filing 823
REDACTED VERSION of #803 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 822
REDACTED VERSION of #802 Amended Complaint, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 821
STIPULATION TO EXTEND TIME by which Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. shall respond to Plaintiffs' Second Amended Complaint for Patent Infringement (D.I. 811) to July 17, 2020 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie)
|
|
Filing 820
Joint Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Expert Discovery. (Dellinger, Megan)
|
|
Filing 819
[SEALED] Joint STIPULATION and [Proposed] Order Concerning Certain Documents and Facts by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 818
STIPULATION TO EXTEND TIME for Plaintiffs and Defendants Sandoz Inc. and Lek Pharmaceuticals d.d. to Submit Their Joint Status Report to July 8, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 817
STIPULATION TO EXTEND TIME for the parties to submit their joint letter regarding expert discovery to July 1, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 816
REPLY to Response to Motion re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 filed by Prinston Pharmaceutical Inc.. (Fineman, Steven)
|
|
Filing 815
Official Transcript of Telephone Conference on June 26, 2020 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, e-mail: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 7/20/2020. Redacted Transcript Deadline set for 7/30/2020. Release of Transcript Restriction set for 9/28/2020. (bpg)
|
|
Document Unsealed -- #813 Memorandum Order. (ntl)
|
|
Filing 814
ORDER re #813 Memorandum Order -- #415 MOTION to Dismiss and for partial Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 6/26/20. (ntl)
|
|
Filing 813
MEMORANDUM ORDER re #415 MOTION to Dismiss and for for Partial Judgment on the Pleadings filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 6/26/20. This order has been emailed to local counsel. (ntl) (Main Document 813 replaced on 6/26/2020) (ntl). (Main Document 813 UNSEALED and replaced on 6/29/2020) (ntl). Modified on 6/29/2020 (ntl).
|
|
Filing 812
[SEALED] Third AMENDED COMPLAINT against Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan)
|
|
Filing 811
[SEALED] Second AMENDED COMPLAINT against Torrent Pharma Inc., Torrent Pharmaceuticals Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 810
[SEALED] Second AMENDED COMPLAINT against Sigmapharm Laboratories LLC- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 809
[SEALED] Third AMENDED COMPLAINT against Lek Pharmaceuticals D.D., Sandoz Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 808
[SEALED] Third AMENDED COMPLAINT against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 807
[SEALED] Second AMENDED COMPLAINT against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 806
[SEALED] Third AMENDED COMPLAINT against Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 805
[SEALED] Second AMENDED COMPLAINT against Lupin Limited, Lupin Pharmaceuticals Inc.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan)
|
|
Filing 804
[SEALED] Third AMENDED COMPLAINT against Apotex Corp., Apotex Inc., Apotex Research Private Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 803
[SEALED] Third AMENDED COMPLAINT against Alkem Laboratories Ltd.- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 802
[SEALED] Third AMENDED COMPLAINT against Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited- filed by Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 6/26/2020. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 801
ORAL ORDER: Having reviewed the parties' various filings relating to pending motions, IT IS HEREBY ORDERED that: (i) Plaintiffs' motion for leave to file amended complaints to add induced infringement of the '096 patent (D.I. 727) is GRANTED - Plaintiffs have demonstrated good cause and exercised diligence, given the timing with respect to which certain FDA label-related decisions were made and provided to Plaintiffs by certain Defendants; the allegations of induced infringement are not futile and will not cause undue prejudice to Defendants; also, judicial economy favors granting leave to resolve all disputes in a single trial; (ii) Lupin's and Macleods' motions to strike portions of Plaintiffs' expert reports served on April 16, 2020 (D.I. 747, 749) are GRANTED - Plaintiffs' parroting of Markush group claim language did not, in the context of the entirety of Plaintiffs' disclosures throughout this case (including especially the final infringement contentions), give these Defendants fair and timely notice that they were accused of infringement due to the presence of potentially every component of that group, and Plaintiffs have no persuasive explanation for taking until a month after final contentions were due (and many months after sample products were provided to and then tested by Plaintiffs) before adding the challenged contention in an expert report; allowing this new contention now would unduly prejudice Lupin and Macleods (who could have approached their infringement and/or invalidity cases differently had Plaintiffs made the new form allegation during fact discovery); nor do the other Pennypack factors help Plaintiffs (who can still proceed on their other timely-asserted claims of infringement of the '630 patent, who appear to have acted in willful disregard of their final infringement contentions deadline, and who have prejudiced and surprised these Defendants in a way that cannot easily be cured without disrupting the trial schedule); and (iii) Defendants' motion to strike the expert report of Dr. Carl Peck (D.I. 767) is DENIED, as the Court expects it will find his testimony (which the Court is not persuaded will be cumulative, improper legal opinion, or improper testimony about FDA intent or state of mind) helpful to it in its role as factfinder. IT IS FURTHER ORDERED that the teleconference tomorrow will not address the now-resolved motions but will instead be devoted to beginning a conversation about the timing and logistics of the remaining expert discovery and trial, all of which have been complicated by the ongoing effects of the coronavirus pandemic. (See generally D.I. 800) In preparation for that discussion, the parties are advised of the following: (i) due to the pandemic, the Court has had to reschedule five jury trials (including a high-priority detained defendant criminal trial) into the same slot in which the bench trial in this case is currently scheduled (October 13-23); (ii) the next open calendar slot during which the Court could give this case five or more largely consecutive, largely uninterrupted trial days is not until 2021; and (iii) the Court will be considering the possibility of conducting this trial remotely (where only court personnel - and no attorneys or witnesses - are in the courtroom) or partially-remotely (where a small number of lawyers and some of the witnesses are in the courtroom but most participants appear remotely) and to conducting it "after-hours" and on non-consecutive days, in an effort to hold the trial in a safe manner sometime during 2020. ORDERED by Judge Leonard P. Stark on 6/25/20. (ntl)
|
|
Filing 800
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Scheduling and Logistical Issues Related to Expert Depositions and Trial. (Dellinger, Megan)
|
|
Filing 799
RESPONSE to Motion re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-B)(Dellinger, Megan)
|
|
Filing 798
ORAL ORDER: IT IS HEREBY ORDERED that the Telephone Conference on June 26, 2020 will begin at 2:30 PM. ORDERED by Judge Leonard P. Stark on 6/23/20. (ntl)
|
|
Filing 797
SO ORDERED, re #796 Consent Judgment -- Party Unichem Laboratories, Limited, Unichem Laboratories, Limited and Unichem Laboratories, Limited terminated. Attorney Michael J. Fink; Megan C. Haney; P. Branko Pejic; John C. Phillips, Jr; David A. Bilson and Paul A. Braier terminated. Signed by Judge Leonard P. Stark on 6/18/20. (ntl)
|
|
Filing 796
PROPOSED CONSENT JUDGMENT between Plaintiffs and Unichem Laboratories, Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 795
DECLARATION re #794 MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 [Brent Batzer] by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Exhibit 1)(Fineman, Steven)
|
|
Filing 794
MOTION to Dismiss Based upon Defendant Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd's Counterclaims Pertaining to U.S. Patent Nos. 9,125,908 and 9,125,909 - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Text of Proposed Order)(Fineman, Steven)
|
|
Filing 793
NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Bart Kahr, Ph.D. filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 792
NOTICE OF SERVICE of Rebuttal Expert Report of Raj Suryanarayanan, Ph.D. filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 791
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Rebuttal Noninfringement Expert Report of Jennifer Swift, Ph.D. filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 790
NOTICE OF SERVICE of Rebuttal Expert Report of Dr. William E. Mayo Regarding NonInfringement of U.S. Patent Nos. 8,722,684, 8,969,355, 9,227,946, 9,861,630 and 9,278,096 filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 789
NOTICE OF SERVICE of Responsive Expert Report of Anthony J. Rothschild and, M.D. and Rebuttal Expert Report of Victor I. Reus, M.D. filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 788
NOTICE OF SERVICE of Rebuttal Expert Report of Salvatore Lepore, Ph.D. filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 787
NOTICE OF SERVICE of the Rebuttal Expert Report of Michael Zaworotko, Ph.D. and the Rebuttal Expert Report of Dr. Mark D. Hollingsworth, Ph.D. on Behalf of Sigmapharm Laboratories, LLC filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 786
NOTICE OF SERVICE of Rebuttal Expert Report of Mark J. Sacchetti, Ph.D. Regarding Noninfringement filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 785
NOTICE OF SERVICE of Expert Opinion filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 784
NOTICE OF SERVICE of Rebuttal Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 783
REDACTED VERSION of #777 Letter, Reply Letter Regarding their Motion to Strike the Expert Report of Dr. Carl Peck, M.D by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 782
NOTICE OF SERVICE of Rebuttal Expert Report filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 781
NOTICE OF SERVICE of Expert Report of Jonathan W. Steed Ph.D. in Rebuttal to the Opening Expert Report of Myerson filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 780
ORAL ORDER: IT IS HEREBY ORDERED that argument on #767 MOTION to Strike will also be heard during the June 26 teleconference. ORDERED by Judge Leonard P. Stark on 6/5/20. (ntl)
|
|
SO ORDERED, re #776 STIPULATION for Leave to File a Motion to Dismiss Certain of Their Counterclaims filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 6/4/20. (ntl)
|
|
SO ORDERED, re #775 STIPULATION TO EXTEND TIME Rebuttal Expert Reports and Reply Expert Reports to June 5, 2020 and July 24, 2020 respectively filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 6/4/20. (ntl)
|
|
Filing 779
REDACTED VERSION of #774 Letter, by Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 778
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding a Request for Teleconference on Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck, #774 Letter, #777 Letter, #768 Letter,. (Gattuso, Dominick)
|
|
Filing 777
[SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Defendants' Reply Letter regarding their Motion to Strike the Expert Report of Dr. Carl Peck, M.D.. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 776
STIPULATION for Leave to File a Motion to Dismiss Certain of Their Counterclaims by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Mowery, Katharine)
|
|
Pro Hac Vice Attorney Karen L. Beckman for Macleods Pharma USA, Inc.,Karen L. Beckman for Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
Filing 775
STIPULATION TO EXTEND TIME Rebuttal Expert Reports and Reply Expert Reports to June 5, 2020 and July 24, 2020 respectively - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Filing 774
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck, #768 Letter,. (Attachments: #1 Exhibits 1-3)(Dellinger, Megan)
|
|
Filing 773
REDACTED VERSION of #768 Letter, Defendants' Opening Letter Regarding their Motion to Strike The Expert Report of Dr. Carl Peck, M.D. by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-D [Shall Remain Under Seal], #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 772
ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear argument by teleconference on the motions to amend and to strike (D.I. 727, 747, 749) on June 26, 2020 beginning at 1:30 p.m. Any party wishing to refer to slides or other materials shall provide a copy to the Court no later than 4:00 p.m. the day before the hearing. The parties can access the teleconference by dialing 877-336-1829 and using the access code 1408971. ORDERED by Judge Leonard P. Stark on 5/27/20. (ntl)
|
|
Filing 771
REDACTED VERSION of #762 Letter, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Delcollo, Renee)
|
|
Filing 770
REDACTED VERSION of #757 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan)
|
|
Filing 769
SO ORDERED, re #761 Consent Judgment -- Party Hetero Labs Limited Unit-V, Hetero Labs Limited Unit-V, Hetero USA Inc., Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited terminated. Attorney John M. Seaman; A. Neal Seth; April M. Kirby and Alexander B. Owczarczak terminated. Signed by Judge Leonard P. Stark on 5/20/20. (ntl)
|
|
Filing 768
[SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Motion to Strike - re #767 MOTION to Strike The Expert Report of Carl C. Peck. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 767
MOTION to Strike The Expert Report of Carl C. Peck - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Attachments: #1 Exhibit Certification Pursuant to 7.1.1, #2 Text of Proposed Order [Proposed] Order)(Gattuso, Dominick)
|
|
Filing 766
REDACTED VERSION of #756 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 765
Letter to The Honorable Leonard P. Stark from James M. Lennon regarding requesting a teleconference on Defendants' Motion to Strike Portions of Plaintiffs' Expert Reports to Lupin - re #748 Letter, #756 Letter, #764 Letter, #747 MOTION to Strike portions of Plaintiffs' expert report. (Lennon, James)
|
|
Filing 764
[SEALED] Letter to The Honorable Leonard P. Stark from James M. Lennon regarding Reply in Support of Defendants' Motion to Strike Portions of Plaintiffs' Expert Reports to Lupin - re #756 Letter, #750 Letter, #747 MOTION to Strike portions of Plaintiffs' expert report, #762 Letter,. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Lennon, James)
|
|
Filing 763
Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding the parties request a teleconference re Defendants' Motion to Strike Plaintiffs UntimelyInfringement Contentions D.I. 749 - re #750 Letter, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions, #757 Letter, #762 Letter,. (Delcollo, Renee)
|
|
Filing 762
[SEALED] SEALED Letter to The Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Reply In Support of Its Motion to Strike Plaintiffs Untimely Infringement Contentions - re #750 Letter, #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions. (Delcollo, Renee)
|
|
Filing 761
PROPOSED CONSENT JUDGMENT between Plaintiffs and Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 760
NOTICE to Take Deposition of Chintan Dholakia on May 20, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 759
SUBPOENA Returned Executed as to Dr. Roger McIntyre on May 5, 2020 (Phillips, John)
|
|
Filing 758
SUBPOENA Returned Executed as to Anita Louise Hammer Clayton, M.D. on May 1, 2020 (Phillips, John)
|
|
Filing 757
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Macleods' Motion to Strike Plaintiffs' Infringement Contentions. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan)
|
|
Filing 756
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Lupin's Motion to Strike Portions of Expert Reports. (Attachments: #1 Exhibit 1-3, #2 Exhibit 4-5, #3 Exhibit 6-8)(Dellinger, Megan)
|
|
Filing 755
REDACTED VERSION of #748 Letter, by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit 1-5)(Lennon, James)
|
|
Filing 754
REDACTED VERSION of #747 MOTION to Strike portions of Plaintiffs' expert report by Lupin Limited, Lupin Pharmaceuticals Inc.. (Attachments: #1 Exhibit A-C)(Lennon, James)
|
|
Filing 753
REDACTED VERSION of #750 Letter, by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Exhibit 1-4)(Delcollo, Renee)
|
|
Filing 752
REDACTED VERSION of #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee)
|
|
Filing 751
STATEMENT re #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Delcollo, Renee)
|
|
Filing 750
[SEALED] Letter to Honorable Chief Judge Leonard P. Stark from Renee Mosley Delcollo regarding Motion to Strike - re #749 MOTION to Strike Plaintiffs' Untimely Infringement Contentions. (Attachments: #1 Exhibit 1 - 4)(Delcollo, Renee)
|
|
Filing 749
[SEALED] MOTION to Strike Plaintiffs' Untimely Infringement Contentions - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: #1 Text of Proposed Order)(Delcollo, Renee)
|
|
CORRECTING ENTRY: Motion and letter docketed at D.I. 749-750 were removed from the docket as duplicative of D.I. 747-748. Exhibits A-C were added to D.I. 747 and Exhibits 1-5 were added to D.I. 748. D.I. 747-748 were placed under seal per the request of counsel. (ntl)
|
|
Filing 748
[SEALED] Letter to Honorable Leonard P. Stark from James M. Lennon regarding Letter Brief regarding Defendants' Motion to Strike - re #747 MOTION to Strike portions of Plaintiffs' expert report. (Lennon, James) Modified on 5/7/2020 (ntl). (Additional attachment(s) added on 5/7/2020: #1 Exhibit 1, #2 Exhibit 2, #3 Exhibit 3, #4 Exhibit 4, #5 Exhibit 5) (ntl).
|
|
Filing 747
[SEALED] MOTION to Strike portions of Plaintiffs' expert report - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James) (Additional attachment(s) added on 5/7/2020: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C) (ntl). Modified on 5/7/2020 (ntl).
|
|
Filing 746
REDACTED VERSION of #739 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
SO ORDERED, re #745 MOTION for Pro Hac Vice Appearance of Attorney Tedd W. Van Buskirk and Aaron S. Eckenthal filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 4/29/20. (ntl)
|
|
Pro Hac Vice Attorney Aaron S. Eckenthal for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam)
|
|
Pro Hac Vice Attorney Tedd W. Van Buskirk for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam)
|
|
Filing 745
MOTION for Pro Hac Vice Appearance of Attorney Tedd W. Van Buskirk and Aaron S. Eckenthal - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 744
REDACTED VERSION of #737 Letter, by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibits 1-12, #2 Exhibit 13, #3 Exhibits 14-15, #4 Exhibit 16)(Phillips, John)
|
|
Filing 743
NOTICE requesting Clerk to remove Allison Schmitt as co-counsel. Reason for request: no longer with firm. (Dellinger, Megan)
|
|
Filing 742
REDACTED VERSION of #728 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C, #2 Exhibit D-H)(Dellinger, Megan)
|
|
Filing 741
REDACTED VERSION of #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1a-7b, #2 Exhibit 8a-14b)(Dellinger, Megan)
|
|
Filing 740
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for Teleconference to Address Plaintiffs' Motion for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Dellinger, Megan)
|
|
Filing 739
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Reply in Support of Motion for Leave to File Amended Complaints Asserting Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Dellinger, Megan)
|
|
Filing 738
Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Limited, Corporate Parent Lupin Inc., Corporate Parent Nanomi B.V. for Lupin Pharmaceuticals Inc. filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
SO ORDERED, re #731 STIPULATION TO EXTEND TIME for Defendants to file their responsive letter in opposition to Plaintiffs' Motion seeking leave to amend to April 20, 2020 filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/22/20. (ntl)
|
|
SO ORDERED, re #730 Consent Judgment -- Party Cipla USA Inc., Cipla USA Inc., Cipla Limited and Cipla Limited terminated. Attorney Karen L. Pascale; Tedd W. Van Buskirk; Robert M. Vrana; Aaron S. Eckenthal and William L. Mentlik terminated. Signed by Judge Leonard P. Stark on 4/22/20. (ntl)
|
|
Filing 737
[SEALED] Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Opposition to Plaintiffs' Motion Seeking Leave to Amend Complaints - re #728 Letter,. (Attachments: #1 Exhibit 1-16)(Phillips, John)
|
|
Filing 736
NOTICE OF SERVICE of Opening Expert Report of Anthony J. Rothschild, M.D. and Opening Expert Report of Victor I. Reus, M.D. filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 735
NOTICE OF SERVICE of Opening Expert Report of Dr. Salvatore Lepore filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Pro Hac Vice Attorney Brent A. Batzer for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 734
NOTICE OF SERVICE of Opening Expert Reports (served on various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 733
MOTION for Pro Hac Vice Appearance of Attorney Grant S. Shackelford - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Text of Proposed Order, #2 Certification of Grant S. Shackelford)(Grivner, Geoffrey)
|
|
SO ORDERED, re #733 MOTION for Pro Hac Vice Appearance of Attorney Grant S. Shackelford filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 4/17/20. (ntl)
|
|
Filing 732
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.s Opening Expert Report of Jonathan W. Steed, Ph.D. Pursuant to Federal Rule of Civil Procedure 26(A)(2)(B) filed by Lek Pharmaceuticals D.D., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 731
STIPULATION TO EXTEND TIME for Defendants to file their responsive letter in opposition to Plaintiffs' Motion seeking leave to amend to April 20, 2020 - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
SO ORDERED, re #726 STIPULATION for Limited Waiver of Protective Order filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/13/20. (ntl)
|
|
Filing 730
PROPOSED CONSENT JUDGMENT between Plaintiffs and Cipla Limited and Cipla USA Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
SO ORDERED, re #721 STIPULATION TO EXTEND TIME Various Deadlines to Various Dates filed by Sigmapharm Laboratories LLC, Zydus Pharmaceuticals (USA) Inc., Unichem Laboratories, Limited, Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 4/7/20. (ntl)
|
|
Filing 729
NOTICE OF SERVICE of Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V (Nos. 1, 2, 7, & 8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 728
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Plaintiffs' Motion for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - re #727 MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent. (Attachments: #1 Exhibit A-C, #2 Exhibit D-H)(Dellinger, Megan)
|
|
Filing 727
[SEALED] MOTION for Leave to File Amended Complaints to Add Induced Infringement of the '096 Patent - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1a-7b, #2 Exhibit 8a-14b)(Dellinger, Megan)
|
|
SO ORDERED, re #725 MOTION for Pro Hac Vice Appearance of Attorney Brian H. Gold and S. Lloyd Smith filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 4/7/20. (ntl)
|
|
Filing 726
STIPULATION for Limited Waiver of Protective Order by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 725
MOTION for Pro Hac Vice Appearance of Attorney Brian H. Gold and S. Lloyd Smith - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Text of Proposed Order, #2 Certification of Brian H. Gold, #3 Certification of S. Lloyd Smith)(Grivner, Geoffrey)
|
|
Filing 724
NOTICE OF SERVICE of (1) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s First Supplemental Responses to Plaintiffs First Set of Interrogatories to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Nos. 115) and (2) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Supplemental Answers to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 723
NOTICE requesting Clerk to remove Philip Hirshchorn, Kimberly Coghill, and Erin Dunston as co-counsel.. (Grivner, Geoffrey)
|
|
Pro Hac Vice Attorney Jason W. Schigelone for Lek Pharmaceuticals D.D. and Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 722
MOTION for Pro Hac Vice Appearance of Attorney Jason W. Schigelone - filed by Lek Pharmaceuticals D.D., Sandoz Inc.. (Gattuso, Dominick)
|
|
SO ORDERED, re #722 MOTION for Pro Hac Vice Appearance of Attorney Jason W. Schigelone filed by Lek Pharmaceuticals D.D., Sandoz Inc. Signed by Judge Leonard P. Stark on 4/2/20. (ntl)
|
|
Filing 721
STIPULATION TO EXTEND TIME Various Deadlines to Various Dates - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 720
NOTICE OF SERVICE of Defendants' Joint Second Supplemental Invalidity Contentions filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 719
NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Supplemental Response to Interrogatories (Nos. 22-25) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 718
NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Supplemental Objections and Responses to Plaintiffs' Interrogatory No. 9 filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 717
NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Supplemental Objections and Answers to Plaintiffs' First Set of Interrogatories to Sigmapharm Laboratories, LLC (Nos. 5, 9-11, & 14) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 716
MEMORANDUM ORDER: Having reviewed the parties' motion and letters regarding Defendants' use of Dr. Rothschild as an expert (D.I. #698 , #704 , #711 ), and having heard argument on March 13, 2020, IT IS HEREBY ORDERED that Plaintiffs' requests to disqualify Dr. Rothschild as an expert and to prevent him from receiving access to materials designated as Confidential Information under the Protective Order are DENIED. Signed by Judge Jennifer L. Hall on 3/18/2020. (ceg)
|
|
Filing 715
REDACTED VERSION of #711 Letter, by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-F [Shall Remain Under Seal], #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
CORRECTING ENTRY: Corrected letter added to D.I. 714 per request of counsel. (ntl)
|
|
Filing 714
REDACTED VERSION of #704 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan) (Main Document 714 replaced on 3/17/2020) (ntl).
|
|
SO ORDERED, re #712 MOTION for Pro Hac Vice Appearance of Attorney Jennifer D. Cieluch of Covington & Burling LLP filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 3/16/20. (ntl)
|
|
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute held on 3/13/2020.(*Court Reporter Adam Miller) (nmg)
|
|
Filing 713
NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions Against Sigmapharm Laboratories, LLC filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 712
MOTION for Pro Hac Vice Appearance of Attorney Jennifer D. Cieluch of Covington & Burling LLP - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 711
[SEALED] Letter to The Honorable Jennifer L. Hall from Dominick T. Gattuso, Esquire regarding Defendants Response to Plaintiffs' Letter Brief - re #704 Letter. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D, #5 Exhibit E, #6 Exhibit F, #7 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 710
REDACTED VERSION of #697 Letter by Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit 1)(Phillips, John)
|
|
SO ORDERED, re #700 MOTION for Pro Hac Vice Appearance of Attorney Dustin L. Taylor filed by Sigmapharm Laboratories LLC. Signed by Judge Leonard P. Stark on 3/11/20. (ntl)
|
|
Pro Hac Vice Attorney Dustin L. Taylor for Sigmapharm Laboratories LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam)
|
|
Filing 709
ORAL ORDER: Having considered Plaintiffs' motion regarding discovery disputes (D.I. 688), and the associated letter briefing (D.I. 692, 697), and having heard argument on March 9, 2020, IT IS HEREBY ORDERED that Plaintiffs' motion is GRANTED-IN-PART and DENIED-IN-PART. (1) Regarding the Rule 30(b)(6) designee in dispute, Zydus shall make the designee available for seven hours of deposition by video conference, which may occur over two days. Zydus shall pay the expenses associated with conducting the video conference. (2) Regarding Plaintiffs' requests for Rule 30(b)(6) deposition testimony, for topic numbers 4, 8, 11, 29, and 31-33, the Court will DENY Plaintiffs' request for a designee to testify about all testing. The record reflects that Zydus has produced all testing data, and Zydus has designated a witness to testify about the types of testing relevant to the asserted claims. For topic numbers 57-60, the Court will DENY Plaintiffs' requests for the reasons argued by Zydus. For topic numbers 34, 35, 37, and 44 the Court will GRANT Plaintiffs' requests because those topics are potentially relevant to validity (particularly objective indicia of non-obviousness) or infringement. Plaintiffs' requests regarding topic numbers 24, 25, and 47 were resolved pursuant to agreement of the parties during the teleconference. (3) Regarding Plaintiffs' requests for supplemental responses to interrogatories 1, 2, 4, 6, 7, 10, 13-18, 21-25, the Court will DENY the requests. In light of the breadth of Plaintiff's requests, the document discovery already provided by Zydus, the Court's decision above regarding Rule 30(b)(6) witness testimony, and the Rule 30(b)(6) testimony already provided by Zydus, the record does not reflect that the additional information sought is proportional to the needs of the case. The Court will GRANT Plaintiffs' request as to interrogatory 9. IT IS FURTHER ORDERED that, not later than March 20, 2020, Zydus shall submit its supplemental response to interrogatory 9 and shall designate a Rule 30(b)(6) witness for the topics authorized above. ORDERED by Judge Jennifer L. Hall on 3/10/20. (JLH)
|
|
Filing 708
ORAL ORDER:Having considered Plaintiffs' motion regarding discovery disputes (D.I. 686), and the associated letter briefing (D.I. 691, 696), and having heard argument on March 9, 2020, IT IS HEREBY ORDERED that Plaintiffs' motion is GRANTED-IN-PART and DENIED-IN-PART. Regarding interrogatories 9, 10, and 14, the Court disagrees with Sigmapharm's assertion that the information sought is irrelevant. Sigmapharm shall provide responses to interrogatories 5, 9, 10, 11, and 14, as those interrogatories are potentially relevant to validity of the patents-in-suit (particularly to objective indicia of non-obviousness) or infringement, proportional to the needs of the case, and the current record before the Court does not reflect that they are cumulative to other discovery provided by Sigmapharm. For the remainder of the interrogatories identified by Plaintiffs (2, 6, 7, 12, 15 and 16), in light of the breadth of Plaintiffs' requests, and in view of the document discovery already provided by Sigmapharm, the record does not demonstrate that the additional information sought is proportional to the needs of the case. IT IS FURTHER ORDERED that, not later than March 20, 2020, Sigmapharm shall submit supplemental responses to interrogatories 5, 9, 10, 11, and 14. ORDERED by Judge Jennifer L. Hall on 3/10/20. (JLH)
|
|
Filing 707
REDACTED VERSION of #694 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 706
REDACTED VERSION of #692 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-11)(Dellinger, Megan)
|
|
SO ORDERED, re #694 Stipulation and Order Regarding Infringement filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 3/10/20. (ntl)
|
|
Minute Entry for proceedings held before Judge Jennifer L. Hall - Discovery Dispute held on 3/9/2020.(*Court Reporter Lorraine Marino) (nmg)
|
|
Filing 705
NOTICE OF SERVICE of Plaintiffs' Final Infringement Contentions Against Defendants (directed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 704
[SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Protective Order Disputes Related to Defendants Expert Dr. Anthony J. Rothschild. (Attachments: #1 Exhibit 1-10)(Dellinger, Megan)
|
|
Filing 703
NOTICE OF SERVICE of Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 702
NOTICE OF SERVICE of Defendants' Joint Supplemental Invalidity Contentions filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 701
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 17, 22, 23) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 700
MOTION for Pro Hac Vice Appearance of Attorney Dustin L. Taylor - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Taylor Pro Hac Certification)(Haney, Megan)
|
|
Filing 699
REDACTED VERSION of #691 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-12)(Dellinger, Megan)
|
|
ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #698 ). A discovery dispute teleconference is scheduled for March 13, 2020 at 02:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than March 9, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 11, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Entered by Judge Jennifer L. Hall on 3/5/2020. (nmg)
|
|
Filing 698
Joint MOTION for Teleconference to Resolve Protective Order Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 697
[SEALED] Letter to The Honorable Jennifer L. Hall from John C. Phillips, Jr. regarding Zydus' Response to Plaintiff's Opening Discovery Letter - re #692 Letter. (Attachments: #1 Exhibit 1)(Phillips, John)
|
|
Filing 696
Letter to The Honorable Jennifer L. Hall from John C. Phillips, Jr. regarding in response to Plaintiffs' February 27, 2020 letter regarding Sigmapharm's responses to certain interrogatories - re #691 Letter,. (Phillips, John)
|
|
Filing 695
REDACTED VERSION of #689 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 694
[SEALED] STIPULATION and [Proposed] Order Regarding Infringement by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 693
NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Supplemental Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 18-24) filed by Sigmapharm Laboratories LLC.(Phillips, John)
|
|
Filing 692
[SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Discovery Disputes with Zydus. (Attachments: #1 Exhibits 1-11)(Dellinger, Megan)
|
|
SO ORDERED, re #689 [SEALED] STIPULATION and [Proposed] Order of Infringement by Torrent of Certain Asserted Claims. Signed by Judge Leonard P. Stark on 2/27/20. (ntl)
|
|
Filing 691
[SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Plaintiffs' Motion to Compel Sigmapharm Laboratories, LLC to Supplement Its Interrogatory Responses - re 687 Order Setting Teleconference,,,,. (Attachments: #1 Exhibit 1-12)(Dellinger, Megan)
|
|
Filing 690
ORAL ORDER Setting Teleconference: The Court has reviewed the Joint Motion for Teleconference to Resolve Discovery Disputes (D.I. #688 ). A discovery dispute teleconference is scheduled for March 9, 2020 at 03:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than February 28, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 4, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that partys reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Signed by Judge Jennifer L. Hall on 2/26/2020. (ceg)
|
|
Filing 689
[SEALED] STIPULATION and [Proposed] Order of Infringement by Torrent of Certain Asserted Claims by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 688
Joint MOTION for Teleconference to Resolve Discovery Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 687
ORAL ORDER Setting Teleconference: The Court has reviewed Plaintiffs' Motion for Teleconference to Resolve Discovery Disputes (D.I. #686 ). A discovery dispute teleconference is scheduled for March 9, 2020 at 02:00 PM Eastern Time before Judge Jennifer L. Hall. By no later than February 27, 2020, the party(ies) seeking relief shall file with the Court a letter, not to exceed three pages, in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than March 3, 2020, any party(ies) opposing the application for relief may file a letter, not to exceed three pages, in no less than 12-point font, outlining that party's reasons for its opposition. Two courtesy copies of the letters are to be hand delivered to the Clerk's Office within one hour of e-filing. The Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Jennifer L. Hall on 2/24/2020. (ceg)
|
|
Filing 686
MOTION for Teleconference to Resolve Discovery Disputes - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 685
REDACTED VERSION of #680 Stipulation by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 684
NOTICE of Withdrawal of Counsel by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited (Pedi, Nicole)
|
|
SO ORDERED, re #680 Stipulation. Signed by Judge Leonard P. Stark on 2/20/20. (ntl)
|
|
SO ORDERED, re #679 Joint STIPULATION and [Proposed] Order Concerning Authenticity of Evidence. Signed by Judge Leonard P. Stark on 2/19/20. (ntl)
|
|
Filing 683
ORDER re #682 Memorandum Opinion regarding claim construction. Signed by Judge Leonard P. Stark on 2/18/20. (ntl)
|
|
Filing 682
MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 2/18/20. (ntl)
|
|
Filing 681
ORAL ORDER: In light of the Stipulation filed on 2/14/2020 (D.I. 680), the ADR teleconference set for 2/18/2020 is cancelled. Ordered by Judge Christopher J. Burke on 2/18/2020. (dlb)
|
|
Filing 680
[SEALED] STIPULATION by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 679
Joint STIPULATION and [Proposed] Order Concerning Authenticity of Evidence by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 678
NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Supplemental Response to Interrogatories (Nos. 2, 13, 16 & 19) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 677
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that counsel shall file a Motion for Teleconference to Resolve Discovery Dispute. The suggested text for this motion can be found in Judge Hall's portion of the Court"s website, in the "Forms" tab, under the heading "Motion for Teleconference to Resolve Discovery/Protective Order Disputes." The parties need not include information previously provided in their letter to Judge Stark. The dispute will thereafter be addressed in the manner set forth in the Scheduling Order. ORDERED by Judge Jennifer L. Hall on 2/6/2020. (ceg)
|
|
Filing 676
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 675
ORAL ORDER: IT IS HEREBY ORDERED that the pending discovery disputes (see D.I. 628, 660, 661) and all future discovery disputes in this matter are REFERRED to Judge Hall for resolution in whatever manner she deems fit. All future requests for resolution of discovery disputes should be addressed to Judge Hall and not to Judge Stark. ORDERED by Judge Leonard P. Stark on 2/5/2020. (ntl)
|
|
Filing 674
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Corrected Supplemental Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 673
NOTICE to Take Deposition of Siva Vaithiyalingam on February 18, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 672
NOTICE to Take Deposition of Manjinder Singh on February 21, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 671
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Supplemental Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
SO ORDERED, re #670 MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss filed by Apicore US LLC. Signed by Judge Leonard P. Stark on 1/30/20. (ntl)
|
|
Filing 670
MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss - filed by Apicore US LLC. (Dorsney, Kenneth)
|
|
Filing 669
ORDER Setting Mediation Conferences: A Telephone Conference is set with Plaintiffs andDefendant Apicore US LLC. for 2/18/2020 at 10:00 AM before Judge Christopher J. Burke.Signed by Judge Christopher J. Burke on 1/28/2020. (dlb)
|
|
Pro Hac Vice Attorney Yixin H. Tang for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 668
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Supplemental Response to Plaintiffs' Interrogatory No. 5 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 667
NOTICE OF SERVICE of Heteros Supplemental Objections and Responses to Plaintiffs First Set of Requests for Admission No. 29 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 666
NOTICE to Take Deposition of Virendra Srivastava on January 30, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
SO ORDERED, re #663 STIPULATION TO EXTEND TIME Regarding Certain Deadlines to Various Dates filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/27/20. (ntl)
|
|
Filing 665
REDACTED VERSION of #658 Notice (Other) Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 664
NOTICE requesting Clerk to remove Richard J. Berman, Janine A. Carlan, Bradford C. Frese, Gary A. Coad and Fannyben D. Patel as co-counsel.. (Mowery, Katharine)
|
|
SO ORDERED, re #662 MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin H. Tang and Brent Batzer filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 1/24/20. (ntl)
|
|
Pro Hac Vice Attorney Shashank D. Upadhye for Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
Filing 663
STIPULATION TO EXTEND TIME Regarding Certain Deadlines to Various Dates - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 662
MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin H. Tang and Brent Batzer - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Fineman, Steven)
|
|
Filing 661
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for a Discovery Conference. (Dellinger, Megan)
|
|
Filing 660
Letter to The Honorable Leonard P. Stark from Renee M. Mosley regarding Joint Request to Schedule Discovery Teleconference. (Mosley, Renee)
|
|
Filing 659
JOINDER by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, joining in #658 Notice (Other) . (Grivner, Geoffrey)
|
|
Filing 658
[SEALED] NOTICE of Defendants' Rule 31 Notice of Deposition by Written Questions to Plaintiffs by Lek Pharmaceuticals d.d., Sandoz Inc. with Exhibit A (Gattuso, Dominick)
|
|
Filing 657
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s First Amended Objections and Responses to Plaintiffs' Notice of Deposition under Fed. R. Civ. P. 30(b)(6) [Confidential] filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 656
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Objections and Responses to Plaintiffs' Rule 30(b)(6) Notice of Deposition to Alembic filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
SO ORDERED, re #652 STIPULATION TO EXTEND TIME to serve final infringement and invalidity contentions to February 14, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/13/20. (ntl)
|
|
Filing 655
NOTICE to Take Deposition of Elizabeth Purcell on January 16, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 654
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Sandoz Inc. and Lek Pharmaceuticals d.d.'s Letter of January 3, 2020 - re #648 Letter,. (Dellinger, Megan)
|
|
Filing 653
MOTION for Pro Hac Vice Appearance of Attorney Sumner, Evan T. - filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Pedi, Nicole)
|
|
SO ORDERED, re #653 MOTION for Pro Hac Vice Appearance of Attorney Evan T. Sumner filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Signed by Judge Leonard P. Stark on 1/9/20. (ntl)
|
|
Pro Hac Vice Attorney Evan T. Sumner for Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak)
|
|
Filing 652
STIPULATION TO EXTEND TIME to serve final infringement and invalidity contentions to February 14, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 651
NOTICE to Take Deposition of Chris Valosky on January 13, 2020 at 8:30 AM CT filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 650
NOTICE to Take Deposition of Chris Valosky on January 13, 2020 at 9:00 CT filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 649
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Defendants Sandoz Inc. and Lek Pharmaceuticals d.d's letter of January 3, 2020. (Dellinger, Megan)
|
|
Filing 648
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Defendant Sandoz Inc. and Lek Pharmaceuticals' Motion to Dismiss [DI 415] - re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Gattuso, Dominick)
|
|
Filing 647
NOTICE to Take Deposition of Vishal Kulkarni on January 8, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 646
NOTICE to Take Deposition of Ujwal Chhabra on January 27, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 645
NOTICE to Take Deposition of Prashant Mandaogade on January 28, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 644
NOTICE to Take Deposition of Hitesh Kumar Maheshwari on January 15, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 643
NOTICE to Take Deposition of G. Kesavan on January 13, 2020 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 642
Official Transcript of Claim Construction Hearing held on December 18, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Email: Brian_Gaffigan@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/23/2020. Redacted Transcript Deadline set for 2/3/2020. Release of Transcript Restriction set for 4/1/2020.(bpg)
|
|
SO ORDERED, re #634 Joint STIPULATION TO EXTEND TIME for taking previously noticed fact depositions to January 28, 2020 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 1/2/20. (ntl)
|
|
SO ORDERED, re #626 STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Set of Requests for Admission to December 24, 2019 filed by Unichem Laboratories, Limited, #632 STIPULATION TO EXTEND TIME Response to Requests for Admission to December 27, 2019 filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 12/30/19. (ntl)
|
|
Filing 641
NOTICE OF SERVICE of 1) Defendants Cipla Limiteds and Cipla USA Inc.s [Supplemental] Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1); 2) Defendants Cipla Limiteds and Cipla USA Inc.s Supplemental Response to Plaintiffs Interrogatory Nos. 1, 5-7, 9, 10, 12, 14, 15, 17, 18 [First Set] [CONFIDENTIAL]; 3) Defendants Cipla Limiteds and Cipla USA Inc.s Response to Plaintiffs Third Set of Interrogatories (Nos. 21-25) [CONFIDENTIAL]; and 4)Defendants Cipla Limiteds and Cipla USA Inc.s Response to Plaintiffs First Set of Requests for Admission (Nos. 1-57) [CONFIDENTIAL], filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 640
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-3) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 639
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Alembic's First Set of Requests for the Production of Documents (Nos. 1-8) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 638
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants Macleods Pharmaceuticals Limited and Macleods Pharma USA Inc.'s First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 637
NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Unichem Laboratories, Limited's First Set of Individual Interrogatories to Plaintiffs (No. 1), (2) Plaintiffs' Objections and Responses to Unichem Laboratories, Limited's First Set of Individual Requests for Production of Documents and Things to Plaintiffs (Nos. 1-4), and (3) Plaintiffs' Objections and Responses to Defendant Unichem Laboratories, Limited's First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 636
NOTICE OF SERVICE of Unichem Laboratories, Limited's Responses and Objections to Plaintiffs' First Set of Requests for Admission (Nos. 1-52) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 635
NOTICE OF SERVICE of (1) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Responses to Plaintiffs First Set of Requests for Admission and (2) Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Answers to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Mosley, Renee)
|
|
Filing 634
Joint STIPULATION TO EXTEND TIME for taking previously noticed fact depositions to January 28, 2020 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 633
REDACTED VERSION of #608 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 632
STIPULATION TO EXTEND TIME Response to Requests for Admission to December 27, 2019 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey)
|
|
Filing 631
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s (1) Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-55), (2) Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 17-23) and (3) Supplemental Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 2, 3, 4, 7, 8, 9,10, 13, 14 and 15) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 630
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s: 1) Responses to Plaintiffs' Requests for Admission (Nos. 1-53); and 2) Response to Plaintiffs' Third Set of Interrogatories (Nos. 17-23) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 629
NOTICE OF SERVICE of (i) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 10-16) and (ii) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-38) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 628
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding request for the scheduling of a discovery conference. (Dellinger, Megan)
|
|
Filing 627
NOTICE OF SERVICE of Plaintiffs' Supplemental Initial Disclosures Pursuant to Rule 26(a)(1) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 626
STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Set of Requests for Admission to December 24, 2019 - filed by Unichem Laboratories, Limited. (Haney, Megan)
|
|
Filing 625
NOTICE OF SERVICE of copies of (i) of Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Fourth Set of Interrogatories (Nos. 24-25) [CONFIDENTIAL]; and, (ii) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Second Set of Requests for Admission (Nos. 12- 57) [ CONFIDENTIAL] was filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 624
NOTICE OF SERVICE of Defendants Objections and Responses to Third Set of Interrogatories (Nos. 10-16) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 623
NOTICE OF SERVICE of Defendants Objections and Responses to First Set of Requests For Admission (Nos. 1-39) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 622
NOTICE OF SERVICE of (1) Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 18-24); and (2) Defendant Sigmapharm Laboratories, LLC's Response to Plaintiffs' First Set of Requests for Admission to Sigmapharm Laboratories, LLC (Nos. 1-57) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 621
NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' First Set of Requests for Admissions (Nos. 1-57); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Third Set of Interrogatories (Nos. 21-25) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 620
NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' Third Set of Interrogatories to Unichem Laboratories, Limited (Nos. 16-22) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 619
NOTICE OF SERVICE of (1) Defendant Lupin Limited and Lupin Pharmaceuticals, Inc.'s Response to Plaintiffs' First Set of Requests for Admission; and (2) Lupin's Responses and Objections to Plaintiffs' Third Set of Interrogatories (Nos. 20-25) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 618
NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' First Set of Requests for Admission; and (2) Apotex's responses to Plaintiffs' Third Set of Interrogatories (Nos. 16-22) filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth)
|
|
Filing 617
NOTICE OF SERVICE of (1) Apicore's response to Plaintiffs' First Set of Requests for Admission; and (2) Apicore's response to Plaintiffs' Third Set of Interrogatories filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 616
NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Responses to Requests for Admissions Nos. 1-57; and 2) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Third Set of Interrogatories (Nos. 17-23) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 615
NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant Apotex's Interrogatories to Plaintiffs (Nos. 1-2) (2) Plaintiffs' Objections and Responses to Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-5) (3) Plaintiffs' Objections and Responses to Defendant Alembic's First Set of Interrogatories to Plaintiffs (Nos. 1-5) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 614
REDACTED VERSION of #605 Letter, to the Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding regarding Sandoz Motion [DI 415] by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A, #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 613
ORAL ORDER Setting Mediation Conference: A Telephone Conference is set for 1/27/2020 at 10:30 AM before Judge Christopher J. Burke to discuss ADR. Counsel for Plaintiffs shall initiate the call. Ordered by Judge Christopher J. Burke on 12/19/2019. (dlb)
|
|
SO ORDERED, re #612 MOTION for Pro Hac Vice Appearance of Attorney Taylor J. Kelson filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/19/19. (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Markman/Oral Argument/Discovery Hearing held on 12/18/2019. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 612
MOTION for Pro Hac Vice Appearance of Attorney Taylor J. Kelson - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 611
NOTICE OF SERVICE of Defendants' Responses and Objections to Plaintiffs' Notice of Deposition to Defendants Cipla Limited and Cipla USA Inc.s Under Fed. R. Civ. P. 30(b)(6) [CONFIDENTIAL] filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
SO ORDERED, re #610 MOTION for Pro Hac Vice Appearance of Attorney Kurt G. Calia filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/17/19. (ntl)
|
|
Filing 610
MOTION for Pro Hac Vice Appearance of Attorney Kurt G. Calia - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 609
NOTICE requesting Clerk to remove Judy K. He as co-counsel. Reason for request: No longer associated with the case. (Gattuso, Dominick)
|
|
Filing 608
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Response to Defendants' December 11, 2019 Letter Regarding Discovery Dispute. (Dellinger, Megan)
|
|
Filing 607
NOTICE OF SERVICE of Defendant Unichem's Supplemental Responses and Objections to Plaintiffs' First Set of Interrogatories to Unichem Laboratories, Limited (Nos. 1-14) filed by Unichem Laboratories, Limited.(Phillips, John)
|
|
Filing 606
NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Supplemental Responses to Interrogatories Nos. 1, 5-7, 9, 10, 12, 14, and 15; and 2) Defendant Alkem Laboratories Ltd.s Responses and Objections to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 605
[SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Sandoz Motion to Dimiss (D.I. 415) - re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Attachments: #1 Exhibit A, #2 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 604
NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Objections and Responses to Plaintiffs' Notice of Deposition to Defendant Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 603
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery Disputes - re #602 Letter, #486 Letter. (Attachments: #1 Exhibit A, #2 Exhibit B-E)(Gattuso, Dominick)
|
|
Filing 602
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery dispute. (Gattuso, Dominick)
|
|
Pro Hac Vice Attorney Fannyben D. Patel for Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (lak)
|
|
Filing 601
NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Pro Hac Vice Attorney Mark H. Remus for Lek Pharmaceuticals d.d., and for Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam)
|
|
Filing 600
NOTICE to Take Deposition of Srinivas Arutla on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 599
NOTICE to Take Deposition of Shital Pathak on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 598
NOTICE to Take Deposition of Meka Lingam on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 597
NOTICE to Take Deposition of B.C. Rajesha on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 596
NOTICE to Take Deposition of Spiro Spireas on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 595
NOTICE to Take Deposition of Lokanath Lenka on December 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 594
NOTICE to Take Deposition of Basil Theofanopoulos on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 593
NOTICE to Take Deposition of Venkata Srinivas Pullela on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 592
NOTICE to Take Deposition of Shrikant Mudgal on December 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 591
NOTICE to Take Deposition of Nidhi Bagree on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 590
NOTICE to Take Deposition of Pritesh Upadhyay on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 589
NOTICE to Take Deposition of Makrand Avachat on December 18, 2019 (Amended) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 588
NOTICE to Take Deposition of Girij Singh on December 17, 2019 (Amended) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
SO ORDERED, re #587 MOTION for Pro Hac Vice Appearance of Attorney Fannyben D. Patel filed by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc. Signed by Judge Leonard P. Stark on 12/6/19. (ntl)
|
|
Filing 587
MOTION for Pro Hac Vice Appearance of Attorney Fannyben D. Patel - filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Fineman, Steven)
|
|
Filing 586
NOTICE OF SERVICE of (1) Lupin's Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 19); and (2) Lupin's Responses and Objections to Plaintiffs' Third Set of Requests for Production (Nos. 186-189) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 585
NOTICE OF SERVICE of 1) Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 187-190), and 2) Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Second Set of Interrogatories (No. 20) filed by Cipla Limited, Cipla USA Inc..(Vrana, Robert)
|
|
Filing 584
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s 1) Response to Plaintiffs' Third Set of Requests for Produciton (Nos. 154-155); and 2) Response to Plaintiffs' Second Set of Interrogatories (No. 16) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 583
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 113-114) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 582
NOTICE OF SERVICE of 1) Responses to Second Set of Interrogatories (No. 16) and 2) Responses to Third Set of Requests for Production of Documents and Things (Nos. 157-158) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 581
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 9) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 580
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s (1) Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 16) and (2) Objections and Responses to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 157-158) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 579
NOTICE OF SERVICE of (1) Defendant Unichem's Responses and Objections to Plaintiffs' Third Set of Requests to Unichem Laboratories, Limited for the Production of Documents and Things (Nos. 154-155); and (2) Defendant Unichem's Responses and Objections to Plaintiffs' Second Set of Interrogatories to Unichem Laboratories, Limited (No. 15) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 578
NOTICE OF SERVICE of Defendant Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 577
NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Second Set of Interrogatories (No. 20); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Third Set of Requests for the Production of Documents and Things (Nos. 188-191) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 576
NOTICE OF SERVICE of 1) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Second Set of Interrogatories (No. 16); and 2) Defendant Alkem Laboratories Ltd.s Response to Plaintiffs Third Set of Requests for the Production of Documents and Things (Nos. 157-158) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 575
NOTICE OF SERVICE of (1) responses to third set of requests for production and (2) responses to second set of interrogatories filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 574
NOTICE OF SERVICE of (i) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Second Set of Interrogatories (No. 9) and (ii) Defendants Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 113-114) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 573
NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' Second Set of Interrogatories (No. 15); and (2) Apotex's responses to Plaintiffs' Third Set of Requests for Production (Nos. 154-155) filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth)
|
|
Filing 572
ORAL ORDER: Regarding the discovery dispute set forth in D.I. 486, IT IS HEREBY ORDERED that the discovery dispute will be heard during the hearing on December 18, 2019. Discovery letters shall be submitted on December 11, 2019 and December 13, 2019. ORDERED by Judge Leonard P. Stark on 12/4/19. (ntl)
|
|
SO ORDERED, re #571 MOTION for Pro Hac Vice Appearance of Attorney Mark H. Remus filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 12/4/19. (ntl)
|
|
Filing 571
MOTION for Pro Hac Vice Appearance of Attorney Mark H. Remus - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 570
NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses to Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-9) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 569
NOTICE OF SERVICE of (i) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Fourth Set of Requests for Production of Documents and Things (Nos. 168-169) [CONFIDENTIAL]; (ii) Sandoz Inc. and Lek Pharmaceuticals d.d.s First Supplemental Responses to Plaintiffs First Set of Interrogatories (Nos. 4-8) [CONFIDENTIAL]; and, (iii) Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Third Set of Interrogatories (No. 23) [CONFIDENTIAL] filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 568
NOTICE OF SERVICE of Responses and Objections to Plaintiffs' Notice of Deposition Pursuant to Federal Rule of Civil Procedure 30(b)(6) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 567
NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited Objections and Responses to Notice of Deposition Pursuant to Fed R Civ P 30(b)(6) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
SO ORDERED, re #561 MOTION for Pro Hac Vice Appearance of Attorney Priscilla G. Dodson and Megan L. Hare filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #564 MOTION for Pro Hac Vice Appearance of Attorney Han Park filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 12/2/19. (ntl)
|
|
Filing 566
NOTICE OF SERVICE of Apotex's Objections to Plaintiffs' 30(b)(6) Deposition Notice filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Filing 565
ORAL ORDER: IT IS HEREBY ORDERED that at the hearing on December 18, 2019 each side will have one (1) hour for argument on all issues. ORDERED by Judge Leonard P. Stark on 11/26/19. (ntl)
|
|
Filing 564
MOTION for Pro Hac Vice Appearance of Attorney Han Park - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 563
NOTICE OF SERVICE of [CORRECTED] Plaintiffs' Objections and Responses to Defendant Sandoz Inc.'s First Set of Individual Interrogatories to Plaintiffs (Nos.1-3) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc..(Dellinger, Megan)
|
|
Filing 562
NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendants' Second Set of Common Interrogatories to Plaintiffs (Nos. 10-17) and (2) Plaintiffs' Objections and Responses to Defendants' Third Set of Requests for Production to Plaintiffs (No. 137) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 561
MOTION for Pro Hac Vice Appearance of Attorney Priscilla G. Dodson and Megan L. Hare - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Pro Hac Vice Attorney Jieun Lee for Lek Pharmaceuticals d.d. and Sandoz Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal)
|
|
Filing 560
NOTICE OF SERVICE of (1)Response to Plaintiff's Notice of Deposition to Jayaraman Kannappan and (2) Response to notice of 30(b)(6) Deposition to Apicore filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 559
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.s Objections and Responses to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 558
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Objections to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur)
|
|
Filing 557
NOTICE of Withdrawal of Joshua E. Ney, Ph.D. by Lek Pharmaceuticals d.d., Sandoz Inc. (Gattuso, Dominick)
|
|
Filing 556
NOTICE OF SERVICE of Plaintiffs' First or Second Sets of Requests for Admission to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 555
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s First Set of Requests for Production of Documents to Plaintiffs (Nos. 1-8) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 554
NOTICE OF SERVICE of (1) Unichem Laboratories, Limited's First Set of Individual Interrogatories to Plaintiffs (No. 1); (2) Unichem Laboratories, Limited's First Set of Individual Requests for Production of Documents and Things to Plaintiffs (Nos. 1-4); and (3) Unichem Laboratories, Limited's First Set of Requests for Admission to Plaintiffs (Nos. 1-20) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 553
NOTICE OF SERVICE of Interrogatories directed to individual defendants (See notice for details) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 552
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.s First Set of Interrogatories to Plaintiffs (Nos. 1-3) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 551
ORAL ORDER: IT IS HEREBY ORDERED that the Markman Hearing scheduled for November 25, 2019 is CANCELLED and is RESCHEDULED for December 18, 2019 at 12:30 PM. ORDERED by Judge Leonard P. Stark on 11/20/19. (ntl)
|
|
Filing 550
NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals Limited and Macleods Pharma USA Inc.'s First Set of Requests for Admission to Plaintiffs filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 549
NOTICE OF SERVICE of Apotex's First Set of Individual Interrogatories to Plaintiffs (Nos. 1-2) filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Pro Hac Vice Attorney Ahmed Abdel-Rahman for Torrent Pharma Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d), Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (sam)
|
|
SO ORDERED, re #546 MOTION for Pro Hac Vice Appearance of Attorney Ahmed Abdel-Rahman of Pillsbury Winthrop Shaw Pittman LLP filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc., #544 MOTION for Pro Hac Vice Appearance of Attorney Jieun Lee filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 11/19/19. (ntl)
|
|
Filing 548
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Objections and Responses to Plaintiffs' Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 547
NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Notice of Deposition Under Federal Rule of Civil Procedure 30(b)(6) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 546
MOTION for Pro Hac Vice Appearance of Attorney Ahmed Abdel-Rahman of Pillsbury Winthrop Shaw Pittman LLP - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Riley, Stephanie)
|
|
Filing 545
NOTICE requesting Clerk to remove Shailendra Maheshwari, Esquire, of the law firm of Pillsbury Winthrop Shaw & Pittman LLP as co-counsel.. (Riley, Stephanie)
|
|
Filing 544
MOTION for Pro Hac Vice Appearance of Attorney Jieun Lee - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 543
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s First Set of Interrogatories to Plaintiffs (Nos. 1-5) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 542
ORDER re #541 Memorandum Order -- #378 Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz Inc. is DENIED. Signed by Judge Leonard P. Stark on 11/15/19. (ntl)
|
|
Filing 541
MEMORANDUM ORDER re #378 Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 11/15/19. (ntl)
|
|
Filing 540
NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' Notice of Deposition to Lupin Limited and Lupin Pharmaceuticals Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 539
NOTICE to Take Deposition of MICHAEL J. MEALY pursuant to Fed. R. Civ. P. 30(b)(1) on December 10, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 538
NOTICE to Take Deposition of MORTEN JORGENSEN pursuant to Fed. R. Civ. P. 30(b)(1) on December 12, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 537
NOTICE to Take Deposition of MICHAEL HAROLD ROCK pursuant to Fed. R. Civ. P. 30(b)(1) on December 11, 2019 filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 536
NOTICE OF SERVICE of Defendants Par Pharmaceutical Inc.'s and Zhejiang Huahai Pharmaceutical Co., Ltd.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-5) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 535
NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-16) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 534
ORDER granting #532 MOTION for Extension of Time to Respond to Plaintiffs' First Set of Interrogatories [UNOPPOSED] - filed by Sigmapharm Laboratories LLC. Signed by Judge Leonard P. Stark on 11/14/19. (etg)
|
|
Filing 533
NOTICE OF SERVICE of (1) Takeda's Objections and Responses to Defendants' Amended Rule 30(b)(6) Notice of Deposition to Takeda and (2) Lundbeck's Objections and Responses to Defendants' Amended Rule 30(b)(6) Notice of Deposition to Lundbeck filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd..(Dellinger, Megan)
|
|
Filing 532
MOTION for Extension of Time to Respond to Plaintiffs' First Set of Interrogatories [UNOPPOSED] - filed by Sigmapharm Laboratories LLC. (Attachments: #1 Text of Proposed Order)(Phillips, John)
|
|
Filing 531
NOTICE to Take Deposition of Y. Ravindra Kumar on December 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 530
NOTICE to Take Deposition of Vimal Kaneria on December 3, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 529
NOTICE to Take Deposition of Vijender Gupta on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 528
NOTICE to Take Deposition of Saumil Shah on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 527
NOTICE to Take Deposition of Pratap Reddy Padi on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 526
NOTICE to Take Deposition of Mehul Patel on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 525
NOTICE to Take Deposition of Makrand Avachat on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 524
NOTICE to Take Deposition of Kumar Singh on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 523
NOTICE to Take Deposition of Jitendra Gajera on December 4, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 522
NOTICE to Take Deposition of Jayaraman Kannappan on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 521
NOTICE to Take Deposition of Dhananjai Shrivastava on December 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 520
NOTICE to Take Deposition of Abhijeet Patil on December 16, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 519
NOTICE to Take Deposition of A.R. Reddy on December 9, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 518
NOTICE to Take Deposition of Shailesh Gohad on December 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 517
NOTICE to Take Deposition of Sanjiv Tomer on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 516
NOTICE to Take Deposition of Ramesh Gupta on December 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 515
NOTICE to Take Deposition of Kondal Reddy Bairy on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 514
NOTICE to Take Deposition of Girij Singh on December 9, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 513
NOTICE to Take Deposition of Dinesh Kumar on December 17, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 512
NOTICE to Take Deposition of Bijay Padhi on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 511
NOTICE to Take Deposition of Dusan Teslic on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 510
NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-156) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 509
NOTICE to Take Deposition of B.S. Natarajan on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 508
NOTICE to Take Deposition of Andreja Kovac on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 507
NOTICE OF SERVICE of (1) Apotex's responses to Plaintiffs' First Set of Interrogatories (Nos. 1-14); and (2) Apotex's responses to Plaintiff's Second Set of Requests for Production (Nos. 117-153) filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Filing 506
NOTICE OF SERVICE of (1) Defendants' Notice of Deposition of Marianne Dragheim; (2) Defendants' Notice of Deposition of Jesper Kjerulff; (3) Defendants' Notice of Deposition of Benny Bang-Andersen; (4) Defendants' Notice of Deposition of Tine Bryan Stensbol; (5) Defendants' Notice of Deposition of Ask Puschl; (6) Defendants' Notice of Deposition of Heidi Lopez de Diego; and (7) Defendants' Notice of Deposition of Kim Andersen filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 505
NOTICE OF SERVICE of Objections to Notice of Deposition of Defendants Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. pursuant to Fed. R. Civ. P. 30(b)(6) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Mosley, Renee)
|
|
Filing 504
NOTICE of Change of Address for Pro Hac Vice Counsel by Cipla Limited, Cipla USA Inc. (Pascale, Karen)
|
|
Filing 503
NOTICE OF SERVICE of Plaintiffs' Second or Third Sets of Interrogatories and Third or Fourth Sets of Requests for Production of Documents and Things (directed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 502
NOTICE OF SERVICE of (1) Responses to Second Set of Requests for Production and (2) Responses to First Set of Interrogatories filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 501
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' Third Set of Requests for Production of Documents and Things (Nos. 131-167) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 500
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Objections and Responses to Plaintiffs' Second Set of Requests for Production of Documents and Things (Nos. 120-156) filed by Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 499
NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-19); and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-187) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 498
NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-18) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 497
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 9-22) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 496
NOTICE of Change of Firm Address of Co-Counsel by Alkem Laboratories Ltd. (Kraman, Pilar)
|
|
Filing 495
NOTICE OF SERVICE of Defendants Macleods Pharmaceuticals, Ltd.s and Macleods Pharma USA, Inc.s Responses to Plaintiffs First Set of Interrogatories to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (Nos.1-15) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 494
NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 119-186) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 493
NOTICE OF SERVICE of Responses and Objections to Second Set of Requests for the Production of Documents and Things (Nos. 76-114) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Cragg, Tyler)
|
|
Filing 492
REDACTED VERSION of #458 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 491
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Response to Plaintiffs' Second Set of Requests for Production (Nos. 117-153) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 490
NOTICE OF SERVICE of Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.s Responses to Plaintiffs Second Set of Requests to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. for the Production of Documents and Things (Nos. 120-156) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 489
NOTICE OF SERVICE of Defendant Alkem Laboratories Ltd.'s Response to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 120-156) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 488
REDACTED VERSION of #446 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 487
ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear argument on the pending motion to dismiss at the same time as the claim construction hearing, which is currently scheduled for November 25 at 9:00 a.m. The Court does not require oral argument on the motion for certification of interlocutory appeal. ORDERED by Judge Leonard P. Stark on 10/25/19. (ntl)
|
|
Filing 486
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso, Esquire regarding Discovery dispute. (Gattuso, Dominick)
|
|
Filing 485
NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' Second Set of Requests for Production (Nos. 118-185) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 484
NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' Second Set of Requests to Unichem Laboratories, Limited for the Production of Documents and Things (Nos. 117-153) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 483
REDACTED VERSION of #460 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 482
REDACTED VERSION of #452 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 481
REDACTED VERSION of #454 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 480
REDACTED VERSION of #445 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 479
REDACTED VERSION of #456 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 478
NOTICE OF SERVICE of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc. and MSN Pharmachem Private Limited's Objection and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 477
REDACTED VERSION of #449 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 476
NOTICE OF SERVICE of Defendant Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' Second Set of Requests for the Production of Documents and Things (Nos. 76-114) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 475
NOTICE OF SERVICE of Torrent Pharmaceuticals Limited and Torrent Pharma Inc.'s Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Riley, Stephanie)
|
|
Filing 474
REDACTED VERSION of #450 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 473
NOTICE OF SERVICE of Defendants Cipla Limited and Cipla USA Inc.'s Response to Plaintiffs' First Set of Interrogatories (Nos. 1 - 19) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 472
NOTICE OF SERVICE of Objections and Responses to First Set of Interrogatories (Nos. 1-8) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 471
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Response to Plaintiffs' First Set of Interrogatories (Nos. 1-15) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 470
NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' First Set of Interrogatories to Unichem Laboratories, Limited (Nos. 1-14) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 469
NOTICE OF SERVICE of Defendant Alkem Laboratories Ltd.s Response to Plaintiffs First Set of Interrogatories (Nos. 1-15) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 468
NOTICE OF SERVICE of Defendant Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit-V's Responses and Objections to Plaintiffs' First Set of Interrogatories (Nos. 1-8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 467
REDACTED VERSION of #457 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 466
REDACTED VERSION of #444 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 465
REDACTED VERSION of #448 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 464
REDACTED VERSION of #455 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 463
NOTICE to Take Deposition of Arne Mork on October 29. 2019 filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 462
REDACTED VERSION of #453 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 461
REDACTED VERSION of #451 Notice to Take Deposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 460
[SEALED] NOTICE to Take Deposition of Defendant Sigmapharm Laboratories, LLC (30(b)(6)) on November 15, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 459
CLAIM Construction Chart by Cipla Limited, Cipla USA Inc.. (Attachments: #1 Exhibit 1)(Vrana, Robert)
|
|
Filing 458
[SEALED] NOTICE to Take Deposition of Defendants Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. (30(b)(6)) on November 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 457
[SEALED] NOTICE to Take Deposition of Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. (30(b)(6)) on November 12, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 456
[SEALED] NOTICE to Take Deposition of Defendants Sandoz Inc., Sandoz AG and LEK Pharmaceuticals, D.D. (30(b)(6)) on November 14, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 455
[SEALED] NOTICE to Take Deposition of Defendant Apicore US LLC (30(b)(6)) on December 2, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 454
[SEALED] NOTICE to Take Deposition of Defendants Hetero (30(b)(6)) on December 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 453
[SEALED] NOTICE to Take Deposition of Defendants Cipla Limited and Cipla USA Inc. (30(b)(6)) on November 19, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 452
[SEALED] NOTICE to Take Deposition of Defendants Apotex Inc., Apotex Corp., and Apotex Research Private Limited (30(b)(6)) on December 6, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 451
[SEALED] NOTICE to Take Deposition of Defendant Alkem Labs Ltd. (30(b)(6)) on November 8, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 450
[SEALED] NOTICE to Take Deposition of Defendants Alembic Pharmaceuticals Limited, Alembic Global Holding S/A and Alembic Pharmaceuticals, Inc. (30(b)(6)) on November 11, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 449
[SEALED] NOTICE to Take Deposition of Defendants Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co. Ltd., Inc. (30(b)(6)) on December 20, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 448
[SEALED] NOTICE to Take Deposition of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited (30(b)(6)) on November 21, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 447
CLAIM CONSTRUCTION ANSWERING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 446
[SEALED] NOTICE to Take Deposition of Defendants Torrent Pharmaceuticals Limited & Torrent Pharma Inc. (30(b)(6)) on November 22, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 445
[SEALED] NOTICE to Take Deposition of Defendants Zydus Pharmaceuticals (USA) Inc. & Cadila Healthcare Ltd. (30(b)(6)) on November 18, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 444
[SEALED] NOTICE to Take Deposition of Unichem Laboratories, Limited (30(b)(6)) on December 13, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 443
DECLARATION re #442 Claim Construction Reply Brief Declaration of Judy K. He In Support of Defendants' Responsive Claim Construction Brief by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit 1)(Gattuso, Dominick)
|
|
Filing 442
Joint CLAIM CONSTRUCTION REPLY BRIEF filed by Defendants filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 441
NOTICE OF SERVICE of Defendants' Second Set of Common Interrogatories to Plaintiffs (Nos. 10-17) and Defendants' Third Set of Requests for Production to Plaintiffs (No. 137) filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 440
NOTICE OF SERVICE of Sandoz Inc.'s First Set of Individual Interrogatories to Plaintiffs (Nos. 1-3) filed by Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 439
NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 438
NOTICE OF SERVICE of (1) Defendants' Amended Rule 30(b)(6) Notice of Deposition to Lundbeck; and (2) Defendants' Amended Rule 30(b)(6) Notice of Deposition to Takeda filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 437
REDACTED VERSION of #433 Declaration, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Partial Judgment on the Pleadings Under FEd. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits P-X, #2 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 436
REDACTED VERSION of #432 Reply Brief, In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Partial Judgment on the Pleadings Under Fed. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 435
NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Interrogatories to Plaintiffs (Nos. 1-2) and (2) Plaintiffs' Objections and Responses to Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Requests for Admission to Plaintiffs (Nos. 1-10) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 434
REQUEST for Oral Argument by Lek Pharmaceuticals d.d., Sandoz Inc. re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c). (Gattuso, Dominick)
|
|
Filing 433
[SEALED] DECLARATION re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c), #432 Reply Brief, by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibit P-X [Under Seal], #2 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 432
[SEALED] REPLY BRIEF re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 431
NOTICE requesting Clerk to remove Howard S. Suh as co-counsel.. (Dorsney, Kenneth)
|
|
Pro Hac Vice Attorney Nicholas P. Chiara for Apicore US LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 430
REDACTED VERSION of #426 Answering Brief in Opposition,, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 429
NOTICE OF SERVICE of Defendant Unichem Laboratories, Limited's Supplemental Disclosures Pursuant to District Court of Delaware Default Standard for Discovery Paragraph 3 filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 428
NOTICE requesting Clerk to remove Daisy Manning as co-counsel. Reason for request: No longer working on the case. (Haney, Megan)
|
|
SO ORDERED, re #427 MOTION for Pro Hac Vice Appearance of Attorney Russell W. Faegenburg filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 10/2/19. (ntl)
|
|
Pro Hac Vice Attorney Russell W. Faegenburg for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd)
|
|
Filing 427
MOTION for Pro Hac Vice Appearance of Attorney Russell W. Faegenburg - filed by Alkem Laboratories Ltd.. (Poff, Adam)
|
|
Filing 426
[SEALED] ANSWERING BRIEF in Opposition re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 10/4/2019. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 425
NOTICE OF SERVICE of (1) Defendants' Rule 30(b)(6) Notice of Deposition to Lundbeck; and (2) Defendants' Rule 30(b)(6) Notice of Deposition to Takeda filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 424
NOTICE OF SERVICE of Plaintiffs' Second or Third Sets of Requests for Production of Documents and Things to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 423
NOTICE OF SERVICE of Plaintiffs' First or Second Sets of Interrogatories to Defendants (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 422
NOTICE requesting Clerk to remove David A. Gerasimow as co-counsel. Reason for request: No long with Husch Blackwell LLP. (Haney, Megan)
|
|
Filing 421
Interim STATUS REPORT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 420
NOTICE OF SERVICE of Plaintiffs' Responsive Initial Infringement Contentions for U.S. Patent Nos. 9,125,908, and 9,125,909 Against Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd. filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 419
REDACTED VERSION of #417 Declaration,, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion to Dismiss by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-O, #2 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 418
REDACTED VERSION of #416 Opening Brief in Support, of Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Partial Judgement on the Pleadings Under Fed. R. Civ. P. 12(c) and to Dismiss for Lack of Subject Matter Jurisdiction Under Fed. R. Civ. P. 12(b)(1) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 417
[SEALED] DECLARATION re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion to Dismiss by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit Exhibits A-O, #2 Certificate of Service)(Gattuso, Dominick) (Attachment 1 replaced on 9/16/2019) (amf).
|
|
Filing 416
[SEALED] OPENING BRIEF in Support re #415 MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1) MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) filed by Lek Pharmaceuticals d.d., Sandoz Inc..Answering Brief/Response due date per Local Rules is 9/27/2019. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 415
MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter UNDER FED. R. CIV. P. 12(b)(1), MOTION for Judgment on the Pleadings UNDER FED. R. CIV. P. 12(c) - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 [Proposed] Order)(Gattuso, Dominick)
|
|
Filing 414
NOTICE of Appearance by Stephanie S. Riley on behalf of Torrent Pharma Inc., Torrent Pharmaceuticals Limited (Riley, Stephanie)
|
|
CORRECTING ENTRY: D.I. 414 has been deleted at the request of the filer (duplicative of D.I. 413). (etg)
|
|
Filing 413
DECLARATION re #412 Claim Construction Opening Brief [Declaration of Joshua E. Ney] by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited and Zydus Pharmaceuticals. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Phillips, John)
|
|
Filing 412
CLAIM CONSTRUCTION OPENING BRIEF filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited and Zydus Pharmaceuticals. (Phillips, John)
|
|
Filing 411
CLAIM CONSTRUCTION OPENING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-9)(Dellinger, Megan)
|
|
Filing 410
CLAIM Construction Chart by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Exhibit 1)(Fineman, Steven)
|
|
Filing 409
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' Second Set of Requests for Production to Plaintiffs (Nos. 95-136) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 408
NOTICE of Withdrawal and Substitution of Co-Counsel by Alkem Laboratories Ltd. (Poff, Adam)
|
|
Filing 407
NOTICE OF SERVICE of Apicore's Revised Paragraph 3 Disclosures filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 406
NOTICE OF SERVICE of (1) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Interrogatories to Plaintiffs (Nos. 1-2); and (2) Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.'s First Set of Individualized Requests for Admission to Plaintiffs (Nos. 1-10) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 405
REDACTED VERSION of #400 Declaration, Second Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit T (UNDER SEAL), #2 Exhibit U, #3 Exhibit V, #4 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 404
REDACTED VERSION of #399 Reply Brief, In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 403
NOTICE OF SERVICE of Defendants' Joint Amended Invalidity Contentions filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 402
NOTICE OF SERVICE of Prinston Pharmaceutical Inc.'s Initial Non-Infringement Contentions for U.S Patent Nos. 9,125,908 and 9,125,909 filed by Prinston Pharmaceutical Inc..(Mowery, Katharine)
|
|
Filing 401
REQUEST for Oral Argument by Lek Pharmaceuticals d.d., Sandoz Inc. re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal. (Gattuso, Dominick)
|
|
Filing 400
[SEALED] Second DECLARATION re #399 Reply Brief, Second Declaration of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit T, #2 Exhibit U, #3 Exhibit V, #4 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 399
[SEALED] REPLY BRIEF re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz AG. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 398
REDACTED VERSION of #393 Answering Brief in Opposition,, Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 397
CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 2 (Volume 2 - Appendix Exhibits T-CC), #2 Exhibit 2 (Volume 2 - Appendix Exhibits DD-HH))(Dellinger, Megan)
|
|
Filing 396
CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit 2 (Volume 1 - Appendix Exhibits A-K), #3 Exhibit 2 (Volume 1 - Appendix Exhibits L-S))(Dellinger, Megan)
|
|
Filing 395
[SEALED] OBJECTIONS by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. to #384 Amended Document, (Plaintiffs' Answer to Alkem's Amended Counterclaims to the Second Amended Complaint). (Dellinger, Megan)
|
|
Filing 394
NOTICE of Change of Address by Kelly E. Farnan (Farnan, Kelly)
|
|
Filing 393
[SEALED] ANSWERING BRIEF in Opposition re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 8/20/2019. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 392
NOTICE OF SERVICE of Plaintiffs' Identification of Rebuttal Evidence in Opposition to Defendants' Proposed Constructions of Disputed Terms filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 391
NOTICE OF SERVICE of Defendants' Revised Preliminary Claim Constructions and Identification of Rebuttal Evidence filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 390
REDACTED VERSION of #384 Amended Document, // ALKEM'S AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' SECOND AMENDED COMPLAINT FOR PATENT INFRINGEMENT by Alkem Laboratories Ltd.. (Attachments: #1 Exhibit A and B)(Kraman, Pilar)
|
|
Filing 389
ORAL ORDER: At the request of counsel for Sandoz, IT IS HEREBY ORDERED that the discovery teleconference scheduled for August 15 is CANCELLED. ORDERED by Judge Leonard P. Stark on 8/8/19. (ntl)
|
|
Filing 388
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for August 15, 2019 at 11:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than August 9, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than August 13, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 8/7/19. (ntl)
|
|
Filing 387
REDACTED VERSION of #379 Declaration, of Judy K. He In Support of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-F, #2 Exhibit G-L, #3 Exhibit M-S, #4 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 386
REDACTED VERSION of #380 Opening Brief in Support, of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 385
REDACTED VERSION of #371 Answer to Counterclaim [MSN] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 384
[SEALED] AMENDED DOCUMENT by Alkem Laboratories Ltd.. Amendment to #344 Answer to Amended Complaint,, Counterclaim, [ALKEM'S AMENDED ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' SECOND AMENDED COMPLAINT FOR PATENT INFRINGEMENT]. (Attachments: #1 Exhibit A, #2 Exhibit B)(Kraman, Pilar)
|
|
Filing 383
REDACTED VERSION of #369 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 382
REDACTED VERSION of #368 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 381
NOTICE OF SERVICE of Defendants' Second Set of Requests for Production to Plaintiffs (Nos. 95-136) filed by Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 380
[SEALED] OPENING BRIEF in Support re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal filed by Lek Pharmaceuticals d.d., Sandoz Inc..Answering Brief/Response due date per Local Rules is 8/13/2019. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 379
[SEALED] DECLARATION re #378 REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A-G, #2 Exhibit H-N, #3 Exhibit O-Q, #4 Exhibit R-S, #5 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 378
REQUEST for Certification of Direct Appeal to the U.S. Court of Appeals Defendant Sandoz Inc. and Lek Pharmaceuticals D.D.'s Motion for Certification for Interlocutory Appeal - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Text of Proposed Order Proposed Order, #2 Rule 7.1.1 Certification)(Gattuso, Dominick)
|
|
Filing 377
NOTICE OF SERVICE of Defendants' Preliminary Claim Constructions filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Cragg, Tyler)
|
|
Filing 376
NOTICE OF SERVICE of Plaintiffs' Preliminary Claim Constructions and Supporting Evidence Pursuant to the Scheduling Order filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 375
ANSWER to #349 Answer to Amended Complaint, Counterclaim (Plaintiffs' Answer to Apotex Inc. and Apotex Corp.'s Counterclaims to the Second Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 374
ANSWER to #345 Answer to Amended Complaint, Counterclaim (Plaintiffs' Answer to Apicore US LLC's Counterclaims to the First Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 373
ANSWER to #344 Answer to Amended Complaint,, Counterclaim, [Alkem] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 372
ANSWER to #343 Answer to Amended Complaint,, Counterclaim, [Torrent] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 371
[SEALED] ANSWER to #351 Answer to Amended Complaint,, Counterclaim, [MSN] by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc..(Dellinger, Megan)
|
|
Filing 370
ANSWER to #348 Answer to Amended Complaint, Counterclaim (Plaintiffs' Answer to Unichem Laboratories, Limited's Counterclaims to the First Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 369
[SEALED] ANSWER to #346 Answer to Amended Complaint, Counterclaim (Plaintiffs' Answer to Lupin Limited's Counterclaims to the First Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 368
[SEALED] ANSWER to #347 Answer to Amended Complaint,, Counterclaim, (Plaintiffs' Answer to Cipla Limited's and Cipla USA Inc.'s Counterclaims to the First Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 367
ANSWER to #342 Answer to Amended Complaint, Counterclaim (Plaintiffs' Answer to Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Counterclaims to the Second Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 366
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Request to Schedule Discovery Teleconference. (Gattuso, Dominick)
|
|
Filing 365
REDACTED VERSION of #343 Answer to Amended Complaint,, Counterclaim, by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Connolly, Arthur)
|
|
Filing 364
REDACTED VERSION of #350 Answer to Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 363
REDACTED VERSION of #346 Answer to Amended Complaint, Counterclaim by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
SO ORDERED, re #360 MOTION for Pro Hac Vice Appearance of Attorney Alissa M. Pacchioli and Jitendra Malik filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Leonard P. Stark on 7/19/19. (ntl)
|
|
Filing 362
REDACTED VERSION of #347 Answer to Amended Complaint,, Counterclaim, by Cipla Limited, Cipla USA Inc.. (Pascale, Karen)
|
|
Filing 361
REDACTED VERSION of #344 Answer to Amended Complaint,, Counterclaim, by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 360
MOTION for Pro Hac Vice Appearance of Attorney Alissa M. Pacchioli and Jitendra Malik - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Filing 359
REDACTED VERSION of #348 Answer to Amended Complaint, Counterclaim by Unichem Laboratories, Limited. (Phillips, John)
|
|
Filing 358
ORDER re #357 Memorandum Opinion regarding claim construction. Signed by Judge Leonard P. Stark on 7/16/19. (ntl)
|
|
Filing 357
MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 7/16/19. (ntl)
|
|
Filing 356
REDACTED VERSION of #341 Answer to Counterclaim, (Answer to Sandoz Inc's Counterclaims to the Second Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 355
Redaction of #264 Transcript as well. (bpg)
|
|
Filing 354
Redaction of #264 Transcript. (bpg)
|
|
Filing 353
NOTICE OF SERVICE of Defendants' Preliminary List of Claim Terms for Construction filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 352
NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 351
[SEALED] ANSWER to Amended Complaint, re: #273 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Certificate of Compliance)(Grivner, Geoffrey)
|
|
Filing 350
[SEALED] ANSWER to #329 Answer to Amended Complaint,, Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 349
ANSWER to Amended Complaint, re: #268 Amended Complaint, , COUNTERCLAIM -- Aporex's Answer, Defenses and Counterclaims to Second Amended Complaint -- against All Plaintiffs by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Filing 348
[SEALED] ANSWER to Amended Complaint, re: #278 Amended Complaint, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Unichem Laboratories, Limited.(Phillips, John)
|
|
Filing 347
[SEALED] ANSWER to Amended Complaint, re: #269 Amended Complaint, [DEFENDANTS CIPLA LIMITEDS AND CIPLA USA INC.'S ANSWER, AFFIRMATIVE DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' FIRST AMENDED COMPLAINT], COUNTERCLAIM against All Plaintiffs by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 346
[SEALED] ANSWER to Amended Complaint, re: #271 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 345
ANSWER to Amended Complaint, re: #267 Amended Complaint, , COUNTERCLAIM -- Apicore's Answer, Defenses and Counterclaims to First Amended Complaint -- against All Plaintiffs by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 344
[SEALED] ANSWER to Amended Complaint, re: #266 Amended Complaint, [ALKEM'S ANSWER, DEFENSES, AND COUNTERCLAIMS TO PLAINTIFFS' SECOND AMENDED COMPLAINT FOR PATENT INFRINGEMENT], COUNTERCLAIM against All Plaintiffs by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 343
[SEALED] ANSWER to Amended Complaint, re: #277 Amended Complaint, , COUNTERCLAIM against H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. by Torrent Pharmaceuticals Limited, Torrent Pharma Inc..(Connolly, Arthur)
|
|
Filing 342
ANSWER to Amended Complaint, re: #272 Amended Complaint, Affirmative Defenses, COUNTERCLAIM to Second Amended Complaint against All Plaintiffs by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 341
[SEALED] ANSWER to #323 Answer to Amended Complaint,, Counterclaim, (Answer to Sandoz Inc.'s Counterclaims to the Second Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 340
SO ORDERED, re #334 STIPULATION AND ORDER TO EXTEND TIME Various Scheduling Order Deadlines to See Stipulation -- Claim Construction Answering Brief due by 10/18/2019. Claim Construction Opening Brief due by 9/6/2019. Discovery due by 12/20/2019. A Markman Hearing is set for 11/25/2019 at 09:00 AM in Courtroom 6B. Signed by Judge Leonard P. Stark on 7/8/19. (ntl)
|
|
Filing 339
ORDER re #327 MOTION to Redact #264 Transcript filed by Lek Pharmaceuticals d.d., Sandoz Inc. Signed by Judge Leonard P. Stark on 7/8/19. (ntl)
|
|
Filing 338
ORDER re #328 MOTION to Redact #264 Transcript filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 7/8/19. (ntl)
|
|
Filing 337
REDACTED VERSION of #329 Answer to Amended Complaint,, Counterclaim, by Alembic Global Holding S/A, Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Seaman, John)
|
|
Filing 336
REDACTED VERSION of #330 Answer to Counterclaim, to Prinston Pharmaceutical Inc.'s by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
SO ORDERED, re #326 Joint STIPULATION TO EXTEND TIME for Defendants Cipla Limited and Cipla USA Inc. to respond to Plaintiffs' First Amended Complaint (D.I. 269) to July 12, 2019 filed by Cipla Limited, Cipla USA Inc. Signed by Judge Leonard P. Stark on 7/3/19. (ntl)
|
|
Filing 335
REDACTED VERSION of #323 Answer to Amended Complaint,, Counterclaim, Affirmative Defenses and Sandoz Inc.'s Counterclaims to Second Amended Complaint for Patent Infringement by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 334
STIPULATION TO EXTEND TIME Various Scheduling Order Deadlines to See Stipulation - filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Filing 333
REDACTED VERSION of #321 Answer to Amended Complaint by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Filing 332
ANSWER to #313 Answer to Amended Complaint, Counterclaim (Answer to Sigmapharm Laboratories, LLC's Counterclaims to First Amended Complaint) by Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 331
ANSWER to #314 Answer to Amended Complaint, Counterclaim (Answer to Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals, Inc.'s First Amended Counterclaims) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 330
[SEALED] ANSWER to #310 Answer to Amended Complaint, Counterclaim (Answer to Prinston Pharmaceutical Inc.'s Counterclaims to the Second Amended Complaint) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 329
[SEALED] ANSWER to Amended Complaint, re: #270 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Attachments: #1 Certificate of Service)(Seaman, John)
|
|
Filing 328
[SEALED] MOTION to Redact #264 Transcript - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Exhibit Exhibit A, #2 Exhibit Exhibit B, #3 Text of Proposed Order Proposed Order, #4 Certificate of Compliance Certificate of Service)(Grivner, Geoffrey)
|
|
Filing 327
[SEALED] MOTION to Redact #264 Transcript Defendants' Unopposed Motion to Redact Transcript - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Text of Proposed Order [Proposed] Order, #4 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
Filing 326
Joint STIPULATION TO EXTEND TIME for Defendants Cipla Limited and Cipla USA Inc.to respond to Plaintiffs' First Amended Complaint (D.I. 269) to July 12, 2019 - filed by Cipla Limited, Cipla USA Inc.. (Pascale, Karen)
|
|
Filing 325
MOTION for Pro Hac Vice Appearance of Attorney Karen L. Beckman - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly)
|
|
SO ORDERED, re #322 STIPULATION TO EXTEND TIME Redaction Request with respect to sealed portion of the Official Transcript (DI 263) held on May 29, 2019 to June 28, 2019 filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc. Signed by Judge Leonard P. Stark on 6/27/19. (ntl)
|
|
SO ORDERED, re #325 MOTION for Pro Hac Vice Appearance of Attorney Karen L. Beckman filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 6/27/19. (ntl)
|
|
Filing 324
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Request to Schedule Discovery Teleconference. (Gattuso, Dominick)
|
|
Filing 323
[SEALED] ANSWER to Amended Complaint, re: #275 Amended Complaint, Affirmative Defenses and Sandoz Inc.'s, COUNTERCLAIM to Second Amended Complaint For Patent Infringement against All Plaintiffs by Lek Pharmaceuticals d.d., Sandoz Inc., Sandoz AG. (Attachments: #1 Exhibit Certificate of Service)(Gattuso, Dominick)
|
|
SO ORDERED, re #319 STIPULATION TO EXTEND TIME re: Macleods Defendants Response to Second Amended Complaint (D.I. 272) to through and including July 12, 2019 filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 6/24/19. (ntl)
|
|
Filing 322
STIPULATION TO EXTEND TIME Redaction Request with respect to sealed portion of the Official Transcript (DI 263) held on May 29, 2019 to June 28, 2019 - filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 321
[SEALED] ANSWER to Amended Complaint, re: #279 Amended Complaint, and Affirmative Defenses by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Phillips, John)
|
|
Filing 320
REDACTED VERSION of #313 Answer to Amended Complaint, Counterclaim by Sigmapharm Laboratories LLC. (Haney, Megan)
|
|
Filing 319
STIPULATION TO EXTEND TIME re: Macleods Defendants Response to Second Amended Complaint (D.I. 272) to through and including July 12, 2019 - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly)
|
|
Filing 318
NOTICE of Appearance by Renee Marie Mosley on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Mosley, Renee)
|
|
Filing 317
REDACTED VERSION of #310 Answer to Amended Complaint, Counterclaim by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Mowery, Katharine)
|
|
Filing 316
NOTICE of Withdrawal of Sara M. Metzler as Counsel for Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Metzler, Sara)
|
|
Filing 315
NOTICE OF SERVICE of Plaintiffs' First Supplemental Objections and Responses to Defendants' First Set of Requests for Production (Nos. 3335, 37, 54, 55, 68, and 69) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 314
ANSWER to Amended Complaint, re: #265 Amended Complaint , COUNTERCLAIM against All Plaintiffs by Alembic Pharmaceuticals Inc., Alembic Global Holding S/A, Alembic Pharmaceuticals Limited.(Farnan, Kelly)
|
|
Filing 313
[SEALED] ANSWER to Amended Complaint, re: #276 Amended Complaint, Affirmative Defenses and, COUNTERCLAIM against All Plaintiffs by Sigmapharm Laboratories LLC.(Phillips, John)
|
|
Filing 312
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,125,908 B2 ;9,125,909 B2 . (Fineman, Steven)
|
|
Filing 311
EXHIBIT re #310 Answer to Amended Complaint, Counterclaim by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Attachments: #1 Exhibit A-B)(Fineman, Steven)
|
|
Filing 310
[SEALED] ANSWER to Amended Complaint, re: #274 Amended Complaint, , COUNTERCLAIM against All Plaintiffs by Zhejiang Huahai Pharmaceutical Co. Ltd, Prinston Pharmaceutical Inc..(Fineman, Steven)
|
|
Filing 309
STIPULATION TO EXTEND TIME Answer Plaintiffs' Second Amended Complaint (D.I. 275) to June 26, 2019 - filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 308
Joint STIPULATION TO EXTEND TIME for Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. to respond to Plaintiffs' Second Amended Complaint (D.I. 268) to July 12, 2019 - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
SO ORDERED, re #309 STIPULATION TO EXTEND TIME Answer Plaintiffs' Second Amended Complaint (D.I. 275) to June 26, 2019 filed by Lek Pharmaceuticals d.d., Sandoz Inc., #308 Joint STIPULATION TO EXTEND TIME for Defendants Lupin Limited and Lupin Pharmaceuticals, Inc. to respond to Plaintiffs' Second Amended Complaint (D.I. 268) to July 12, 2019 filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Leonard P. Stark on 6/14/19. (ntl)
|
|
SO ORDERED, re #307 STIPULATION TO EXTEND TIME for Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. to respond to Plaintiffs' First Amended Complaint [D.I. 277] to July 12, 2019 filed by Torrent Pharmaceuticals Limited, Torrent Pharma Inc., #306 STIPULATION TO EXTEND TIME re: Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. Response to Plaintiffs' Second Amended Complaint (D.I. 272) to through and including June 28, 2019 filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc., #305 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiffs' Second Amended Complaint (D.I. 279) to June 21, 2019 filed by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. Signed by Judge Leonard P. Stark on 6/13/19. (ntl)
|
|
Filing 307
STIPULATION TO EXTEND TIME for Defendants Torrent Pharmaceuticals Limited and Torrent Pharma Inc. to respond to Plaintiffs' First Amended Complaint [D.I. 277] to July 12, 2019 - filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited. (Connolly, Arthur)
|
|
Filing 306
STIPULATION TO EXTEND TIME re: Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. Response to Plaintiffs' Second Amended Complaint (D.I. 272) to through and including June 28, 2019 - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly)
|
|
Filing 305
STIPULATION TO EXTEND TIME to answer, move or otherwise respond to Plaintiffs' Second Amended Complaint (D.I. 279) to June 21, 2019 - filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
SO ORDERED, re #301 STIPULATION TO EXTEND TIME for defendants Cipla Limited and Cipla USA Inc.to respond to Plaintiffs First Amended Complaint to June 28, 2019 filed by Cipla Limited, Cipla USA Inc., #302 STIPULATION TO EXTEND TIME for Defendants Apotex Corp. and Apotex Inc. to respond to Plaintiffs' Second Amended Complaint to July 12, 2019 filed by Apotex Inc., Apotex Corp., #298 STIPULATION TO EXTEND TIME TO ANSWER COMPLAINT to JULY 12, 2019 filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., #303 STIPULATION TO EXTEND TIME Resond to amended complaint to July 12, 2019 filed by Apicore US LLC, #282 STIPULATION TO EXTEND TIME for defendants Hetero USA Inc., Hetero Labs Ltd., and Hetero Labs Limited Unit-V to respond to Plaintiffs' First Amended Complaint to June 28, 2019 filed by Hetero Labs Limited Unit-V, Hetero USA Inc., Hetero Labs Limited, #304 STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Amended Supplemental Complaint to July 12, 2019 filed by Unichem Laboratories, Limited, #299 STIPULATION TO EXTEND TIME to move against, answer or otherwise respond to the Second Amended Complaint to July 12, 2019 filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 6/12/19. (ntl)
|
|
Filing 304
STIPULATION TO EXTEND TIME for Defendant Unichem Laboratories, Limited to respond to Plaintiffs' First Amended Supplemental Complaint to July 12, 2019 - filed by Unichem Laboratories, Limited. (Haney, Megan)
|
|
Filing 303
STIPULATION TO EXTEND TIME Resond to amended complaint to July 12, 2019 - filed by Apicore US LLC. (Dorsney, Kenneth)
|
|
Filing 302
STIPULATION TO EXTEND TIME for Defendants Apotex Corp. and Apotex Inc. to respond to Plaintiffs' Second Amended Complaint to July 12, 2019 - filed by Apotex Corp., Apotex Inc.. (Dorsney, Kenneth)
|
|
Filing 301
STIPULATION TO EXTEND TIME for defendants Cipla Limited and Cipla USA Inc.to respond to Plaintiffs First Amended Complaint to June 28, 2019 - filed by Cipla Limited, Cipla USA Inc.. (Pascale, Karen)
|
|
Filing 300
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Second Amended Initial Disclosures filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 299
STIPULATION TO EXTEND TIME to move against, answer or otherwise respond to the Second Amended Complaint to July 12, 2019 - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 298
STIPULATION TO EXTEND TIME TO ANSWER COMPLAINT to JULY 12, 2019 - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Grivner, Geoffrey)
|
|
Filing 297
REDACTED VERSION of #279 Amended Complaint, Second Amended Complaint against Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan)
|
|
Filing 296
REDACTED VERSION of #278 Amended Complaint, First Amended Supplemental Complaint against Unichem Laboratories, Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 295
REDACTED VERSION of #274 Amended Complaint, Second Amended Complaint against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 294
REDACTED VERSION of #273 Amended Complaint, First Amended Complaint against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., and MSN Pharmachem Private Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 293
REDACTED VERSION of #269 Amended Complaint, First Amended against Cipla Limited and Cipla USA Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-E)(Dellinger, Megan)
|
|
Filing 292
REDACTED VERSION of #268 Amended Complaint, Second Amended Complaint against Apotex Corp., Apotex Inc., and Apotex Research Private Limited by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 291
REDACTED VERSION of #265 Amended Complaint Second Amended Complaint Against Alembic Pharmaceuticals Limited, Alembic Global Holding SA and Alembic Pharmaceuticals, Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 290
REDACTED VERSION of #276 Amended Complaint, First Amended Complaint against Sigmapharm Laboratories LLC by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 289
REDACTED VERSION of #267 Amended Complaint, First Amended Complaint against Apicore US LLC by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 288
REDACTED VERSION of #266 Amended Complaint, Second Amended Complaint Against Alkem Laboratories Ltd. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 287
REDACTED VERSION of #275 Amended Complaint, Second Amended Complaint against Lek Pharmaceuticals d.d. and Sandoz Inc by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 286
REDACTED VERSION of #270 Amended Complaint, First Amended Complaint against Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 285
REDACTED VERSION of #277 Amended Complaint, First Amended Complaint Against Torrent Pharmaceuticals Limited and Torrent Pharma Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 284
REDACTED VERSION of #271 Amended Complaint, First Amended Complaint against Lupin Limited and Lupin Pharmaceuticals Inc. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan)
|
|
Filing 283
REDACTED VERSION of #272 Amended Complaint, Second Amended Complaint against Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 282
STIPULATION TO EXTEND TIME for defendants Hetero USA Inc., Hetero Labs Ltd., and Hetero Labs Limited Unit-V to respond to Plaintiffs' First Amended Complaint to June 28, 2019 - filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Seaman, John)
|
|
Filing 281
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Apicore US LLC's First Set of Requests for Production (Nos. 95-96) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 280
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,144,884 ;8,476,279 ;8,722,684 ;8,969,355 ;9,227,946 ;9,861,630 ;9,125,910 9,278,096. (Dellinger, Megan)
|
|
Filing 279
[SEALED] Second AMENDED COMPLAINT against Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-I)(Dellinger, Megan)
|
|
Filing 278
[SEALED] First AMENDED COMPLAINT (Supplemental) against Unichem Laboratories, Limited- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 277
[SEALED] First AMENDED COMPLAINT against Torrent Pharma Inc., Torrent Pharmaceuticals Limited- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 276
[SEALED] First AMENDED COMPLAINT against Sigmapharm Laboratories LLC- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 275
[SEALED] Second AMENDED COMPLAINT against Lek Pharmaceuticals d.d., Sandoz Inc.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 274
[SEALED] Second AMENDED COMPLAINT against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 273
[SEALED] First AMENDED COMPLAINT against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-C)(Dellinger, Megan)
|
|
Filing 272
[SEALED] Second AMENDED COMPLAINT against Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 271
[SEALED] First AMENDED COMPLAINT against Lupin Limited, Lupin Pharmaceuticals Inc.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-D)(Dellinger, Megan)
|
|
Filing 270
[SEALED] First AMENDED COMPLAINT against Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 269
[SEALED] First AMENDED COMPLAINT against Cipla Limited, Cipla USA Inc.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-E)(Dellinger, Megan)
|
|
Filing 268
[SEALED] Second AMENDED COMPLAINT against Apotex Corp., Apotex Inc., Apotex Research Private Limited- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 267
[SEALED] First AMENDED COMPLAINT against Apicore US LLC- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 266
[SEALED] Second AMENDED COMPLAINT against Alkem Laboratories Ltd.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 265
[SEALED] Second AMENDED COMPLAINT against Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited- filed by H. Lundbeck A/S. (Attachments: #1 Exhibit A-F)(Dellinger, Megan)
|
|
Filing 264
[SEALED] Transcript of Claim Construction Hearing held on May 29, 2019 before Chief Judge Leonard P. Stark. (bpg)
|
|
Filing 263
Official Transcript of Claim Construction Hearing held on May 29, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone number (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 6/21/2019. Redacted Transcript Deadline set for 7/1/2019. Release of Transcript Restriction set for 8/29/2019.(bpg)
|
|
Filing 262
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Plaintiffs' Claim Construction Presentation. (Attachments: #1 Plaintiffs' Claim Construction Presentation)(Dellinger, Megan)
|
|
Filing 261
NOTICE OF SERVICE of Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA Inc.'s Amended Initial Disclosures Pursuant to the Default Standard, Paragraph 3 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 260
ORAL ORDER: For the reasons stated at the hearing today, IT IS HEREBY ORDERED that Plaintiffs' Motion for Leave to File Amended Complaints (D.I. 224) is GRANTED. ORDERED by Judge Leonard P. Stark on 5/29/19. (ntl)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing held on 5/29/2019. (Court Reporter B. Gaffigan.) (ntl)
|
|
Filing 259
ORAL ORDER: IT IS HEREBY ORDERED that the parties come prepared to discuss Plaintiffs' Motion for Leave to File Amended Complaints (D.I. 224) and the MSN discovery dispute (D.I. 257) at tomorrow's hearing. ORDERED by Judge Leonard P. Stark on 5/28/19. (ntl)
|
|
Pro Hac Vice Attorney Charles T. Wysocki for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (myr)
|
|
Filing 258
ORAL ORDER: IT IS HEREBY ORDERED that each side will be allocated one (1) hour for argument at the Markman Hearing scheduled for May 29, 2019. ORDERED by Judge Leonard P. Stark on 5/23/19. (ntl)
|
|
Filing 257
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for Discovery Teleconference. (Dellinger, Megan)
|
|
Filing 256
REDACTED VERSION of #253 Claim Construction Reply Brief,,, by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC, Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit D, #2 Exhibit E, #3 Exhibit F)(Phillips, John)
|
|
Filing 255
REDACTED VERSION of #251 Claim Construction Reply Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-3)(Dellinger, Megan)
|
|
Filing 254
CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit 2)(Dellinger, Megan)
|
|
Filing 253
[SEALED] CLAIM CONSTRUCTION REPLY BRIEF re #232 Claim Construction Answering Brief, filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit D, #2 Exhibit E, #3 Exhibit F)(Phillips, John)
|
|
Filing 252
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding May 29, 2019 claim construction hearing - re #31 Scheduling Order,,,. (Dellinger, Megan)
|
|
Filing 251
[SEALED] CLAIM CONSTRUCTION REPLY BRIEF re #230 Claim Construction Answering Brief, filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-3)(Dellinger, Megan)
|
|
Filing 250
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,684 B2 ;8,969,355 B2 ;9,227,946 B2 ;9,896,630 B1 [Amended to include 9,861,630 B1. (Dellinger, Megan)
|
|
Filing 249
AMENDED DOCUMENT by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. Amendment to #1 Complaint, [First Amended Complaint for Patent Infringement Against Sandoz Inc. and Lek Pharmaceuticals D.D.]. (Attachments: #1 Exhibit A-D)(Dellinger, Megan)
|
|
SO ORDERED, re #246 STIPULATION to Amend the Complaint against the Sandoz Defendants. Signed by Judge Leonard P. Stark on 5/14/19. (ntl)
|
|
Filing 248
REDACTED VERSION of #242 Letter, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 247
NOTICE OF SERVICE of Apicore's responses to first set of requests for production (Nos. 1-119) filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 246
Joint STIPULATION to Amend the Complaint against the Sandoz Defendants & (Proposed) Order by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit A-D, #3 Exhibit 2)(Dellinger, Megan)
|
|
Filing 245
REDACTED VERSION of #235 Notice of Filing Multi Media Materials, by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John)
|
|
Filing 244
REDACTED VERSION of #234 Letter, by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Alkem Laboratories Ltd., Apicore US LLC, Apotex Corp., Apotex Inc., Apotex Research Private Limited, Cadila Healthcare Ltd., Cipla Limited, Cipla USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Lek Pharmaceuticals d.d., Lupin Limited, Lupin Pharmaceuticals Inc., MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Prinston Pharmaceutical Inc., Sandoz AG, Sandoz Inc., Sigmapharm Laboratories LLC, Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Unichem Laboratories, Limited, Zhejiang Huahai Pharmaceutical Co. Ltd, Zydus Pharmaceuticals (USA) Inc.. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D)(Phillips, John)
|
|
Filing 243
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding request for teleconference - re #224 MOTION for Leave to File Amended Complaints. (Dellinger, Megan)
|
|
Filing 242
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Reply in Support of Request for Leave to File Amended Complaints - re #224 MOTION for Leave to File Amended Complaints. (Attachments: #1 Exhibit H-L)(Dellinger, Megan)
|
|
Filing 241
REDACTED VERSION of #230 Claim Construction Answering Brief, by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C)(Pedi, Nicole)
|
|
Filing 240
REDACTED VERSION of #233 Declaration, (Declaration of Gregory W. Mattingly) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit H-L, #2 Exhibit M (Part 1), #3 Exhibit M (Part 2), #4 Exhibit N)(Dellinger, Megan)
|
|
Filing 239
REDACTED VERSION of #232 Claim Construction Answering Brief, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10, #2 Exhibit 11-15, #3 Exhibit 16 (Part 1), #4 Exhibit 16 (Part 2), #5 Exhibit 17)(Dellinger, Megan)
|
|
Filing 238
REDACTED VERSION of #231 Statement by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Cragg, Tyler)
|
|
Filing 237
NOTICE OF SERVICE of Defendant Apicore US LLC's First Set of Requests for Production to Plaintiffs (Nos. 1-96) filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 236
[SEALED] MULTI MEDIA DOCUMENT filed by Defendants in the form of a flash drive. Filing related to #234 Letter, #235 Notice of Filing Multi Media Materials. (Media on file in Clerk's Office). (ntl)
|
|
Filing 235
[SEALED] NOTICE of filing the following Non-Paper material(s) in multi media format: Thumb Drive. Original Non-paper material(s) to be filed with the Clerk's Office. Notice filed by John C. Phillips, Jr on behalf of Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc. (Phillips, John)
|
|
Filing 234
[SEALED] Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Opposition to Plaintiffs' Motion for Leave to File Amended Complaints - re #225 Letter, #224 MOTION for Leave to File Amended Complaints. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C, #4 Exhibit D)(Phillips, John)
|
|
Filing 233
[SEALED] DECLARATION re #232 Claim Construction Answering Brief, (Declaration of Gregory W. Mattingly, M.D.) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit H-L, #2 Exhibit M (Part 1), #3 Exhibit M (Part 2), #4 Exhibit N)(Dellinger, Megan)
|
|
Filing 232
[SEALED] CLAIM CONSTRUCTION ANSWERING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-10, #2 Exhibit 11-15, #3 Exhibit 16 (Part 1), #4 Exhibit 16 (Part 2), #5 Exhibit 17)(Dellinger, Megan)
|
|
Filing 231
[SEALED] STATEMENT re #213 Letter [Defendants' Comments Regarding Plaintiffs' Tutorial Concerning the Technology at Issue by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd. (Mowery, Katharine)
|
|
Filing 230
[SEALED] CLAIM CONSTRUCTION ANSWERING BRIEF re #201 Claim Construction Opening Brief, filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C)(Farnan, Kelly)
|
|
Filing 229
STATEMENT re #214 Notice (Other) (Plaintiffs' Response to Defendants' Technology Tutorial) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-5)(Dellinger, Megan)
|
|
Filing 228
REDACTED VERSION of #225 Letter, by Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG. (Attachments: #1 Exhibits A-G)(Dellinger, Megan)
|
|
Filing 227
REDACTED VERSION of #224 MOTION for Leave to File Amended Complaints by Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG. (Attachments: #1 Exhibits 1A-7B, #2 Exhibits 8A-15B)(Dellinger, Megan)
|
|
SO ORDERED, re #226 STIPULATION and [Proposed] Order to Extend Page Limits and Time Limits for Briefing of Plaintiffs' Motion to Amend. Signed by Judge Leonard P. Stark on 4/24/19. (ntl)
|
|
CORRECTING ENTRY: Corrected documents added to D.I. 224 and D.I. 225 per request of counsel. (ntl)
|
|
Filing 226
STIPULATION and [Proposed] Order to Extend Page Limits and Time Limits for Briefing of Plaintiffs' Motion to Amend re #224 MOTION for Leave to File Amended Complaints by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 225
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding motion for leave to file amend complaints - re #224 MOTION for Leave to File Amended Complaints. (Attachments: #1 Exhibits A-G)(Dellinger, Megan) (Main Document 225 replaced on 4/23/2019) (ntl). (Attachment 1 replaced on 4/23/2019) (ntl).
|
|
Filing 224
[SEALED] MOTION for Leave to File Amended Complaints - filed by Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1A-7B, #2 Exhibits 8A-15B)(Dellinger, Megan) (Attachment 2 replaced on 4/23/2019) (ntl).
|
|
Filing 223
NOTICE of by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc. Notice of Service of Defendants Sandoz, Inc. and Lek Pharmaceuticals d.d.'s First Amended Initial Disclosures (Gattuso, Dominick)
|
|
SO ORDERED, re #222 Stipulation and Order to Extend Page Limits. Signed by Judge Leonard P. Stark on 4/17/19. (ntl)
|
|
Filing 222
STIPULATION to Extend Page Limits by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 221
NOTICE OF SERVICE of Plaintiffs' First Set of Requests to Apicore US LLC for the Production of Documents and Things (Nos. 1-119) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 220
ORDER Setting Mediation Conference: A Telephone Conference is set with Plaintiffs and Defendants Cipla Limited and Cipla USA, Inc. for 4/15/2019 at 10:15 AM before Judge Christopher J. Burke. Ordered by Judge Christopher J. Burke on 3/28/2019. (dlb)
|
|
Filing 219
NOTICE to Take Deposition of Bankole Akindeinde Johnson on March 29, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 218
NOTICE to Take Deposition of Bankole Akindeinde Johnson on March 26, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 217
NOTICE to Take Deposition of Allan S. Myerson, Ph.D. on March 27, 2019 beginning at 9:00 a.m. filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 216
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-9) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 215
NOTICE to Take Deposition of William E. Mayo on March 21, 2019 filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 214
NOTICE of Lodging by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited of Defendants Technology Tutorial (Pedi, Nicole)
|
|
Filing 213
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding enclosing a DVC containing Plaintiffs' tutorial concerning technology at issue - re #31 Scheduling Order,,,. (Dellinger, Megan)
|
|
Filing 212
NOTICE to Take Deposition of Gregory W. Mattingly, M.D. on March 18, 2019 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
SO ORDERED, re #211 MOTION for Pro Hac Vice Appearance of Attorney Jennifer Liu filed by MSN Pharmachem Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc. Signed by Judge Leonard P. Stark on 3/13/19. (ntl)
|
|
Filing 211
MOTION for Pro Hac Vice Appearance of Attorney Jennifer Liu - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited. (Attachments: #1 Certificate of Compliance for Jennifer Liu, #2 Text of Proposed Order for Jennifer Liu)(Grivner, Geoffrey)
|
|
SO ORDERED, re #209 Joint STIPULATION TO EXTEND TIME to submit Technology Tutorials to March 15, 2019 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 3/6/19. (ntl)
|
|
Filing 210
Official Transcript of Oral Argument Hearing held on February 26, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/27/2019. Redacted Transcript Deadline set for 4/8/2019. Release of Transcript Restriction set for 6/4/2019. (bpg)
|
|
Filing 209
Joint STIPULATION TO EXTEND TIME to submit Technology Tutorials to March 15, 2019 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 208
REDACTED VERSION of #195 Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Oral Order - re 191 Order by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit 1 - 8)(Gattuso, Dominick)
|
|
Filing 207
REDACTED VERSION of #196 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Discovery Disputes and Responding to the Court's February 22, 2019 Oral Order (D.I. 191) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 206
DECLARATION re #200 Claim Construction Opening Brief (William E. Mayo, Ph.D.) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit A - H)(Gattuso, Dominick)
|
|
Filing 205
DECLARATION re #201 Claim Construction Opening Brief, -- Declaration of Allan S. Myerson, Ph.D. -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-T)(Dellinger, Megan)
|
|
Filing 204
DECLARATION re #200 Claim Construction Opening Brief (Bankole Akindeinde Johnson) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit 1-4)(Gattuso, Dominick)
|
|
Filing 203
DECLARATION re #201 Claim Construction Opening Brief, -- Declaration of Gregory W. Mattingly, M.D. -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits A-G)(Dellinger, Megan)
|
|
Filing 202
DECLARATION re #200 Claim Construction Opening Brief (Judy K. He) by Lek Pharmaceuticals d.d., Sandoz Inc.. (Attachments: #1 Exhibit 1-6)(Gattuso, Dominick)
|
|
Filing 201
CLAIM CONSTRUCTION OPENING BRIEF filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibits 1-12)(Dellinger, Megan)
|
|
Filing 200
CLAIM CONSTRUCTION OPENING BRIEF (DEFENDANTS) filed by Lek Pharmaceuticals d.d., Sandoz Inc.. (Gattuso, Dominick)
|
|
Filing 199
NOTICE requesting Clerk to remove Daniel J. Ritterbeck as co-counsel. Reason for request: no longer with Sterne, Kessler, Goldstein & Fox P.L.L.C.. (Kraman, Pilar)
|
|
SO ORDERED, re #193 STIPULATION TO EXTEND TIME re: Technology Tutorials to March 8, 2019 filed by Alembic Global Holding S/A, Macleods Pharmaceuticals Ltd., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 2/28/19. (ntl)
|
|
Filing 198
NOTICE of Change of Address by Arthur G. Connolly, III (Connolly, Arthur)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Oral Argument held on 2/26/2019. (Court Reporter B. Gaffigan.) Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00177-LPS (ntl)
|
|
Filing 197
ORAL ORDER: For the reasons stated at the hearing today, IT IS HEREBY ORDERED that Sandoz AG's motion to dismiss (C.A. No. 18-177 D.I. 23) is GRANTED. ORDERED by Judge Leonard P. Stark on 2/26/19. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00177-LPS (ntl)
|
|
Filing 196
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Discovery Disputes and Responding to the Court's February 22, 2019 Oral Order (D.I. 191). (Attachments: #1 Exhibit A-H)(Dellinger, Megan)
|
|
Filing 195
[SEALED] Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Oral Order - re 191 Order,,,. (Attachments: #1 Exhibit 1 - 8)(Gattuso, Dominick)
|
|
Filing 194
ORAL ORDER: IT IS HEREBY ORDERED that the Oral Argument set for 2/26/2019 at 03:00 PM will take place in Courtroom 6B before Judge Leonard P. Stark. Ordered by Judge Leonard P. Stark on 2/25/2019. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00177-LPS (ntl)
|
|
Filing 193
STIPULATION TO EXTEND TIME re: Technology Tutorials to March 8, 2019 - filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Farnan, Kelly)
|
|
Filing 192
ORAL ORDER: IT IS HEREBY ORDERED that the Oral Argument set for 2/26/2019 at 03:00 PM will take place in Courtroom 4A before Judge Leonard P. Stark. Ordered by Judge Leonard P. Stark on 2/22/2019. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00177-LPS(etg)
|
|
Filing 191
ORAL ORDER: Having been advised by Plaintiffs and Defendants Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals d.d. (collectively, "Defendants") of their inability to resolve a discovery matter that they wish to address at the February 26 hearing on Sandoz AG's motion to dismiss, IT IS HEREBY ORDERED that not later than February 25, 2018, Plaintiffs and Defendants shall file simultaneous letters with the Court, not to exceed five (5) pages, outlining not only the discovery issues in dispute and their position on those issues, but also their position on how the Court's recent opinion, Adverio Pharma GmbH v. Alembic Pharmaceuticals Limited, 2019 WL 581618 (D. Del. Feb. 13, 2019), impacts Sandoz AG's motion. ORDERED by Judge Leonard P. Stark on 2/22/19. (ntl)
|
|
Filing 190
Letter to the Honorable Leonard P. Stark from Megan E. Dellinger regarding Request for Discovery Teleconference. (Dellinger, Megan)
|
|
Filing 189
NOTICE OF SERVICE of Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' First Set of Requests for Admission (Nos. 1-11) [COMPETITIVELY SENSITIVE CONFIDENTIAL INFORMATION - SUBJECT TO PROTECTIVE ORDER]; and Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' First Set of Interrogatories (Nos. 1-8) [COMPETITIVELY SENSITIVE CONFIDENTIAL INFORMATION - SUBJECT TO PROTECTIVE ORDER] filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 188
NOTICE OF SERVICE of Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals d.d.'s Objections and Responses to Plaintiffs' Second Set of Requests for Production (Nos. 122-130) [CONFIDENTIAL SUBJECT TO PROTECTIVE ORDER] filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 187
CLAIM Construction Chart by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1, #2 Exhibit 2 (Joint Appendix))(Dellinger, Megan)
|
|
Filing 186
NOTICE OF SERVICE of Defendants' First Set of Common Interrogatories to Plaintiffs (Nos. 1-9) filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 185
NOTICE OF SERVICE of Defendant Apicore US LLC's Initial Invalidity Contentions filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 184
NOTICE OF SERVICE of Plaintiffs' Identification of Rebuttal Evidence in Opposition to Apicore's Proposed Constructions of Disputed Terms filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 183
NOTICE OF SERVICE of Apicore's Production of Drug Master Files and Samples filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 182
NOTICE OF SERVICE of Apicore's identification of rebuttal evidence in support of proposed claim constructions filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
ORAL ORDER: If during the history of this case, Plaintiff(s) and Defendant(s) jointly wish to schedule a form of alternative dispute resolution ("ADR"), such as mediation, with Judge Burke, they should contact chambers by e-mail at Deborah_Benyo@ded.uscourts.gov or by phone. Additionally, if either side wishes to speak ex parte with Judge Burke regarding ADR matters, they may contact chambers via e-mail or by phone to arrange a time for a call. Ordered by Judge Christopher J. Burke on 1/16/2019. Associated Cases: 1:18-cv-00088-LPS et al.(dlb)
|
|
Filing 181
NOTICE OF SERVICE of Plaintiffs' Identification of Rebuttal Evidence in Opposition to Defendants' Proposed Construction of Disputed Terms Purusant to the Scheduling Order filed by H. Lundbeck A/S, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 180
NOTICE OF SERVICE of Defendants' Identification of Rebuttal Evidence in Support of Their Proposed Claim Constructions filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 179
NOTICE OF SERVICE of Apotex's Responses to Plaintiffs' First Set of Requests for Production (Nos. 1-116) filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at # http://www.ded.uscourts.gov/general-orders/magistrate-judges-standing-order-adr-mediation Associated Cases: 1:18-cv-00088-LPS et al.(cak)
|
|
Filing 178
NOTICE OF SERVICE of Plaintiff's Preliminary Claim Constructions and Supporting Evidence to Apicore filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 177
NOTICE OF SERVICE of Defendant Apicore US LLC's Preliminary Claim Constructions filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 176
NOTICE OF SERVICE of (1) Plaintiffs' First Set of Requests for Admission to Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals, D.D. (Nos. 1-11); (2) Plaintiffs' First Set of Interrogatories to Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals, D.D. (Nos. 1-8); and (3) Plaintiffs' Second Set of Requests to Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals, D.D. for the Production of Documents and Things (Nos. 122-130) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Blumenfeld, Jack)
|
|
Filing 175
NOTICE OF SERVICE of (1) MSN PHARMACEUTICALS, INC. AND MSN LABORATORIES PRIVATE LIMITED OBJECTIONS, MSN PHARMACHEM PRIVATE LIMITED, AND RESPONSES TO PLAINTIFFS FIRST SET OF REQUESTS FOR THE PRODUCTION OF DOCUMENTS AND THINGS (NOS. 1-118); and (2) MSN PHARMACEUTICALS, INC. AND MSN LABORATORIES PRIVATE LIMITED OBJECTIONS, MSN PHARMACHEM PRIVATE LIMITED, AND RESPONSES TO PLAINTIFFS SECOND SET OF REQUESTS FOR THE PRODUCTION OF DOCUMENTS AND THINGS (NOS. 119-124) filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 174
NOTICE OF SERVICE of Alkem Laboratories Ltd.s Objections and Responses to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-119) filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 173
NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions Against Apicore US LLC filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 172
NOTICE OF SERVICE of Objections and Responses to Plaintiffs' First Set of Requests to Sandoz Inc., Sandoz AG, and LEK Pharmaceuticals, d.d. for the Production of Documents and Things (Nos. 1-121) (CONFIDENTIAL) filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 171
ORAL ORDER: IT IS HEREBY ORDERED that the Court will hear oral argument on the motion to dismiss (D.I. 23 in 18-177-LPS) on February 26, 2019 beginning at 3:00 p.m. Each side will be allocated up to 30 minutes to present its argument. ORDERED by Judge Leonard P. Stark on 1/4/19. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00177-LPS (ntl)
|
|
Filing 170
[SEALED] ORDER re #160 Joint MOTION to Dismiss filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd., Party Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Company GmbH and Amneal Pharmaceuticals LLC terminated. Attorney Samantha G. Wilson; Michael R. Dzwonczyk and Anne Shea Gaza terminated. Signed by Judge Leonard P. Stark on 12/26/18. This order has been emailed to local counsel. (ntl)
|
|
Filing 169
REDACTED VERSION of #158 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Discovery Dispute Conference Scheduled for December 21, 2018 by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A)(Dellinger, Megan)
|
|
Filing 168
NOTICE OF SERVICE of Plaintiffs' Preliminary Identification of Claim Terms to Apicore filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 167
NOTICE OF SERVICE of 1) Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Responses to Plaintiffs' First Set of Requests to Macleods for the Production of Documents and Things (Nos. 1-119) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 166
NOTICE OF SERVICE of Sigmapharm Laboratories, LLC's Objections and Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-119) filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 165
NOTICE OF SERVICE of Defendant Apicore's Proposed Claim Terms for Construction filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 164
REDACTED VERSION of #152 Letter by Sigmapharm Laboratories LLC. (Attachments: #1 Exhibit 1)(Phillips, John)
|
|
Filing 163
NOTICE OF SERVICE of Defendant Unichem's Responses and Objections to Plaintiffs' First Set of Requests to Unichem Laboratories, Limited for the Production of Documents and Things (Nos. 1-116) filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 162
ORAL ORDER: Having reviewed the parties' letters (D.I. 149, 152) concerning Plaintiffs' request for an order compelling Sigmapharm to produce an unredacted version of DMF No. 031898, including all documents listed in Exhibit 1 (D.I. 149-1 Ex. 1), to be shared only with Plaintiffs' outside counsel and outside experts, IT IS HEREBY ORDERED that Plaintiffs' request is GRANTED. Sigmapharm does not dispute that the redacted information is relevant to infringement and was already ordered to be produced on September 14 pursuant to the Scheduling Order. (D.I. 31 at 10) Sigmapharm's proposal that Plaintiffs' request be denied without prejudice to renew only after Plaintiffs show infringement through testing or some other evidence is not unreasonable, but neither is Plaintiffs' rejection of that proposal unreasonable. Plaintiffs have the burden to prove infringement, evidently believe in good faith they will be able to do so, and are therefore entitled to obtain relevant discoverable information, including Sigmapharm's trade secrets, pursuant to the protections provided by the Protective Order an order which was extensively negotiated and litigated and which clearly contemplates that trade secrets (particularly in the DMF) will need to be disclosed. (See D.I. 132 at 12) The Court's decision is further supported by the reasoning it provided in Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., C.A. No. 17-374-LPS D.I. 455 at 35-39 (Nov. 30, 2018). The Court also agrees with Plaintiffs (see D.I. 158) that to the extent Sigmapharm intended its letter of December 14 (D.I. 152) to be construed as a motion to preclude all of Plaintiffs' experts from accessing Sigmapharm's samples and/or documents (whether already produced or to be produced as a consequence of today's order), Sigmapharm has not followed any proper procedure for seeking such relief. Should Sigmapharm wish to move pursuant to paragraph 11 of the Protective Order to preclude one or more experts from accessing the unredacted DMF, Sigmapharm must first meet and confer and then, upon an impasse, timely follow the Court's discovery disputes procedures. IT IS FURTHER ORDERED that the teleconference scheduled for tomorrow, December 21, is CANCELLED. ORDERED by Judge Leonard P. Stark on 12/20/18. (ntl)
|
|
Filing 161
REDACTED VERSION of #160 Joint MOTION to Dismiss by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Attachments: #1 Exhibit A, #2 Text of Proposed Order)(Gaza, Anne)
|
|
Filing 160
[SEALED] Joint MOTION to Dismiss - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Attachments: #1 Exhibit A, #2 Text of Proposed Order)(Gaza, Anne)
|
|
Filing 159
REDACTED VERSION of #149 Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding discovery dispute with Sigmapharm by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1-11)(Dellinger, Megan)
|
|
Filing 158
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding Discovery Dispute Conference Scheduled for December 21, 2018. (Attachments: #1 Exhibit A)(Dellinger, Megan)
|
|
SO ORDERED, re #155 STIPULATION TO EXTEND TIME for Various Deadlines (see Stipulation for Details) to December 21, 2018 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 12/19/18. (ntl)
|
|
SO ORDERED, re #157 MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Chiara filed by Apicore US LLC. Signed by Judge Leonard P. Stark on 12/19/18. (ntl)
|
|
Filing 157
MOTION for Pro Hac Vice Appearance of Attorney Nicholas P. Chiara - filed by Apicore US LLC. (Dorsney, Kenneth)
|
|
Filing 156
NOTICE OF SERVICE of Response to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-119) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur)
|
|
Filing 155
STIPULATION TO EXTEND TIME for Various Deadlines (see Stipulation for Details) to December 21, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 154
NOTICE OF SERVICE of Defendants' Preliminary Claim Constructions filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 153
NOTICE OF SERVICE of Plaintiff's Preliminary Claim Constructions and Supporting Evidence Pursuant to the Scheduling Order filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 152
[SEALED] Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Discovery Dispute Between Plaintiffs and Sigmapharm Laboratories, LLC - re #149 Letter. (Attachments: #1 Exhibit 1)(Phillips, John)
|
|
Filing 151
NOTICE OF SERVICE of (1) Initial Disclosures Pursuant to F.R.C. P. 26(a)(1) and (2) Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Apicore US LLC.(Dorsney, Kenneth)
|
|
Filing 150
NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Pursuant to Rule 26(a)(1) to Apicore, (2) Plaintiffs' Initial Paragraph 3 Disclosures to Apicore, and (3) Plaintiffs' Identification of Accused Products and Asserted Patents to Apicore filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 149
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding discovery dispute with Sigmapharm. (Attachments: #1 Exhibits 1-11)(Dellinger, Megan)
|
|
Filing 148
NOTICE OF SERVICE of Lupin's Responses and Objections to Plaintiffs' First Set of Requests for Production (Nos. 1-117) filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
SO ORDERED, re #139 Stipulation and Order to Extend Time filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 12/10/18. (ntl)
|
|
Filing 147
NOTICE OF SERVICE of Defendants Cipla Limited's and Cipla USA Inc.'s Response to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1 - 118) filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 146
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s Response to Plaintiffs' First Set of Requests for Production (Nos. 1-116) filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Pedi, Nicole)
|
|
Filing 145
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd.s Responses and Objections to Plaintiffs First Set of Requests for the Production of Documents and Things (Nos. 1-75) filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Mowery, Katharine)
|
|
Filing 144
NOTICE OF SERVICE of Hetero's Objections and Responses to Plaintiffs' First Set of Requests for Production of Documents and Things (Nos. 1-75) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 143
NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (Nos. 1-119) filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 142
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Sandoz's First Set of Individual Requests for Production to Plaintiffs (Nos. 1-3) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 141
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for December 21, 2018 at 10:45 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than December 12, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 14, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/10/18. (ntl)
|
|
Filing 140
NOTICE OF SERVICE of Plaintiffs' Identification of Claim Terms filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Blumenfeld, Jack)
|
|
Filing 139
STIPULATION and [Proposed] Order to Extend Time to December 14, 2018 for (i) Amneal to serve initial invalidity contentions and (ii) Plaintiffs and Amneal to exchange lists of claim term(s)/phrase(s) that they believe need construction by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 138
NOTICE OF SERVICE of Defendants' Preliminary List of Claim Terms for Construction filed by Lek Pharmaceuticals d.d., Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
SO ORDERED, re #132 PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 11/20/18. (ntl)
|
|
SO ORDERED, re #137 STIPULATION TO EXTEND TIME and [Proposed] Order for Amneal to Serve Initial Invalidity Contentions, Pursuant to Parahraph 8(e) of the Scheduling Order to November 30, 2018 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 11/20/18. (ntl)
|
|
Filing 137
STIPULATION TO EXTEND TIME and [Proposed] Order for Amneal to Serve Initial Invalidity Contentions, Pursuant to Parahraph 8(e) of the Scheduling Order to November 30, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 136
NOTICE OF SERVICE of Defendants' Joint Initial Invalidity Contentions filed by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 135
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding request for discovery teleconference. (Dellinger, Megan)
|
|
Filing 134
NOTICE OF SERVICE of Plaintiffs' Second Set of Requests to MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited for the Production of Documents and Things (Nos. 119-124) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 133
NOTICE OF SERVICE of Plaintiffs' First Set of Requests to for the Production of Documents and Things (addressed to various defendants as outlined in notice) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Blumenfeld, Jack)
|
|
Filing 132
PROPOSED ORDER [Proposed] Protective Order by Cadila Healthcare Ltd., Sigmapharm Laboratories LLC, Unichem Laboratories, Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan)
|
|
Filing 131
NOTICE OF SERVICE of Sandoz's First Set of Individual Requests for Production to Plaintiffs (Nos. 1-3) filed by Sandoz AG, Sandoz Inc..(Gattuso, Dominick)
|
|
SO ORDERED, re #128 Stipulation and Order to Stay as to Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 11/5/18. (ntl)
|
|
CORRECTING ENTRY: D.I. 131 was removed from the docket per request of counsel (filed in wrong case). (ntl)
|
|
Filing 130
NOTICE of Subpoena (as to MSN Pharmaceuticals, Inc.) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (Dellinger, Megan)
|
|
Filing 129
NOTICE of Change of Address by Jack B. Blumenfeld (Blumenfeld, Jack)
|
|
Filing 128
STIPULATION and [Proposed] Order to Stay by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 127
ORAL ORDER: Having reviewed the parties' letters regarding their protective order dispute (D.I. 124, 125), IT IS HEREBY ORDERED that Defendants' amended proposal (D.I. 124 Ex. A) is ADOPTED. The Court finds that Defendants' revised provision, which would designate a narrow subset of "Confidential Information" as "Competitively Sensitive Confidential Information" that would be protected from nonconsensual disclosure to other Defendants except in court filings and hearings, significantly alleviates the Court's prior concern about unduly burdening the Court. The Court expects Defendants to comply with their representations that the "Competitively Sensitive Confidential Information" will be limited to trade secret information and that they will not withhold their consent unreasonably. (See D.I. 124 at 2-3) Such compliance will further alleviate the burden that this provision will impose on Plaintiffs. Plaintiffs could have proposed a provision that may have even more fairly balanced the parties' competing concerns, but they chose not to do so. As Plaintiffs observe, "[t]he lack of a Protective Order is negatively impacting the course of this litigation" (D.I. 125 at 3), so the time has come to resolve the parties' disputes and enter such an order. IT IS FURTHER ORDERED that the teleconference scheduled for tomorrow is CANCELLED. Ordered by Judge Leonard P. Stark on 10/25/2018. (etg)
|
|
Filing 126
NOTICE OF SERVICE of Plaintiffs' Objections and Responses to Defendants' First Set of Requests for Production (Nos. 1-94) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 125
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding protective order dispute - re 119 Oral Order,,,,, Set Hearings,,,, #124 Letter. (Attachments: #1 Exhibits A-C)(Dellinger, Megan)
|
|
Filing 124
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants Opening Letter regarding Protective Order Dispute. (Attachments: #1 Exhibit A, #2 Exhibit B, #3 Exhibit C)(Phillips, John)
|
|
SO ORDERED, re #118 Stipulation and Order Regarding Infringement (Prinston and Zhejiang Huahai); #117 Stipulation and Order Regarding Infringement (Hetero Defendants). Signed by Judge Leonard P. Stark on 10/17/18. (ntl)
|
|
SO ORDERED, re #121 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order are extended to 10/26/18 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 10/17/18. (ntl)
|
|
Filing 123
REDACTED VERSION of #118 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 122
REDACTED VERSION of #117 Stipulation, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 121
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order (D.I. 31) to October 26, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 120
NOTICE OF SERVICE of Plaintiffs' Initial Infringement Contentions Against Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc. filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Filing 119
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for October 26, 2018 at 4:30 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than October 17, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than October 19, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Leonard P. Stark on 10/9/2018. (etg)
|
|
Filing 118
[SEALED] STIPULATION Regarding Infringement (Prinston, Huahai) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 117
[SEALED] STIPULATION Regarding Infringement and [Proposed] Order (Hetero Defendants) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 116
Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Request for a Discovery Teleconference. (Phillips, John)
|
|
SO ORDERED, re #114 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order are Extended to 10/12/18 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 10/2/18. (ntl)
|
|
Filing 115
NOTICE OF SERVICE of (1) Plaintiffs' Initial Infringement Contentions Against Alembic Pharmaceuticals Limited, Alembic Global Holding S/A, and Alembic Pharmaceuticals, Inc.; (2) Plaintiffs' Initial Infringement Contentions Against Alkem Labs Ltd.; (3) Plaintiffs' Initial Infringement Contentions Against Apotex Inc., Apotex Corp., and Apotex Research Private Limited; (4) Plaintiffs' Initial Infringement Contentions Against Cipla Limited and Cipla USA Inc.; (5) Plaintiffs' Initial Infringement Contentions Against Lupin Limited and Lupin Pharmaceuticals, Inc.; (6) Plaintiffs' Initial Infringement Contentions Against MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., and MSN Pharmachem Private Limited; (7) Plaintiffs' Initial Infringement Contentions Against Sandoz Inc., Sandoz AG, and Lek Pharmaceuticals, d.d.; (8) Plaintiffs' Initial Infringement Contentions Against Sigmapharm Laboratories, LLC; (9) Plaintiffs' Initial Infringement Contentions Against Torrent Pharmaceuticals Limited and Torrent Pharma Inc.; (10) Plaintiffs' Initial Infringement Contentions Against Unichem Laboratories, Limited; and (11) Plaintiffs' Initial Infringement Contentions Against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd., filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Dellinger, Megan)
|
|
Pro Hac Vice Attorney George F. Pappas for H. Lundbeck A/S added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (dmp, )
|
|
Filing 114
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order (D.I. 31) to October 12, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 113
ANSWER to #96 Answer to Amended Complaint, Counterclaim -- Answer to Unichem's Counterclams -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Blumenfeld, Jack)
|
|
SO ORDERED, re #110 MOTION for Pro Hac Vice Appearance of Attorney Charles T. Wysocki filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 9/25/18. (ntl)
|
|
Filing 112
NOTICE OF SERVICE of Defendants Cipla Limited's and Cipla USA Inc.'s Amended Paragraph 3 Initial Disclosures filed by Cipla Limited, Cipla USA Inc..(Pascale, Karen)
|
|
Filing 111
NOTICE OF SERVICE of Defendant Sigmapharm Laboratories, LLC's First Amended Disclosures Pursuant to Paragraph 3 of the Delaware Default for Discovery filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 110
MOTION for Pro Hac Vice Appearance of Attorney Charles T. Wysocki - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
Filing 109
NOTICE OF SERVICE of Supplemental Rule 26(a)(1) Initial Disclosures filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
SO ORDERED, re #108 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduli filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 9/18/18. (ntl)
|
|
Filing 108
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order to September 28, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 107
REDACTED VERSION of #100 Letter by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
Filing 106
ORAL ORDER: Having reviewed the parties' submissions relating to disputes over the otherwise agreed-upon protective order ("PO"), IT IS HEREBY ORDERED that: (1) Defendants' proposal with respect to paragraph 13, which would preclude Plaintiffs (and presumably the Court, but not Defendants) from sharing any Defendant's confidential information ("CI") with anyone (including outside counsel and experts who are subject to the PO) associated with any other Defendant without the particular Defendant's prior consent, is REJECTED, as such an approach risks imposing an undue burden on the Court (independent of the burden it imposes on Plaintiffs) -- this decision is without prejudice to Defendants having an opportunity to propose a more targeted provision to address their concerns; (2) Lupin's request (paragraph 5(e)) to disclose CI to Ms. Naidu, a non-attorney whose activities have been recognized by courts to at least relate to competitive decisionmaking, is REJECTED; Lupin has an in-house attorney, to whom Plaintiffs do not object, and Lupin's staffing preferences do not outweigh the concerns raised by Plaintiffs about the sharing of their CI nor is it even clear that Ms. Naidu will be unable to manage the litigation without access to CI; and (3) Defendants' proposal (paragraphs 30-33) to permit clawback of inadvertently-produced irrelevant, non-privileged information is REJECTED, as Defendants' concerns are adequately protected by other provisions (e.g., regarding mistaken confidentiality designations) and the breadth of Defendants' proposal threatens to unreasonably burden the Court (in connection with, e.g., disputes regarding relevance). IT IS FURTHER ORDERED that the teleconference scheduled for tomorrow is CANCELLED. Ordered by Judge Leonard P. Stark on 9/13/2018. (etg)
|
|
Filing 105
NOTICE requesting Clerk to remove Jay R. Deshmukh as co-counsel. Reason for request: no longer with the firm. (Cragg, Tyler)
|
|
Filing 104
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding Response to Plaintiffs' September 7, 2018 Letter - re #100 Letter. (Attachments: #1 Exhibit C, #2 Exhibit D)(Gattuso, Dominick)
|
|
Filing 103
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding protective order issues - re 97 Order Setting Teleconference,,,, #98 Letter. (Attachments: #1 Exhibit 1)(Dellinger, Megan)
|
|
Filing 102
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding clawback provision - re #101 Letter, 97 Order Setting Teleconference,,,,. (Attachments: #1 Exhibit 1)(Dellinger, Megan)
|
|
CORRECTING ENTRY: Corrected Exhibit A added to D.I. 101 per request of counsel. (ntl)
|
|
Filing 101
Letter to The Honorable Leonard P. Stark from Dominick T. Gattuso regarding the parties have reached an agreement on most terms of a proposed Protective Order but have three unresolved disputes - re #94 Letter, 97 Order Setting Teleconference,,,,. (Attachments: #1 Exhibit A, #2 Exhibit B)(Gattuso, Dominick) (Attachment 1 replaced on 9/10/2018) (ntl).
|
|
Filing 100
[SEALED] Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding protective order dispute - re 97 Order Setting Teleconference,,,,. (Attachments: #1 Exhibit A)(Dellinger, Megan)
|
|
Filing 99
NOTICE OF SERVICE of Defendants' First Requests for Production Directed to Plaintiffs filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 98
Letter to The Honorable Leonard P. Stark from James M. Lennon regarding issue in proposed Protective Order. (Attachments: #1 Exhibit A)(Lennon, James)
|
|
Filing 97
ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for September 14, 2018 at 3:45 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than September 7, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than September 11, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 9/6/18. (ntl)
|
|
Filing 96
ANSWER to Amended Complaint, re: #88 Amended Complaint,, , COUNTERCLAIM against All Plaintiffs by Unichem Laboratories, Limited.(Phillips, John)
|
|
SO ORDERED, re #95 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduli filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 9/4/18. (ntl)
|
|
Pro Hac Vice Attorney Stephanie M. Nguyen for Alkem Laboratories Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (ceg)
|
|
Filing 95
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order (D.I. 31) to September 14, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 94
Letter to The Honorable Leonard P. Stark from Megan E. Dellinger regarding the parties write to request the scheduling of a discovery teleconference. (Dellinger, Megan)
|
|
SO ORDERED, re #93 MOTION for Pro Hac Vice Appearance of Attorney Stephanie M. Nguyen filed by Alkem Laboratories Ltd. Signed by Judge Leonard P. Stark on 8/28/18. (ntl)
|
|
Filing 93
MOTION for Pro Hac Vice Appearance of Attorney Stephanie M. Nguyen - filed by Alkem Laboratories Ltd.. (Kraman, Pilar)
|
|
SO ORDERED, re #92 STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to August 29, 2018 filed by Lupin Pharmaceuticals Inc., Lupin Limited. Signed by Judge Leonard P. Stark on 8/24/18. (ntl)
|
|
Filing 92
STIPULATION TO EXTEND TIME to Submit Proposed Protective Order to August 29, 2018 - filed by Lupin Limited, Lupin Pharmaceuticals Inc.. (Lennon, James)
|
|
Filing 91
REDACTED VERSION of #86 Declaration (Judy K. He) by Sandoz AG. (Attachments: #1 Exhibit I - K)(Gattuso, Dominick)
|
|
Filing 90
REDACTED VERSION of #85 Reply Brief In Support of Motion to Dismiss for Failure to State a Claim Under Fed. R. Civ. P. 12 (b)(6) by Sandoz AG. (Gattuso, Dominick)
|
|
SO ORDERED, re #89 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order are extended to 8/31/18 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 8/20/18. (ntl)
|
|
Filing 89
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order to August 31, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Filing 88
AMENDED COMPLAINT -- Supplemental Complaint Against Unichem Laboratories, Limited -- against Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.- filed by Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibits A-D)(Blumenfeld, Jack)
|
|
SO ORDERED, re #84 STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to August 22, 2018; #87 STIPULATION Regarding Supplemental Complaint and [Proposed] Order. Signed by Judge Leonard P. Stark on 8/16/18. (ntl)
|
|
Filing 87
STIPULATION Regarding Supplemental Complaint and [Proposed] Order by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit A - Supplemental Complaint, #2 Exhibits A-D to Supplemental Complaint)(Blumenfeld, Jack)
|
|
Filing 86
[SEALED] DECLARATION re #85 Reply Brief (Judy K. He) by Sandoz AG. (Attachments: #1 Exhibit I, #2 Exhibit J, #3 Exhibit K, #4 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 85
[SEALED] REPLY BRIEF In Support of Motion to Dismiss for Failure to State a Claim Under Fed. R. Civ. P. 12 (b)(6) (D.I. 23 in C.A. No. 18-177) filed by Sandoz AG. (Attachments: #1 Certificate of Service)(Gattuso, Dominick)
|
|
Filing 84
STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to August 22, 2018 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Pro Hac Vice Attorney Philip L. Hirschhorn for H. Lundbeck A/S added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00114-LPS, 1:18-cv-00853-LPS(ceg)
|
|
SO ORDERED, re #82 STIPULATION TO EXTEND TIME for Amneal to serve (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order extended to 8/17/18 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 8/8/18. (ntl)
|
|
Filing 83
NOTICE OF SERVICE of 1) Initial Disclosures Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure; and 2) Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Farnan, Kelly)
|
|
Filing 82
STIPULATION TO EXTEND TIME for Amneal to serve (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard, pursuant to Paragraph 2 of the Scheduling Order to August 17, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
Pro Hac Vice Attorney Erin M. Dunston for MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-00114-LPS, 1:18-cv-00088-LPS, 1:18-cv-00853-LPS(ceg)
|
|
SO ORDERED, re #75 MOTION for Pro Hac Vice Appearance of Attorney Alaina Whitt filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., #66 MOTION for Pro Hac Vice Appearance of Attorney Allison Schmitt of COVINGTON & BURLING LLP filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/31/18. (ntl)
|
|
Pro Hac Vice Attorney Matthew L. Fedowitz for MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., MSN Pharmachem Private Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-00114-LPS, 1:18-cv-00088-LPS, 1:18-cv-00853-LPS(crb)
|
|
Pro Hac Vice Attorney Mythili Markowski for MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., MSN Pharmachem Private Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:18-cv-00114-LPS, 1:18-cv-00088-LPS, 1:18-cv-00853-LPS(crb)
|
|
Filing 81
NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 80
NOTICE OF SERVICE of Defendant Unichem Laboratories, Limited's Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 79
NOTICE OF SERVICE of Defendant Sigmapharm Laboratories, LLC's Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 78
REDACTED VERSION of #49 Answering Brief in Opposition, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Exhibit 1 - 13)(Noreika, Maryellen)
|
|
Filing 77
NOTICE OF SERVICE of Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur)
|
|
Filing 76
NOTICE OF SERVICE of Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Objections re Paragraph 8(c) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 75
MOTION for Pro Hac Vice Appearance of Attorney Alaina Whitt - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Noreika, Maryellen)
|
|
Filing 74
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd.s core technical documents filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Cragg, Tyler)
|
|
Filing 73
NOTICE OF SERVICE of Objections pursuant to Paragraph 8(c) of the Scheduling Order filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC.(Wilson, Samantha)
|
|
Filing 72
NOTICE OF SERVICE of Alkems Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 71
NOTICE OF SERVICE of Apotex's Objections pursuant to Paragraph 8(c) of the Scheduling Order filed by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
SO ORDERED, re #59 STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to August 15, 2018 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/30/18. (ntl)
|
|
Filing 70
NOTICE OF SERVICE of (i) Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V's Objections Pursuant to Paragraph 8(c) of the Scheduling Order; and (ii) this Notice of Service filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Seaman, John)
|
|
Filing 69
NOTICE OF SERVICE of Objections Pursuant to Paragraph 8(c) of the Scheduling Order re #31 Scheduling Order,,, filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited.(Grivner, Geoffrey)
|
|
Filing 68
NOTICE OF SERVICE of Sandoz Inc. and Lek Pharmaceuticals d.d.'s Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 67
NOTICE OF SERVICE of Cipla Limited's and Cipla USA Inc.'s Objections Pursuant to Paragraph 8(c) of the Scheduling Order filed by Cipla Limited, Cipla USA Inc..(Vrana, Robert)
|
|
Filing 66
MOTION for Pro Hac Vice Appearance of Attorney Allison Schmitt of COVINGTON & BURLING LLP - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
SO ORDERED, re #54 MOTION for Pro Hac Vice Appearance of Attorney Yiye Fu of COVINGTON & BURLING LLP filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/26/18. (ntl)
|
|
Filing 65
NOTICE OF SERVICE of Defendants Cipla Limited's and Cipla USA Inc.'s Core Technical Document Production filed by Cipla Limited, Cipla USA Inc..(Vrana, Robert)
|
|
Filing 64
NOTICE OF SERVICE of Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.'s Core Technical Documents, bearing Bates Numbers MAC-VOR-000001 through MAC-VOR-020193 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 63
NOTICE OF SERVICE of Defendants Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals Company GmbH, and Amneal Pharmaceuticals of New York, LLC's Core Technical Documents filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC.(Wilson, Samantha)
|
|
Filing 62
NOTICE OF SERVICE of Defendants Alembic Pharmaceuticals, Ltd., Alembic Global Holdings S/A and Alembic Pharmaceuticals, Inc.'s core technical documents filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited.(Farnan, Kelly)
|
|
Filing 61
NOTICE OF SERVICE of Core Technical Documents filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur)
|
|
Filing 60
NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Production of Core Technical Documents filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 59
STIPULATION TO EXTEND TIME for the parties to submit a proposed Protective Order to August 15, 2018 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 58
NOTICE OF SERVICE of Alkem Laboratories Ltd.'s Core Technical Documents filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 57
CERTIFICATE OF SERVICE of Core Techinical Documents by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited (Grivner, Geoffrey)
|
|
Filing 56
NOTICE OF SERVICE of Core Technical Documents filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 55
NOTICE OF SERVICE of Defendant Sigmapharm Laboratories, LLC's Production of Core Technical Documents filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 54
MOTION for Pro Hac Vice Appearance of Attorney Yiye Fu of COVINGTON & BURLING LLP - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Noreika, Maryellen)
|
|
Filing 53
NOTICE OF SERVICE of Defendant Unichem Laboratories, Limited's Production of Core Technical Documents Bearing Bates Numbers UniVort00000001-UniVort00018936 filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 52
NOTICE OF SERVICE of Apotex's production of core technical documents filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth)
|
|
Filing 51
NOTICE OF SERVICE of Sandoz Inc.'s Production of Core Technical Documents Bearing Bates Numbers SANDOZ-VORT00007156 to SANDOZ-VORT00042955 [HIGHLY CONFIDENTIAL] filed by Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 50
CERTIFICATE OF SERVICE of Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limiteds Rule 26(a)(1) Initial Disclosures and (2) Defendants MSN Laboratories Private Limited, MSN Pharmaceuticals, Inc., and MSN Pharmachem Private Limiteds Paragraph 3 Disclosures by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmachem Private Limited (Grivner, Geoffrey)
|
|
SO ORDERED, re #37 STIPULATION TO EXTEND TIME for Alembic to serve their Initial Disclosures under Fed. R. Civ. P. 26(a) and Paragraph 3 of the Delaware Default Standard on Discovery to August 3, 2018 filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. Signed by Judge Leonard P. Stark on 7/24/18. (ntl)
|
|
Filing 49
[SEALED] ANSWERING BRIEF in Opposition to Defendant Sandoz AG's Motion to Dismiss for Failure to State a Claim Under Fed. R. Civ. P. 12(b)(6) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..Reply Brief due date per Local Rules is 7/30/2018. (Attachments: #1 Exhibits 1-13)(Blumenfeld, Jack)
|
|
SO ORDERED, re #34 STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard to August 3, 2018 filed by Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals of New York LLC, Amneal Pharmaceuticals Pvt. Ltd. Signed by Judge Leonard P. Stark on 7/23/18. (ntl)
|
|
Filing 48
NOTICE OF SERVICE of Defendants Prinston Pharmaceutical Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd.'s Initial Disclosures Pursuant to Federal Rule 26(a)(1) and Paragraph 3 of the Delaware Default Standard for Discovery filed by Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd.(Cragg, Tyler)
|
|
Filing 47
NOTICE OF SERVICE of Defendants Sandoz Inc. and Lek Pharmaceuticals d.d.'s Initial Disclosures filed by Lek Pharmaceuticals d.d., Sandoz Inc..(Gattuso, Dominick)
|
|
Filing 46
NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan)
|
|
Filing 45
NOTICE OF SERVICE of (1) Defendant Sigmapharm Laboratories, LLC's Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; and (2) Defendant Sigmapharm Laboratories, LLC's Rule 26(a)(1) Initial Disclosures filed by Sigmapharm Laboratories LLC.(Haney, Megan)
|
|
Filing 44
NOTICE OF SERVICE of Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Defendants Lupin Limited and Lupin Pharmaceuticals, Inc.s Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Lupin Limited, Lupin Pharmaceuticals Inc..(Lennon, James)
|
|
Filing 43
NOTICE OF SERVICE of (1) Initial Disclosures of Unichem Laboratories, Ltd. Pursuant to Fed. R. Civ. P. 26(a)(1); and (2) Defendant Unichem Laboratories Limited's Disclosures Pursuant to District Court of Delaware Default Standard for Discovery Paragraph 3 filed by Unichem Laboratories, Limited.(Haney, Megan)
|
|
Filing 42
NOTICE OF SERVICE of Rule 26 and Paragraph 3 Disclosures filed by Torrent Pharma Inc., Torrent Pharmaceuticals Limited.(Connolly, Arthur)
|
|
Filing 41
NOTICE OF SERVICE of (1) Plaintiffs' Initial Paragraph 3 Disclosures and (2) Plaintiffs' Initial Disclosures Pursuant to Rule 26(a)(1) filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Noreika, Maryellen)
|
|
Filing 40
NOTICE OF SERVICE of 1) Alkems Rule 26(a)(1) Initial Disclosures and 2) Alkems Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Alkem Laboratories Ltd..(Kraman, Pilar)
|
|
Filing 39
NOTICE OF SERVICE of (1) Initial Disclosures Pursuant to F.R.C.P 26(a)(1) and (2) Initial Disclosures Pursuant to Paragraph 3 of the DE Default Standard filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited.(Dorsney, Kenneth)
|
|
Filing 38
NOTICE OF SERVICE of 1) Defendants Cipla Limited's and Cipla USA Inc.'s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1), and 2) Defendants Cipla Limited's and Cipla USA Inc.'s Paragraph 3 Initial Disclosures filed by Cipla Limited, Cipla USA Inc..(Vrana, Robert)
|
|
Filing 37
STIPULATION TO EXTEND TIME for Alembic to serve their Initial Disclosures under Fed. R. Civ. P. 26(a) and Paragraph 3 of the Delaware Default Standard on Discovery to August 3, 2018 - filed by Alembic Global Holding S/A, Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited. (Farnan, Kelly)
|
|
Filing 36
ANSWER to Complaint , Counterclaim - Plaintiffs' Answer to MSN's Counterclaim (D.I. 12 in C.A. No. 18-853) by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Noreika, Maryellen)
|
|
Filing 35
NOTICE OF SERVICE of 1) Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA, Inc.s Rule 26(a)(1) Initial Disclosures and 2) Macleods Pharmaceuticals, Ltd. and Macleods Pharma USA Inc.s Initial Disclosures Pursuant to the Default Standard, 3 filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Farnan, Kelly)
|
|
Filing 34
STIPULATION TO EXTEND TIME for Amneal to serve: (i) initial disclosures pursuant to Federal Rule of Civil Procedure 26(a)(1); and (ii) initial disclosures required by Paragraph 3 of the D. Del. Default Standard to August 3, 2018 - filed by Amneal Pharmaceuticals Company GmbH, Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals Pvt. Ltd., Amneal Pharmaceuticals of New York LLC. (Wilson, Samantha)
|
|
SO ORDERED, re #32 STIPULATION TO EXTEND TIME for Plaintiffs to file their answering brief in opposition to Sandoz AG's motion to dismiss (D.I. 23 in C.A. No. 18-177) and for Sandoz AG to file its reply brief to July 23, 2018 and August 15, 2018, respectively filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 7/17/18. (ntl)
|
|
Filing 33
NOTICE OF SERVICE of Plaintiffs' Identification of Accused Products and Asserted Patents filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Noreika, Maryellen)
|
|
Filing 32
STIPULATION TO EXTEND TIME for Plaintiffs to file their answering brief in opposition to Sandoz AG's motion to dismiss (D.I. 23 in C.A. No. 18-177) and for Sandoz AG to file its reply brief to July 23, 2018 and August 15, 2018, respectively - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Noreika, Maryellen)
|
|
Filing 31
SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. The actions are consolidated for all purposes and all papers shall be filed in Civil Action No. 18-88-LPS. Discovery due by 10/11/2019. Status Report due by 7/19/2019. Claim Construction Opening Brief due by 3/1/2019. Claim Construction Answering Brief due by 4/26/2019. Claim Construction Reply Brief due by 5/14/2019. A Markman Hearing is set for 5/29/2019 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 9/25/2020. A Final Pretrial Conference is set for 10/2/2020 at 09:00 AM in Courtroom 6B before Judge Leonard P. Stark. A 9-day Bench Trial is set for 10/13/2020 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 7/9/18. (ntl)
|
|
Filing 30
PROPOSED ORDER -- Scheduling Order -- by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Letter to The Honorable Leonard P. Stark)(Blumenfeld, Jack)
|
|
Minute Entry for proceedings held before Judge Leonard P. Stark - Case Management Conference held on 6/19/2018. (Court Reporter: Hawkins Reporting) Associated Cases: 1:18-cv-00088-LPS et al. (ntl)
|
|
Filing 29
PROPOSED ORDER Scheduling Order by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Attachments: #1 Cover Letter)(Blumenfeld, Jack)
|
|
SO ORDERED, re (21 in 1:18-cv-00177-LPS, 21 in 1:18-cv-00089-LPS, 23 in 1:18-cv-00114-LPS, 17 in 1:18-cv-00147-LPS, 41 in 1:18-cv-00175-LPS, 15 in 1:18-cv-00092-LPS, 12 in 1:18-cv-00672-LPS, 13 in 1:18-cv-00671-LPS, 28 in 1:18-cv-00088-LPS, 23 in 1:18-cv-00113-LPS, 11 in 1:18-cv-00753-LPS, 9 in 1:18-cv-00777-LPS, 23 in 1:18-cv-00148-LPS, 20 in 1:18-cv-00150-LPS, 20 in 1:18-cv-00176-LPS, 19 in 1:18-cv-00091-LPS, 17 in 1:18-cv-00090-LPS, 16 in 1:18-cv-00149-LPS) STIPULATION TO EXTEND TIME for the parties to submit a proposed Scheduling Order to June 12, 2018 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 6/7/18. Associated Cases: 1:18-cv-00088-LPS et al. (ntl)
|
|
Filing 28
STIPULATION TO EXTEND TIME for the parties to submit a proposed Scheduling Order to June 12, 2018 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 27
ORAL ORDER: IT IS HEREBY ORDERED that the Court will hold a Case Management Conference in courtroom 6B on June 19, 2018 at 9:00 a.m. In preparation for the CMC, counsel shall meet and confer and address the items listed in the "Checklist," and submit a proposed scheduling order no later than June 6, 2018. ORDERED by Judge Leonard P. Stark on 5/23/18. Associated Cases: 1:18-cv-00088-LPS et al. (ntl)
|
|
Filing 26
ANSWER to #25 Amended Answer to Complaint,, Counterclaim, by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc..(Noreika, Maryellen)
|
|
Filing 25
AMENDED ANSWER to #14 Amended Complaint,, COUNTERCLAIM against H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. by Apotex Corp., Apotex Research Private Limited, Apotex Inc.. (Dorsney, Kenneth)
|
|
Filing 24
NOTICE of Withdrawal of Defendant Apotex Research Private Limited's Motion to Dismiss for Lack of Personal Jurisdiction by Apotex Research Private Limited re #18 MOTION to Dismiss for Lack of Jurisdiction Over the Person (Dorsney, Kenneth)
|
|
SO ORDERED, re (14 in 1:18-cv-00147-LPS, 19 in 1:18-cv-00148-LPS, 12 in 1:18-cv-00177-LPS, 14 in 1:18-cv-00149-LPS, 14 in 1:18-cv-00090-LPS, 17 in 1:18-cv-00150-LPS, 18 in 1:18-cv-00176-LPS, 11 in 1:18-cv-00092-LPS, 16 in 1:18-cv-00114-LPS, 19 in 1:18-cv-00113-LPS, 18 in 1:18-cv-00089-LPS, 23 in 1:18-cv-00088-LPS, 23 in 1:18-cv-00175-LPS, 16 in 1:18-cv-00091-LPS) MOTION for Pro Hac Vice Appearance of Attorney George F. Pappas, Einar Stole, and Brianne Bharkhda of Covington & Burling LLP filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 4/26/18. Associated Cases: 1:18-cv-00088-LPS et al. (ntl)
|
|
Filing 23
MOTION for Pro Hac Vice Appearance of Attorney George F. Pappas, Einar Stole, and Brianne Bharkhda of Covington & Burling LLP - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Dellinger, Megan)
|
|
SO ORDERED, re #22 STIPULATION TO EXTEND TIME for plaintiffs to respond to Apotex Research Private Limited's motion to dismiss for lack of jurisdiction (D.I. 18) to May 1, 2018 filed by Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc. Signed by Judge Leonard P. Stark on 4/24/18. (ntl)
|
|
Filing 22
STIPULATION TO EXTEND TIME for plaintiffs to respond to Apotex Research Private Limited's motion to dismiss for lack of jurisdiction (D.I. 18) to May 1, 2018 - filed by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. (Blumenfeld, Jack)
|
|
Filing 21
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Apotex Pharmaceutical Holdings, Inc. for Apotex Research Private Limited filed by Apotex Research Private Limited. (Dorsney, Kenneth)
|
|
Filing 20
DECLARATION re #19 Opening Brief in Support of Motion to Dismiss for Lack of Personal Jurisdiction (executed by Seema Manku) by Apotex Research Private Limited. (Dorsney, Kenneth)
|
|
Filing 19
OPENING BRIEF in Support re #18 MOTION to Dismiss for Lack of Jurisdiction Over the Person filed by Apotex Research Private Limited.Answering Brief/Response due date per Local Rules is 4/24/2018. (Dorsney, Kenneth)
|
|
Filing 18
MOTION to Dismiss for Lack of Jurisdiction Over the Person - filed by Apotex Research Private Limited. (Dorsney, Kenneth)
|
|
Filing 17
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Apotex Holdings, Inc. for Apotex Corp.; Corporate Parent Apotex Pharmaceutical Holdings, Inc. for Apotex Inc. filed by Apotex Corp., Apotex Inc.. (Dorsney, Kenneth)
|
|
Filing 16
ANSWER to Amended Complaint, re: #14 Amended Complaint, , COUNTERCLAIM against H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. by Apotex Corp., Apotex Inc..(Dorsney, Kenneth)
|
|
Filing 15
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,861,630 B1; . (Noreika, Maryellen)
|
|
Filing 14
First AMENDED COMPLAINT against Apotex Corp., Apotex Inc., Apotex Research Private Limited- filed by H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A - D)(Noreika, Maryellen)
|
|
Filing 13
WAIVER OF SERVICE returned executed by H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd.: For Apotex Corp. waiver sent on 1/31/2018, answer due 4/2/2018. (Noreika, Maryellen)
|
|
Filing 12
REQUEST FOR WAIVER of Service sent to Apotex Corp. on 1/31/2018 by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. Waiver of Service due by 3/5/2018. (Noreika, Maryellen)
|
|
Filing 11
WAIVER OF SERVICE returned executed by H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd.: For Apotex Research Private Limited waiver sent on 1/31/2018, answer due 4/2/2018. (Noreika, Maryellen)
|
|
Filing 10
REQUEST FOR WAIVER of Service sent to Apotex Research Private Limited on 1/31/2018 by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. Waiver of Service due by 3/5/2018. (Noreika, Maryellen)
|
|
Filing 9
WAIVER OF SERVICE returned executed by H. Lundbeck A/S, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd.: For Apotex Inc. waiver sent on 1/31/2018, answer due 4/2/2018. (Noreika, Maryellen)
|
|
Filing 8
REQUEST FOR WAIVER of Service sent to Apotex Inc. on 1/31/2018 by H. Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc.. Waiver of Service due by 3/5/2018. (Noreika, Maryellen)
|
|
SO ORDERED, re #7 MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten, Ian Scott, Philip Y. Kouyoudjain and Richard T.Ruzich filed by Apotex Inc., Apotex Corp., Apotex Research Private Limited. Signed by Judge Leonard P. Stark on 1/22/18. (ntl)
|
|
Filing 7
MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten, Ian Scott, Philip Y. Kouyoudjain and Richard T.Ruzich - filed by Apotex Corp., Apotex Inc., Apotex Research Private Limited. (Dorsney, Kenneth)
|
|
Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-00088-LPS, 1:18-cv-00089-LPS, 1:18-cv-00090-LPS, 1:18-cv-00091-LPS, 1:18-cv-00092-LPS (rjb)
|
|
Filing 6
Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Takeda Pharmaceutical Company Ltd., Corporate Parent Takeda Pharmaceutical International AG for Takeda Pharmaceuticals U.S.A., Inc.; Corporate Parent Takeda Pharmaceutical Company Ltd., Corporate Parent Takeda Pharmaceutical Company Ltd., Corporate Parent Takeda Pharmaceutical Company Ltd., Corporate Parent Takeda Pharma A/S, Corporate Parent Takeda Europe Holdings B.V., Corporate Parent Takeda Europe Holdings B.V. for Takeda Pharmaceuticals International AG; Corporate Parent Takeda Pharmaceuticals U.S.A., Inc. for Takeda Pharmaceuticals America, Inc.; Corporate Parent Takeda Pharma A/S for Takeda Pharmaceutical Company Ltd. filed by Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. (crb)
|
|
Filing 5
Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by H. Lundbeck A/S. (crb)
|
|
Filing 4
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,684 B2; 8,969,355 B2; 9,227,946 B2. (crb)
|
|
Filing 3
Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/1/2017. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 3/30/2021. (crb)
|
|
Filing 2
Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (crb)
|
|
Filing 1
COMPLAINT FOR PATENT INFRINGEMENT filed against Apotex Corp., Apotex Inc., Apotex Research Private Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2300400.) - filed by Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Ltd.. (Attachments: #1 Exhibit A - C, #2 Civil Cover Sheet)(crb)
|
|
Summons Issued with Magistrate Consent Notice attached as to Apotex Corp. on 1/12/2018; Apotex Inc. on 1/12/2018; Apotex Research Private Limited on 1/12/2018. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (crb)
|
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
